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MODULATION OF THE ALPHA-7 NICOTINIC ACETYLCHOLINE 
RECEPTOR FOLLOWING EXPERIMENTAL RAT BRAIN INJURY 
IMPROVES CELLULAR AND BEHAVIORAL OUTCOMES 
 
Traumatic brain injury (TBI) is a leading cause of death and long-term 
disability worldwide, and survivors are often left with cognitive deficits and 
significant problems with day to day tasks.  To date, therapeutic pharmacological 
treatments of TBI remain elusive despite numerous clinical trials.  An improved 
understanding of the molecular and cellular response to injury may help guide 
future treatment strategies.  One promising marker for brain injury is the 
translocator protein (TSPO), which is normally expressed at a low level, but is 
highly expressed following brain damage and is associated with 
neuroinflammation.  The isoquinoline carboxamide PK11195 binds selectively to 
the TSPO in many species, and has therefore become the most-studied TSPO 
ligand.  To characterize the time-course of TSPO expression in the controlled 
cortical injury (CCI) model of TBI we subjected Sprague-Dawley rats to CCI and 
euthanatized them after 30 minutes, 12 hours, 1, 2, 4, or 6 days.  
Autoradiography with radiolabelled PK11195 was used to assess the time-course 
of TSPO binding following CCI.  Autoradiographs were compared to adjacent 
tissue slices stained with the microglia/macrophage marker ED-1, with which a 
moderate positive correlation was discovered.  PK11195 autoradiography was 
used as a tool with which to assess neuroinflammation following CCI and the 
administration of an α7 nAChR antagonist, methyllycaconitine (MLA).  We 
hypothesized that blocking the calcium permeable α7 nAChR after brain injury 
would have a neuroprotective effect by attenuating excitotoxicity in the short-
term.  Our study revealed clear dose-dependent tissue sparing in rats 
administered MLA after trauma and a modest improvement in functional 
outcome.  The relatively modest recovery of function with MLA, which could be 
due to prolonged α7 nAChR blockade or downregulation lead us to explore the 
potential of α7 nAChR partial agonists in treating TBI.  The α7 nAChR partial 
agonists tropisetron, ondansetron, and DMXB-A produced a moderate 
attenuation of cognitive deficits, but did not have a neuroprotective effect on 
tissue sparing.  These studies show that following TBI, α7 nAChR modulation 
can have neuroprotective effects and attenuate cognitive deficits.  Whether this 
modulation is best achieved through partial agonist treatment alone or a 
combination antagonist/agonist treatment remains to be determined.  
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1. CHAPTER 1 
Introduction & Background 
1.1 An overview of traumatic brain injury 
Traumatic brain injury (TBI) is one of the leading causes of death and 
long-term disability worldwide.  At least 10 million people sustain a TBI that 
results in death or hospitalization every year (Langlois et al., 2006), a 
conservative estimate since many TBIs go unreported.  Survivors of TBI are 
frequently left with long-term or life-long cognitive impairments that have a 
significant impact on quality of life (Pagulayan et al., 2006; Strandberg, 2009).  In 
addition to these cognitive impairments, people who have sustained a TBI are at 
significantly higher risk of developing other health problems.  Compared to the 
general population, TBI victims are twice as likely to binge drink (Horner et al., 
2005), several times more likely to develop epilepsy (Frey, 2003), and 7.5 times 
as likely to die 1-3 years after the initial injury (Selassie et al., 2005).  
Furthermore, moderate and severe TBI increases the probability of developing 
depression and Alzheimer’s disease (AD) in later life (Plassman et al., 2000). 
In the United States civilian population TBI is responsible for about 1.5 
million new hospital visits every year (Rutland-Brown et al., 2006), and it has 
been estimated that there are currently over 5.3 million TBI patients (Langlois et 
al., 2006).  The most frequent causes of moderate to severe TBIs are road traffic 
accidents, followed by falls and assaults.  The incidence of TBI is highest in 
people between 15 and 24 years of age, and those persons over the age of 75 
(Kraus et al., 1984).  The direct cost of care associated with TBI is estimated to 
be greater than $30 billion, and additional lifetime costs associated with TBI are 
estimated to be another $30 billion.  Despite the huge amount of money spent on 
treating TBI, a recent study found that as many as 40% of those hospitalized 
experienced significant unmet needs one year later (Corrigan et al., 2004).  
Needs most often cited were improvement in memory and problem solving, 
managing stress and emotional upset, controlling one’s temper, and improving 
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one’s job skills.  It is also important to note that the true number of people who 
sustain a TBI is difficult to determine, since large numbers of victims of mild TBI’s 
may not visit the emergency room. 
1.1.1 Epidemiology and financial burden of TBI in the United States 
An increased awareness of TBI has been brought about in the United 
States of America by various reports from warzones in Afghanistan and Iraq.  
Those in military service have always had a higher incidence of TBI than the 
general population, and while penetrating injuries are common, the incidence of 
closed head injury is known to be much higher (Galarneau et al., 2008).  Most of 
these injuries are the result of an explosion (e.g. an improvised explosive 
device), and the term ‘blast injuries’ is used to describe them.  The injury is 
caused by large and sudden changes in air pressure as a direct result of an 
explosion (Taylor and Ford, 2009; Wolf et al., 2009).  However, brain injuries can 
also be sustained from impact of objects put in motion by the blast, or by impact 
of the head against another object.  Because of the nature of blast injuries the 
incidence of TBI in military personnel fighting in the “War on Terror” is difficult to 
estimate as they can often go unrecognized.  A recent survey of military 
personnel returning from the theatre of war revealed a 12% incidence of mild 
TBI, a condition that can significantly affect quality of life (Schneiderman et al., 
2008).  The increased awareness of TBI has lead to the Department of Defense 
and the Department of Veterans Affairs instituting routine screening of veterans 
for TBI (Affairs, 2007), and medical professionals are now being trained to 
recognize and treat these brain injuries (Martin et al., 2008). 
1.1.2 Classification of TBI: closed versus penetrating head injuries 
There are many different ways in which a person can sustain a TBI, 
including, but not limited to, motor vehicle collisions, falls, and gun-shots.  In 
order to develop treatment strategies for TBI it is important to understand how 
these injuries vary, and therefore, it is necessary to categorize these injuries 
based on similarities.  The easiest way of classifying injuries is to determine 
whether they are skull penetrating brain injuries, or closed skull injuries.  
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Penetrating brain injuries are most often caused by gunshots associated with 
combat or other acts of violence (e.g. stab wounds).  Closed head injuries are 
significantly more common (Styrke et al., 2007), and are caused when static or 
dynamic forces are applied to the head.  The rapid acceleration, deceleration, 
and rotational forces involved in vehicular collisions are the most common cause 
of this injury (Denny-Brown and Russell, 1941; Ivancevic, 2008; Krave et al., 
2005).  Injuries caused by dynamic forces can be further sub-divided into injuries 
involving an impact, and those that do not (impulsive).  In many instances injuries 
will be the result of both inertial forces and of an impact.  Obviously, the amount 
of force acting on the brain is an important factor in influencing the severity of the 
TBI. 
1.1.3 Classification of TBI: primary and secondary injuries 
It is clear that there is significant variation in the types and severity of TBIs 
and it is easy to presume that following the initial insult, the brain healing process 
begins.  Unfortunately this is not the case, and it is widely recognized that brain 
injuries can become more severe with time (Anderson et al., 2005; Himanen et 
al., 2006; Sato et al., 2001; Shiozaki et al., 2001).  This is due to the evolution of 
a secondary injury that occurs in the minutes, hours, days, and even months 
after the initial (primary) injury.  The primary injury causes a disruption in the 
homeostasis of the brain; axons are damaged or sheared, cells are ruptured, 
blood vessels are damaged, and tissue may be lost (Gaetz, 2004; Gennarelli, 
1993; Gennarelli and Graham, 1998; Hammoud and Wasserman, 2002; Strich, 
1961; Strich, 1956).  An immediate and significant effect of this damage is often 
ischemia, which contributes significantly to secondary damage (Bramlett and 
Dietrich, 2004; Graham et al., 1978; Graham et al., 1988; Nortje and Gupta, 
2006; Zauner et al., 2002).  Damaged or ruptured cells release a multitude of 
different messenger molecules, including pro-inflammatory cytokines and the 
excitatory neurotransmitters glutamate and acetylcholine (ACh).  Increased levels 
of these molecules lead to activation of their respective ionotrophic receptors and 
an influx of calcium (Ca2+) and sodium (Na+) into neurons.  Under normal 
conditions ACh and glutamate are released in precisely controlled areas, and are 
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then rapidly degraded (ACh) or taken up into presynaptic neurons or astrocytes 
via energy dependant transporters (glutamate).  However, following an injury the 
haphazard nature of neurotransmitter release combined with the amount 
released leads to the activation of many cellular pathways and damaging 
enzymes.  The end result of this is cellular dysfunction and cell death via 
apoptosis or necrosis. 
1.1.4 Classification of TBI: injury severity 
TBI patients can be categorized as having a severe, moderate, or mild TBI 
when admitted to the hospital.  The most widely used tool for assessment of the 
severity of injury is the Glasgow Coma Score (GCS).  The GCS consists of a 
battery of tests for eye response (1-4 points), verbal response (1-5 points), and 
motor response (1-6 points).  The test therefore rates patients on a scale of 3-15, 
3 being deep coma/death, and 15 being fully awake (Teasdale and Jennett, 
1974).  It is generally accepted that a score of ≥13 is a mild injury, 9-12 is 
moderate, and a score ≤8 is classed as a severe injury  (Jennett, 1998; Parikh et 
al., 2007).  In addition to the GCS, doctors may take into account measures such 
as the duration of post-traumatic amnesia and loss of consciousness to make a 
final assessment of injury severity.  While this scale has been shown to be of 
prognostic value (Narayan et al., 2002), a recent workshop convened by the 
Veterans Brain Injury Center and the National Institute of Disability and 
Rehabilitation criticized its use in recruiting for clinical trials because of the lack of 
assessment of factors such as age, extra-cranial injury, and pre-existing 
neurological impairment that may override treatment effects (Saatman et al., 
2008).  Furthermore, the GCS does not discriminate well in less severely injured 
patients, which comprise the majority of cases. 
Since these clinical assessments are clearly not applicable in animal 
models of TBI the injury severity is frequently defined by the parameters of the 
injury-producing device (Cernak, 2005; Morales et al., 2005).  Because of this 
discrepancy, it is important to realize that while a mild/moderate/severe injury in a 
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rodent paradigm models some aspects of the human condition it is not 
necessarily fully equivalent (see below for a more detailed discussion).  
1.1.5 The secondary injury cascade 
Excitotoxicity is the term used to describe the process by which excitatory 
neurotransmitters can adversely affect the survival of neurons by over-stimulating 
their respective ionotrophic receptors.  T. Hayashi is credited with being the first 
to report the excitotoxic effects of glutamate in 1954, when  he observed that 
glutamate applied directly to the cortex induced convulsions (Hayashi, 1954).  
But it was not until 1969 that J. Olney coined the term excitotoxicity when he 
noticed that monosodium glutamate fed to mice or monkeys produced lesions in 
the brain (Olney, 1969; Olney and Sharpe, 1969).  Since these early studies the 
mechanisms by which glutamate causes neuronal death have been thoroughly 
elucidated. 
Once released into the synaptic cleft, glutamate can bind to and activate a 
family of glutamate receptors.  Activation of ionotrophic receptors leads to 
depolarization of the post-synaptic membrane by facilitation of cation flow into the 
neuronal cytoplasm.  In total there are 11 types of glutamate receptor, 8 are 
metabotrophic and 3 are ionotrophic.  The three types of ionotrophic glutamate 
receptors are the kainite receptor, the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor, and the N-methyl-D-aspartic acid 
(NMDA) receptor (Dingledine et al., 1999; Liu and Zhang, 2000; Paoletti and 
Neyton, 2007).  AMPA and NMDA receptors are found on post-synaptic neurons 
in intimate proximity to presynaptic nerve terminals (Antal et al., 2008; Kharazia 
et al., 1996).  Whereas activation of AMPA receptors is dependant only on 
glutamate binding, NMDA receptors require the binding of co-agonist glycine 
(Kleckner and Dingledine, 1988), depolarization-induced removal of magnesium 
ion blockade of the ion channel (Nowak et al., 1984; Ruppersberg et al., 1994) 
and binding of glutamate.  The initial activation of AMPA receptors by glutamate 
leads to sodium influx and membrane depolarization, which facilitates the 
removal of the magnesium block in nearby NMDA receptors and allows for 
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NMDA receptor activation by glutamate when the co-agonist glycine is present.  
Once activated NMDA receptors are selectively permeable to calcium ions (Jahr 
and Stevens, 1993; MacDermott et al., 1986), further depolarizing the post-
synaptic membrane and leading to activation of intracellular signaling pathways.  
However, sustained high levels of glutamate can lead to prolonged activation of 
excitatory glutamate receptors.  It is the NMDA receptor that is believed to be the 
major contributor to the toxic effects of glutamate due to its relatively high 
permeability to calcium. 
Calcium is an important secondary messenger that has various 
physiological actions inside a cell (Berridge et al., 2003; Petersen et al., 2005).  
Under normal physiological conditions the extracellular calcium concentration is 
10,000 fold higher than the intracellular concentration (approximately 1 mM 
versus 100 nM, respectively).  This high degree of control is maintained by the 
elimination of calcium from the cell via the sodium/calcium exchanger (Yu and 
Choi, 1997), calcium ATPase (Jensen et al., 2004), or by sequestration in 
calcium ‘sinks’ such as the endoplasmic reticulum and the mitochondria (Pizzo 
and Pozzan, 2007).  However, when there is an excess of extracellular 
glutamate, prolonged activation of NMDA receptors may lead to the accumulation 
of calcium in the cell (Dubinsky, 1993).  The mitochondria can take up a lot of 
calcium via the mitochondrial calcium uniporter (Kirichok et al., 2004), which has 
a much higher activity than the extrusion pathway via 2Na+/Ca2+ exchange.  In 
this way the mitochondria play a role in maintaining cellular calcium homeostasis 
(Carafoli, 2003), but when too much calcium is present adenosine-5'-triphosphate 
(ATP) synthesis is inhibited and reactive oxygen species (ROS) including 
superoxide and peroxonitrite are produced (Brookes et al., 2004; Hall et al., 
2004).  Peroxidation of lipids by ROS is damaging to the cell and could result in 
cell death.  Furthermore, the lack of ATP will have many detrimental effects in the 
cell; including failure of energy-dependent glutamate transporters.  Normally, 
glutamate is cleared from the extracellular space by active transport across the 
plasma membrane; therefore a failure of these transporters will lead to a reduced 
clearance of glutamate and exacerbated NMDA receptor stimulation.  Calcium 
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overload can lead to the formation of the permeability transition pore (Crompton, 
1999) and subsequent release of cytochrome c (Luetjens et al., 2000).  In the 
cytoplasm, cytochrome c can activate the intrinsic apoptosis pathway via 
activation of caspase 9, which then activates caspases 3 and 7 (Cohen, 1997).  
The excess calcium produced by over-stimulation of NMDA receptors is very 
different from normal physiological circumstances where the effects of calcium on 
the cell are regulated by discrete, localized increases.  These large-magnitude 
global increases in calcium concentration within the cell activate numerous 
signaling cascades and enzymes, including phospholipases, proteases, and 
endonucleases.  Once activated, these enzymes lead to membrane damage, 
loss of membrane potential, cytoskeletal damage, and deoxyribonucleic acid 
(DNA) damage.  The disruption of cellular homeostasis in a disease state can 
lead to programmed cell death via apoptosis, or to a disorderly cell death via 
necrosis.  Taken together this demonstrates the damage that excitotoxicity can 
cause and the integral role of the mitochondria in secondary injury and neuronal 
dysfunction.  Studies in rodent models of TBI have demonstrated the early onset 
of mitochondrial dysfunction and lipid peroxidation (Singh et al., 2006). 
Although many studies focus on the role of glutamate it is important to 
realize that several other excitatory neurotransmitters could potentially contribute 
to calcium-related excitotoxicity.  Acetylcholine is one such neurotransmitter best 
known for its prominent role at the neuromuscular junction (NMJ) in the 
peripheral nervous system (PNS).  It is now well established that ACh also has a 
critical role in the CNS, where it acts at G-protein coupled muscarinic 
acetylcholine receptors (mAChR) as well as a number of ionotrophic receptors.  
Of particular interest with regard to excitotoxicity is the α7 nicotinic acetylcholine 
receptor (nAChR); a ligand-gated ion channel with high permeability to calcium 
(Delbono et al., 1997; Sands et al., 1993).  Also of note is the serotonin receptor 
5-HT3 (5-hydroxytryptamine), since unlike other serotonin receptors it is a 
sodium-permeable ion-channel rather than a G-protein coupled receptor.  While 
the 5-HT3 receptor is not selectively permeable to calcium like the NMDA and α7 
nAChR (Mochizuki et al., 1999), it is of interest because it is unique among 
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serotonin receptors, sharing a great deal of homology with the α7 nAChR 
receptor, and is found in areas of the brain known to be especially vulnerable to 
injury such as the hippocampus (Fletcher and Barnes, 1999; Ge et al., 1997; 
Parker et al., 1996). 
In addition to excitotoxicity, the contribution of inflammation to secondary 
injury is an important consideration.  In the periphery, the inflammatory response 
has numerous roles including phagocytosis of dead cells and invading 
pathogens, and the promotion of recovery.  However, in the brain an 
inflammatory response could contribute to post-injury damage and loss of 
function.  The brain has long been considered to be an immunologically 
privileged organ (Murphy and Strum, 1923; Shirai, 1921), able to tolerate 
introduction of antigen without eliciting an immune response.  However, it is now 
becoming apparent that immune cells play a central role in the pathogenesis of 
secondary injury (for a review see Galea et al., 2007).  Microglia are the main 
immune cell in the brain, accounting for an estimated 10-20% of all non-neuronal 
cells in the central nervous system (CNS) (Lawson et al., 1990).  Microglia are 
known to have multiple phenotypes that are seen depending on their 
environment (Gehrmann et al., 1995).  In normal brain, resting microglia have 
small cell bodies and numerous long processes that constantly elongate and 
shorten giving the impression that they have a surveillance role (Kreutzberg, 
1996; Nimmerjahn et al., 2005).  Several factors are known to lead to microglial 
activation, including pro-inflammatory cytokines and cell necrosis factors.  Such 
conditions can be found in the brain under neurodegenerative or injury states, 
which leads to the transformation of microglia to an activated state (Ransohoff 
and Perry, 2009).  The activation of microglia can be very rapid; several studies 
have shown that activation can be detected within hours or minutes of an insult 
(Kelley et al., 2007; Liu et al., 2009; Raghavendra Rao et al., 2000; Suma et al., 
2008).  The transformation of quiescent microglia to a fully activated phagocytic 
cell is a graded response.  Non-phagocytic activated microglia exhibit fewer, 
thicker, retracted processes and larger cell bodies.  Activated microglia begin to 
proliferate and secrete cytotoxic factors and pro-inflammatory cytokines.  When 
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fully activated they are phagocytic, taking on a completely amoeboid appearance 
(Gehrmann et al., 1995).  These phagocytic microglia migrate to the site of injury 
and engulf foreign material and cellular debris, while also secreting pro-
inflammatory cytokines to amplify the immune response.  Therefore, modulation 
of microglial cell activation may be one possible way to decrease brain 
inflammation and secondary neuropathology following TBI. 
1.1.6 Current treatment strategies for TBI patients 
In individuals that suffer a TBI the primary focus is on stabilizing the 
patient to improve their chances of a favorable clinical outcome.  This can be 
achieved by first immobilizing the patient to lessen the risk of further CNS injury.  
To reduce the risk of cerebral ischemia healthcare workers must ensure the 
patient has adequate airway patency, breathing and oxygenation.  Close 
attention is paid to insure a proper oxygen supply to the brain by maintaining 
blood flow and blood pressure.  In the hospital careful monitoring of intracranial 
pressure (ICP), and mean arterial blood pressure provides an estimate of the 
cerebral perfusion pressure (CPP).  The CPP is maintained at a satisfactory level 
to prevent additional brain damage (Rosner, 1995; van Santbrink et al., 2002).  
ICP can be continuously monitored by surgically implanting a catheter into one of 
the lateral ventricles.  Maintenance of ICP can be achieved by administering 
sedatives, paralytics, and if necessary by draining cerebrospinal fluid (CSF) from 
a lateral ventricle.  More drastic measures may be taken in severe cases, 
including a decompressive craniectomy to allow the brain to swell until ICP is 
resolved (Schirmer et al., 2008). 
When ready, moderately and severely injured patients discharged from 
the acute care setting will receive physical/occupational, speech/language 
therapy, or be referred to a psychiatrist, or social worker as required.  
Rehabilitation and therapy for survivors of TBI focuses on helping the patient to 
function independently at home and at work.  However, the services received 
often fail to address the emotional, cognitive, and behavioral needs of the patient 
(Martin et al., 2001).  Even victims of mild injuries can experience long-lasting 
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cognitive deficits that include memory loss, problems with concentration and 
attention, and deficits in executive functions such as judgment, planning, 
problem-solving and reasoning. 
1.2 Modeling TBI in the laboratory 
1.2.1 Overview of in vivo TBI paradigms 
In the clinic a wide range of types and severity of head injury are seen that 
often result in vastly different outcomes.  Due to this heterogeneity in TBI there is 
no one model that can mimic the full range of injury severities and clinical 
sequelae seen in human TBI (Park et al., 2007; Saatman et al., 2008).  For this 
reason several models are widely used in pre-clinical TBI research to model the 
full range of injury severities and pathological characteristics seen in TBI 
patients.  Although in vitro models of TBI facilitate the evaluation of 
pharmacological treatments in a rapid and cost-efficient manner, they lack face 
validity.  In vivo models, summarized below, allow for assessment of the whole 
animal response to injury, including measurement of cognitive and behavioral 
deficits after experimental brain injury.  This makes for a more relevant model at 
the expense of increased cost, variability, and difficulty in sampling. 
One of the first standardized in vivo models of TBI was the weight-drop 
model in which a free-falling weight impacts the exposed skull of an anesthetized 
rat to produce what is usually referred to as a ‘focal’ injury (Shapira et al., 1988).  
The model has since been adapted for use on mice (Chen et al., 1996; Flierl et 
al., 2009).  A key feature of this model is its simplicity; minimal surgical 
preparation required and the severity of injury can be easily altered by adjusting 
the mass and height of the impacting weight.  Weight drop injury leads to 
immediate and brief unconsciousness, cortical contusion, selective neuronal 
death in the cortex, hippocampus and thalamus, and behavioral deficits (Chen et 
al., 1996).  The model does have disadvantages, including the likelihood of 
rebound injury and a high variability, necessitating larger group sizes to see 
effects of a comparable magnitude as those seen in similar models.  
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Furthermore, this model has a relatively high mortality rate, again increasing the 
number of animals that must be used. 
A related model is the impact acceleration model (Foda and Marmarou, 
1994; Marmarou et al., 1994), in which the injury is again produced by a free 
falling weight.  However, in this model a stainless steel plate is glued to the skull 
to distribute the force of impact over a wide area, minimizing the probability of 
skull fracture and producing a more diffuse injury.  A second critical difference 
between this model and the weight-drop model is that the animal is unrestrained, 
and its head is placed on a piece of foam of known spring constant to allow 
movement of the head after impact.  The physical properties of the foam, 
combined with the mass and height from which the weight is dropped, determine 
the severity of injury (Piper et al., 1996).  This model produces measurable 
neurological and cognitive deficits in rats, and more severe injuries can be 
obtained by increasing the height at which the weight is dropped from or by the 
addition of a hypoxic insult (Beaumont et al., 1999).  More recently the impact-
acceleration model has been modified to produce a diffuse axonal injury (DAI) 
(Kallakuri et al., 2003), or to produce mild TBIs (Ucar et al., 2006) since the 
model is predominantly used to produce severe injuries.  Like the weight-drop 
model, since this model also utilizes a free-falling weight to produce injury there 
remains the possibility of a second rebound injury. 
Fluid percussion injury (FPI) is one of the most commonly used and best 
characterized in vivo models of TBI.  Before performing the injury, the rat is 
anaesthetized, its skull exposed, and a craniotomy performed.  Like the previous 
two models, the energy used to produce injury comes from a falling weight, here 
in the form of a pendulum.  Unlike the other models the pendulum strikes a 
saline-filled syringe that forces a saline bolus through the sealed craniotomy to 
impact the dural membrane causing a pressure wave that spreads throughout  
the epidural space producing a diffuse injury (McIntosh et al., 1989).  The injury 
severity can be adjusted by changing the height of the pendulum, and therefore 
the force of the pressure pulse that is transmitted through the saline reservoir.  
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The model produces damage with characteristics consistent with that of a diffuse 
brain injury.  However, a significant drawback of the FPI model is the high 
mortality rate associated with injury to the brainstem, especially at higher injury 
severities (McIntosh et al., 1989; Thibault et al., 1992). 
The controlled cortical injury (CCI) model of TBI was developed in 1988 
for use by General Motors and was originally designed for ferrets (Lighthall, 
1988).  It was modified for use in rodents (Dixon et al., 1991; Hamm et al., 1992) 
and is now commonly used in rats and mice to produce fairly consistent focal 
injuries (relative to other TBI models).  The model utilizes a pneumatically driven 
impactor to administer a single mechanical deformation of the exposed brain 
without rebound injury.  Due to the precision machinery used the injury severity 
and type can be adjusted by using different shape and size impactor tips, 
adjusting the impactor velocity, or altering the depth of cortical deformation.  In 
our laboratory the surgery is performed on anesthetized rats that have been 
immobilized in a Kopf stereotaxic frame (David Kopf Instruments, CA).  This 
allows for the precise positioning of a craniotomy midway between bregma and 
lambda (bregma -4.5 mm), and 5-7 mm laterally over the somatosensory cortex.  
Injury in this location on the somatosensory cortex leads to cortical tissue loss 
and damage to the hippocampus either through direct energy transfer or via the 
perforant pathway following damage to the entorhinal cortex.  Work in our 
laboratory and others have shown that this placement produces measurable 
cognitive deficits (Dixon et al., 1995b; Guseva et al., 2008; Verbois et al., 2003a).  
In addition, this model benefits from a lower rate of mortality when compared to 
other models of brain injury (Kochanek et al., 1995). 
1.2.2 Measuring CNS damage following experimental TBI 
Well established methods to assess the short and long-term 
neuropathological effects of the experimental TBI and potential 
pharmacotherapies are needed.  Post-mortem assessments of gross tissue 
loss/disruption, individual neuronal or glial cell loss, and expression of cell or cell 
cycle specific enzymes and genes help provide a more detailed characterization 
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of the injury.  Post-injury assessments can measure markers such as cell death 
via apoptosis or necrosis, or could utilize markers of reactive gliosis.  Reactive 
gliosis refers to the accumulation of activated glial cells including microglia, 
macrophages and astrocytes immediately after CNS injury.  The term 
‘neuroinflammation’ is now more commonly used to describe this process.  
Astrocytes synthesize more glial fibrillary acidic protein (GFAP) and undergo 
some morphological changes including the elongation of more pseudopodia that 
form a dense mesh to fill space left by dead neurons.  Microglia, the CNS 
equivalent of macrophages, rapidly become activated and secrete cytokines, 
neurotropic factors, and other biologically active factors.  Macrophages are 
difficult to delineate from microglia, being from the same lineage.  They are 
known to cross the blood brain barrier after brain injury and are thought to play a 
similar role to microglia. 
For models that result in a visible loss of cortical tissue the simplest and 
quickest assessment that can be made is that of cortical tissue sparing analysis 
(Scheff and Sullivan, 1999).  The analysis is carried out on nissl-stained (e.g. 
Cresyl violet) coronal brain sections.  This makes it easy to distinguish viable 
tissue so that measurements can be made of the area of tissue remaining, i.e. 
spared.  For unilateral injuries measurements of area can be taken for both 
hemispheres, allowing for a calculation of the lesion’s area by subtracting the 
ipsilateral area from the contralateral ‘control’ area in each section.  When 
studying the neuroprotective effects of certain treatments it makes more sense to 
express these numbers as ‘tissue spared’ as opposed to lesion size.  This is 
easily achieved by dividing the ipsilateral area by the contralateral area (and 
multiplying by 100) to yield a percentage of tissue spared.  While this method is a 
good measure of the severity and extent of injury, it does not give any indication 
of functional injury or cell loss that could be occurring in other areas of the brain, 
or indeed in regions of the ipsilateral cortex distal to the site of impact.  More 
sensitive techniques are required to quickly assess and quantify these more 
subtle, but potentially significant changes. 
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To assess changes that occur on a cellular level after injury, radioligands 
or antibodies can be employed to mark specific receptors or antigens expressed 
by certain cell types.  For example, neuronal survival can be assessed with 
antibodies against NeuN (neuronal nuclei), a DNA binding protein found in most 
neuronal nuclei (Mullen et al., 1992).  Degenerating neurons long been known to 
be argyrophilic and silver staining methods have developed to visualize the cell 
bodies and neuronal processes of these neurons (Tenkova and Goldberg, 2007).  
A more straightforward and recent technique to label degenerating neurons is 
fluoro-jade, an anionic fluorescein derivative.  Fluoro-jade is thought to bind to 
polyamines that are found in degenerating cells (Schmued and Hopkins, 2000a, 
b).  Additionally, apoptotic cells can be visualized by terminal deoxynucleotidyl 
transferase mediated dUTP nick end labeling (TUNEL). To be useful in 
identifying the cell types that are dying TUNEL is often carried out as a double or 
triple staining with antibodies against specific cell types such as 
microglia/macrophages (e.g. anti-CD68, OX-42, F4/80, iba-1), astrocytes (e.g. 
anti-GFAP), or neurons (e.g. NeuN).  In addition, the identification of microglial 
activation and macrophage infiltration by immunohistochemical techniques can 
provide a good assessment of the degree of cellular damage resulting from a 
particular injury or damaging agent (Nixon et al., 2008).  A drawback of each of 
these assessments is the difficulty of obtaining an accurate quantification.  
Precise quantification of cell numbers can be very time-consuming and little 
information on expression on individual cells can be acquired.  To this end, 
another useful tool to assess damage and inflammation after TBI may be 
autoradiography using the ligand [3H]-PK11195 (Banati et al., 1997; Sitte et al., 
2001; Vowinckel et al., 1997).  Autoradiography allows for a rapid assessment of 
ligand binding density in multiple discrete regions within the brain.  Studies that 
have utilized [3H]-PK11195 autoradiography have demonstrated its potential as a 
sensitive marker of inflammation in models of neurodegenerative disease and 
brain injury (Chen and Guilarte, 2006; Grossman et al., 2003; Pedersen et al., 
2006; Roberts et al., 2009).  Although the precise antigen and cell types to which 
PK11195 binds have not been fully elucidated, it appears to be associated with 
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mitochondrial cholesterol transport in inflammatory cell types (Banati et al., 1997; 
Giannaccini et al., 2000).  Further evaluation of the binding profile of [3H]-
PK11195 in a model of TBI could help to establish the technique as a valuable 
tool in the assessment of post-traumatic inflammation. 
1.2.3 Assessing functional deficits 
To be clinically relevant, models of TBI should be able to produce 
functional and cognitive deficits that are measureable by well defined tests in the 
laboratory.  To this end several methods have been developed to characterize 
the deficits seen after injury in rodent models.  The rotorod is one such test in 
which a mouse or rat is placed on a rotating drum in a semi-enclosed chamber.  
The drum slowly accelerates and the latency of the animal to fall is recorded, 
giving an indication of motor coordination, balance and stamina.  Another test is 
the ledged tapered beam, in which animals must traverse a suspended ledged 
beam which begins wide enough to walk comfortably, and tapers to a point.  The 
number of times each paw slips onto the ledge and at what point on the beam 
can be recorded as an indication of balance and motor function.  Other 
assessments include locomotor activity monitoring and open field testing.  More 
complete assessments of overall neurological functioning can be made using a 
battery of simple tests.  An example of such a scoring modality is the composite 
“neuroscore”, which takes into account forelimb flexion when suspended by the 
tail, resistance to pulsion, hindlimb splay, toe-spread and toe-extension, and 
ability to stand on an inclined surface facing up, down, left or right (Gruner et al., 
1996; McIntosh et al., 1989).  Another battery of tests is the neurological severity 
score (NSS) which assesses hemiparesis, ability to traverse beams of various 
widths, ability to balance on round or square sticks, failure to exit a circle, startle 
reflex, and seeking behavior (Beni-Adani et al., 2001; Panikashvili et al., 2005).  
While useful in assessing acute motor deficits it should be remembered that a 
large number of people suffer mild injuries in which cognitive and other 
neuropsychiatric changes cause the most damage to the routines of daily living.  
Fortunately, there are some well established tests of cognitive performance in the 
rodent, including the T-maze and the commonly used Morris water-maze (MWM). 
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The MWM was developed in 1984 by Richard Morris to test spatial 
memory in rats (Morris, 1984).  The testing apparatus consists of a circular pool 
1.5-2 m in diameter and about 60 cm deep, filled with water to a depth of about 
30 cm.  The water is made opaque by the addition of a pigment to obscure the 
location of a 15 cm diameter escape platform hidden approximately 1 cm below 
the water level, and to provide contrast against the color of the animal being 
tested.  Visual cues are placed around the outside of the pool in plain sight of the 
test subject.  The rat or mouse is carefully placed in the pool rear end first facing 
the edge of the pool to reduce stress and bias respectively.  The animal then 
searches the pool for an exit, and its escape from the pool and rescue by the 
experimenter reinforces its desire to find the escape platform swiftly in 
subsequent trials.  Improvement in performance in the MWM comes about 
because the rat/mouse has learned the position of the escape platform in the 
pool relative to the visual cues around the test room.  The entire experiment is 
recorded using a video camera mounted above the pool so that a more thorough 
evaluation of each rats’ search pattern can be made. 
Various training paradigms exist that include acquisition training and 
memory retention testing (Brandeis et al., 1989; Wenk, 1998).  Acquisition 
training usually consists of a block of 4 swim trials in which the animal starts at 
each of 4 randomly chosen positions around the pool.  If the animal successfully 
finds the platform it must remain there for a short amount of time (e.g. 15 s) 
before being rescued.  If a pre-determined amount of time passes without the 
animal finding the platform (e.g. 60 s) it is manually guided or placed on the 
platform.  The data from each of the 4 trials in the block can then be averaged.  
Further blocks of training trials can be performed on consecutive days or even on 
the same day (Kraemer et al., 1996).  Following the acquisition testing, a memory 
retention test is usually performed in which the escape platform is removed from 
the pool.  Each animal is allowed to swim in the pool for a set amount of time 
(e.g. 30 s, 60 s, 120 s).  During this memory retention test the animals’ spatial 
ability can be assessed by measuring the amount of time it spends searching in 
the vicinity of the escape platform, the number of times it crosses into the 
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platform area, or the number of times it crosses into the target quadrant.  The 
ability of researchers to make accurate assessments of these parameters has 
been greatly improved by the availability of electronic tracking systems such as 
Videomex (Columbus Instruments, Columbus, OH). 
Since the first description of the water maze by Morris in 1984, which 
utilized hooded rats, there have been thousands of studies utilizing the technique 
with a variety of both rat and mouse strains.  It is therefore important to consider 
whether these or indeed other factors could influence MWM performance when 
comparing studies.  For example, differences in spatial performance between 
men and women have been well documented (Astur et al., 1998; Duff and 
Hampson, 2001; Newhouse et al., 2007; Rizk-Jackson et al., 2006), and similar 
sex-differences have been reported in rodents (Frye, 1995; Galea et al., 1996).  
These differences could obviously be due to sex hormones as suggested in 
several studies (Daniel et al., 1999; Roof, 1993; Warren and Juraska, 1997).  In 
addition to sex differences significant differences have been found in the 
performance of different rodent species, specifically mice in the MWM (Lipp and 
Wolfer, 1998).  Mice have a tendency to float or swim along the edge of the pool 
(thigmotaxis) more than rats, and often perform quite poorly in comparison.  A 
comparison study has found similar performance for mice and rats in ‘dry’ spatial 
learning tasks but not for the water maze task, indicating that a difference in 
spatial ability is not the factor at play (Whishaw and Tomie, 1996).  Another major 
factor to consider is the age of animals within a study, as it is well established 
that MWM performance declines with age (Brandeis et al., 1989; Gower and 
Lamberty, 1993).  Furthermore, it has been recognized that the MWM causes a 
stress response in rodents that could potentially confound results (Engelmann et 
al., 2006). 
The MWM is known as a hippocampal dependant task because the 
hippocampal formation is clearly essential for spatial learning, as demonstrated 
by impaired performance in animals with hippocampal lesions (Morris, 1984; 
Morris et al., 1982; Moser et al., 1993; Pearce et al., 1998).  However, the 
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involvement of other brain regions cannot be ruled-out.  In addition to the 
involvement of the hippocampal formation in spatial learning other brain regions 
including the caudate putamen (a.k.a. stiatum) (Whishaw et al., 1987), basal 
forebrain (Mandel et al., 1989), cortical regions (Liu and Bilkey, 1998; Mogensen 
et al., 1995; Roof et al., 1993), and cerebellum (Lalonde, 1994) have been 
implicated.  This demonstrates that spatial learning requires the coordinated 
action of multiple brain regions and is a complex process.  Despite the apparent 
complexity the process, long-term potentiation (LTP), is considered to be one of 
the major cellular/synaptic mechanisms involved in learning (Lynch, 2004).  LTP 
is process by which the efficacy of signaling between two neurons is increased 
following repeated stimulation.  This effect is long-term and mediated by changes 
in gene expression and protein synthesis.  In the hippocampus spatial learning is 
thought to involve place cells, which exhibit a high rate of firing when an animal is 
in a specific position within and environment corresponding to the cell’s ‘place 
field’ (Buzsaki, 2005; O'Keefe and Dostrovsky, 1971; Poucet et al., 2000).  In the 
rat hippocampus there are hundreds of thousands of pyramidal cells in close 
proximity with a high degree of connectivity (Li et al., 1994).  The fields of place 
cells within this population are distributed evenly across the environment (Muller 
et al., 1987), so any pair of fields in the environment could be represented by 
hundreds of connected cells.  Therefore, because the firing frequency of each 
place cell varies as a function of the distance between them, place cells with 
overlapping place fields could undergo LTP and thus encode spatial distance 
(Isaac et al., 2009; Muller et al., 1996).  The importance of LTP in spatial learning 
is highlighted by studies in which NMDA antagonists are administered.  Morris et 
al. originally demonstrated impaired water maze performance of rats 
administered the NMDA antagonist (2R)-amino-5-phosphonovaleric acid (AP5) 
via intraventricular infusion (Morris et al., 1986), and subsequent studies have 
highlighted the role of NMDA receptors in spatial learning (McNamara and 
Skelton, 1993).  As well as NMDA involvement it has long been known that the 
cholinergic system plays a significant role in spatial localization (Sutherland et al., 
1982). 
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The neuropharmacology of spatial learning continues to be studied, but 
the involvement of cholinergic and glutamatergic neurotransmitter systems are 
well established (Hagan and Morris, 1987; McNamara and Skelton, 1993).  
Several studies have shown that NMDA receptor blockade impairs MWM 
performance (Davis et al., 1992; Hauben et al., 1999; McLamb et al., 1990; 
Morris et al., 1986; Upchurch and Wehner, 1990).  It has also been shown that 
acute treatment with an NMDA agonist (D-cycloserine) can improve spatial 
memory following lesioning of the hippocampus in rats (Schuster and Schmidt, 
1992).  The water maze has been used extensively in the study of neurotrauma 
because of the need for a treatment for the cognitive impairments reported after 
TBI in humans.  The MWM has been shown to be capable of testing for cognitive 
deficits in rodents following experimental trauma (Kraemer et al., 1996; Scheff et 
al., 1997; Smith et al., 1995; Yamaki et al., 1998).  The precise mechanisms 
leading to these deficits are unclear, but glutamatergic and cholinergic disruption 
has been demonstrated (Dixon et al., 1999). 
1.2.4 Acetylcholine receptors 
Acetylcholine is a major neurotransmitter in the mammalian nervous 
system where it acts on a diverse family of receptors.  Sir Henry Dale first 
discovered that there are 2 distinct subclasses of cholinergic receptors in 1914 
when he observed that crude extracts of Amanita muscarina (muscarine) or 
Nicotinana tabacum (nicotine) mimicked the effects of ‘esters of choline’ (now 
known as acetylcholine) in different tissues (Dale, 1914).  It is now known that 
the mAChRs are G-protein coupled receptors that function via activation of 
secondary messenger molecules, and nAChRs are ligand-gated ion channels 
permeable to sodium and calcium ions (Millar and Gotti, 2009). 
The mAChRs can be excitatory or inhibitory depending on the secondary 
messenger system that they are coupled with.  The M1, M3, and M5 subtypes 
activate phospholipase C via the Gαq protein (Guo and Schofield, 2003), which 
produces phosphatidylinositol trisphosphate (IP3) that leads to release of calcium 
from intracellular stores.  In contrast, the M2 and M4 subtypes inhibit adenylyl 
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cyclase via Gαi/o thereby giving ACh an inhibitory action (Caulfield and Birdsall, 
1998; Ishii and Kurachi, 2006).  Although mAChRs are more abundant in the 
brain and have been implicated in several neurological conditions, compared to 
nAChRs they are not as diverse in their subtypes and pharmacological 
properties. 
Relative to mAChRs, nAChRs elicit a fast response by directly facilitating 
the flow of cations across the plasma membrane, thereby leading to a rapid 
depolarization.  The first nAChR to be characterized was from the electric organ 
of the marine ray Torpedo.  The natural abundance of receptors in this species 
made it well suited to studies of nAChR structure and dynamics (Kosower, 1987; 
Mishina et al., 1984).  Since these early studies nAChRs have been found 
throughout the CNS as well as the PNS (Sargent, 1993).  Electron microscopic 
techniques have made it clear that nAChR subunits form pentamers around a 
central ion channel (Miyazawa et al., 1999).  However, the lack of 
crystallographic data has precluded the acquisition of more detailed atomic 
structures.  In the well studied NMJ the nicotinic receptor is composed of two α 
subunits (termed “α1”), a β subunit (termed “β1”), a δ subunit, and a γ or ε 
subunit (Green and Millar, 1995).  In contrast, the stoichiometry of neuronal 
nAChRs is still being elucidated.  Two subtypes of nAChR subunits have been 
identified in the CNS: alpha (α) subunits of which 9 are known (α2-α10), and beta 
(β) subunits of which 3 are known (β2-β4).  Although the number of subunit types 
presents the possibility of a huge array of nAChR compositions it appears that 
the assembly of nAChRs is tightly regulated and results in a limited number of 
channel types.  In general, nAChR subunits form heteromeric receptors made up 
of three alpha and two beta subunits (α(3) β(2)) (Anand et al., 1991; Boorman et 
al., 2000; Cooper et al., 1991), and are selectively permeable to sodium.  
Exceptions to the rule are the α7, α8, and α9 subunits, which are able to form 
functional homomeric receptors in vivo (Elgoyhen et al., 1994; Gerzanich et al., 
1994; Gotti et al., 1994).  The predominant nAChR compositions in the 
mammalian brain are thought to be α4β2 (Lindstrom et al., 1995; Papke et al., 
1989; Picciotto et al., 1998; Zoli et al., 1998), and the homomeric α7 receptor 
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(Chen and Patrick, 1997; Couturier et al., 1990; Orr-Urtreger et al., 1997).  Unlike 
other nAChRs, the α7 nAChR has been found to be much more permeable to 
calcium than sodium (Delbono et al., 1997; Sands et al., 1993).  This high 
permeability to calcium is intriguing because calcium is an important secondary 
messenger in the CNS, and plays a major role in excitotoxicity as discussed 
earlier. 
1.2.5 Evidence for cholinergic disruption following TBI 
It is now well established that the cholinergic system is significantly 
impaired following brain injury.  Impaired choline transport (Dixon et al., 1994a) 
and decreases in the activity of the ACh synthesizing enzyme choline 
acetyltransferase (ChAT) (Leonard et al., 1994), contribute to a widespread 
disruption of the cholinergic system.  Earlier receptor binding studies focused on 
the expression of mAChRs, and found variable effects of injury, including 
increased, decreased and unchanged expression in animal models of 
neurotrauma (DeAngelis et al., 1994; Jiang et al., 1994; Lyeth et al., 1994; Sihver 
et al., 2001).  A reduction in nAChR expression following brain injury could 
contribute to impaired cognitive ability in these animals (Verbois et al., 2002; 
Verbois et al., 2000).  Indeed, improvements in cognitive functioning have been 
correlated with increased levels of nAChRs (Kadir et al., 2006).  Further support 
for the role of nAChRs in cognition and cholinergic disruption in TBI comes from 
studies in our laboratory that have demonstrated a modest recovery of MWM 
performance in animals given chronic intermittent nicotine injections (Verbois et 
al., 2003a).  Interestingly, this nicotine treatment regimen did not attenuate the 
reduction in α7 nAChRs suggesting that the stimulation of the remaining 
receptors may be sufficient for cognitive enhancement. 
Further information on cholinergic disruption after injury comes from some 
interesting parallels between the pathophysiology of TBI patients and sufferers of 
chronic neurodegenerative diseases.  For instance, TBI has some parallels with 
schizophrenia, in that deficits in auditory and sensory gating are found in both 
schizophrenics (Adler et al., 1982; Braff and Geyer, 1990) and TBI patients 
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(Arciniegas et al., 1999; Arciniegas et al., 2000).  Furthermore, TBI patients with 
sensory gating deficits have shown improvement when administered an 
acetylcholinesterase (AChE) inhibitor (Arciniegas et al., 2000; Arciniegas et al., 
2002), implicating the involvement of AChRs.  The α7 nAChR is of special 
interest since decreased levels of the receptor in post-mortem brains may explain 
the lack of pre-pulse inhibition of sensory stimuli in schizophrenics compared to 
controls (Freedman et al., 1995).  This hypothesis is bolstered by studies that 
determined that the deficit in sensory gating in schizophrenics can be linked to a 
genetic mutation of the α7 nAChR gene (Freedman et al., 1997; Raux et al., 
2002).  Several studies have demonstrated a normalization of auditory gating in 
schizophrenics after nicotine administration (Adler et al., 1993; Adler et al., 
1992), as well as more general improvements (Myers et al., 2004; Smith et al., 
2002).  Furthermore, the rate of smoking is much higher amongst schizophrenics 
(around 80%) than in the general population (de Leon et al., 1995), raising the 
possibility that schizophrenics are self-medicating with nicotine to treat their 
symptoms.  It should also be noted that one of the treatments for schizophrenia 
is clozapine.  Clozapine is pharmacologically non-selective drug that acts on 
serotinergic, dopaminergic, and cholinergic receptors.  It is clozapines’ agonist 
activity on α7 nAChRs which is thought to normalize sensory gating in 
schizophrenics (Martin et al., 2004a). 
Another neurodegenerative condition with some similarities to TBI is AD, 
where those inflicted have a significantly impaired cholinergic system (Terry and 
Buccafusco, 2003).  Furthermore, TBI has been identified as a positive risk-factor 
for developing AD (Jellinger et al., 2001).  The decline of cholinergic activity is 
hypothesized to contribute significantly to the devastating cognitive deficits seen 
in AD patients.  A loss of α4β2 nAChRs has been well documented in AD (Perry 
et al., 2000; Schmaljohann et al., 2004; Wevers et al., 1999).  The role of the α7 
nAChR in AD is less clear, some studies have reported a modest increase (Chu 
et al., 2005; Counts et al., 2007; Dineley et al., 2001), and some a decrease 
(Wevers et al., 1999).  Studies in our laboratory have consistently found similar 
reductions in α7 nAChR binding following brain injury (Guseva et al., 2008; Kelso 
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et al., 2006; Verbois et al., 2002; Verbois et al., 2000), but only modest 
reductions in α4 nAChR binding (Verbois et al., 2002).  In addition, people with 
AD have a significant reduction in high affinity choline uptake sites (Rodriguez-
Puertas et al., 1994) and a reduction in ChAT activity (Waller et al., 1986).  
Current therapies seek to maintain cholinergic signaling by inhibiting AChE, and 
evidence gathered from rodent studies suggests that nAChR agonists may 
enhance cognition (Arendash et al., 1995a; Boess et al., 2007; Kem, 2000).  
Taken together these findings demonstrate a deficit in nAChR expression in both 
AD and TBI that could be liked to cognitive deficits. 
1.2.6 Agonists, antagonists and partial agonists of nAChRs 
The study of nAChRs has been significantly aided by the discovery and 
molecular characterization of selective pharmacological antagonists and 
agonists.  Since nicotinic cholinergic transmission regulates the NMJ and somatic 
nervous system a large number of predatory animals have evolved potent 
venoms that target the α1 nAChR.  One of the first of such toxins discovered was 
α-bungarotoxin (α-BTX) from the banded krait (Bungarus multicinctus) which is 
an irreversible antagonist at the NMJ nAChR (Changeux et al., 1970).  Shortly 
after, α-BTX was found to bind in brain fractions (Salvaterra and Moore, 1973), 
and autoradiographic characterization of its binding in the brain was carried out 
(Polz-Tejera et al., 1975).  Later the α7 nAChR was shown to be the site to which 
α-BTX binds in the CNS (Couturier et al., 1990).  In addition to snake venom, 
venoms from the many species of predatory cone snails are now of great interest 
and since they have been shown to contain an abundance of selective nAChR 
ligands (Cartier et al., 1996; Luo et al., 1998; Luo et al., 1999; McIntosh et al., 
1999; McIntosh et al., 1994; Terlau and Olivera, 2004).  While only a small 
proportion of these toxins have been purified and characterized their value and 
utility in studying the structure and function of specific nAChR subtypes is clear 
(Nicke et al., 2004).  It is not only animal venom derived toxins that are of interest 
with relation to nAChRs.  Aside from nicotine there is a range of plant alkaloids 
that act upon various nAChR subtypes, including curare, and methyllycaconitine 
(MLA, see appendix Figure 7.1).  MLA is an alkaloid isolated from the tall 
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larkspur (Delphinium brownii) and is responsible for numerous cattle poisonings 
in the American Midwest.  It causes paralysis in cattle by antagonizing the NMJ 
nAChRs (Pfister et al., 1999).  In addition to its NMJ effects MLA has been 
shown to be a potent and competitive antagonist at CNS α7 nAChRs (Macallan 
et al., 1988).  This property makes MLA a valuable tool for use in studying the 
function and localization of α7 nAChR subunits in the brain (Ward et al., 1990).  
Furthermore, unlike the large polypeptide chains of α-bungarotoxins and α-
conotoxins, MLA has some ability to cross the blood-brain barrier (BBB) in 
rodents (Navarro et al., 2002; Stegelmeier et al., 2003; Turek et al., 1995).  
Combined, these properties make MLA a potential therapeutic agent with which 
to inhibit the calcium-mediated effects of ACh in the CNS. 
In addition to full agonists and antagonists a range of nicotinic receptor 
partial agonists are available.  Similar to a full agonist, a partial agonist binds to 
and activates the target receptor. However, unlike a full agonist the partial 
agonist has limited efficacy, meaning that a smaller proportion of the target 
receptors are in an activated state when saturated with ligand.  For example, 
varenicline is a partial agonist of α4β2 nAChRs, and is now marketed as a tool 
for smoking cessation.  As a partial agonist it can alleviate the symptoms of 
nicotine cravings and withdrawal, while also inhibiting the effects of nicotine 
exposure.  α7-nAChR partial agonists  such as 3-2,4 dimethoxybenzylidene 
anabaseine (DMXB-A, code-name GTS-21), tropisetron and ondansetron (for 
molecular structures see appendix, Figure 7.1) have been tested, and continue to 
be tested for therapeutic value in conditions such as AD and schizophrenia 
(Freedman et al., 2008; Kem, 2000; Koike et al., 2005; Oliveira et al., 2008).  The 
utility of these α7 nAChR partial agonists in TBI remains to be determined.  
However, the potential for partial agonists to treat TBI has been demonstrated in 
a rat model, in which an NMDA partial agonist (D-cycloserine) or mAChR partial 
agonist (Lu 25-109-T) improved cognitive performance following injury (Pike and 
Hamm, 1997b; Temple and Hamm, 1996). 
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1.3 Specific aims and hypotheses 
Evidence to-date suggests that following TBI acute increases in ACh could 
contribute to excitotoxicity, and more long-term deficits in ACh may contribute to 
cognitive deficits and other neuropsychiatric aspects of recovery.  The α7 nAChR 
is of particular interest because it is widely expressed in the brain, is highly 
permeable to calcium (Fucile et al., 2003; Sands et al., 1993; Seguela et al., 
1993), and its expression is significantly affected by brain injury (Verbois et al., 
2002; Verbois et al., 2000).  Previous studies in our laboratory have shown that 
post-traumatic nicotine can attenuate cognitive deficits in rats (Verbois et al., 
2003a).  In a separate study chronic nicotine treatment reversed α7 nAChR 
binding deficits (Verbois et al., 2003b).  Furthermore, we have demonstrated that 
dietary supplementation with the selective agonist choline results in a modest 
degree of improvement in the MWM, spares cortical tissue, and reduces 
neuroinflammation in a rat model of TBI (Guseva et al., 2008). 
Since nicotine has numerous central and peripheral effects a more 
selective drug is needed to target the post-injury excitotoxic cascade and to treat 
long-term cognitive deficits.  Therefore, we hypothesize that administration of a 
selective antagonist immediately after injury will attenuate excitotoxicity and 
consequently lead to measurable improvements in cognition.  While attenuating 
the excitotoxic effects of ACh may be neuroprotective, it does not directly treat 
the long-term cognitive deficits frequently reported by TBI patients.  Another 
strategy might be to administer a partial agonist, thereby forgoing the efficacy of 
a full agonist or antagonist but eliminating some concerns over the timing of 
administration.  Administration of a competitive partial agonist immediately after 
injury may attenuate α7 nAChR activation, potentially reducing the excitotoxic 
effects of elevated acetylcholine levels.  Furthermore, administration of partial 
agonists beyond the initial period of increased cholinergic activity may still be 
therapeutic by improving cholinergic tone and thereby potentially improving 
cognitive outcomes. 
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In order to easily quantify the level of brain injury and make assessments 
of neuroprotective effects of experimental treatments it is important to have new, 
innovative tools.  Although tissue sparing is frequently used it is only relevant if 
the injury is severe enough to produce tissue loss, and animals must be 
euthanatized at a time point long enough to allow tissue encavitation.  To this 
end we propose the use of labeled PK11195 as a sensitive tool for assessment 
of brain damage.  Previous studies in both rodents and humans have 
demonstrated the ability of PK11195 to reveal subtle brain damage likely 
attributable to a microglial response (Banati et al., 1997; Chen and Guilarte, 
2006; Grossman et al., 2003; Pedersen et al., 2006; Roberts et al., 2009; Sitte et 
al., 2001; Vowinckel et al., 1997).  Therefore, we aim to develop this tool for easy 
assessment of brain inflammation that can be used to evaluate the 
pharmacological studies. 
With these aims in mind we hypothesize that the characterization of a 
post-CCI time-course of neuroinflammation will aid in the assessment of the 
efficacy of α7 nAChR antagonist and α7 nAChR partial agonist treatments 
following experimental rat brain injury.  Additionally, post-CCI treatment with a α7 
nAChR antagonist or α7 nAChR partial agonists will lead to a significant 
improvement in cellular and functional outcomes. 
This hypothesis will be tested by performing a series of experiments that 
will (1) characterize the time course of post-traumatic neuroinflammation; (2) 
assess the ability of an α7 nAChR antagonist to produce a neuroprotective effect 
and improve functional recovery; and (3) determine the therapeutic potential of 
α7 nAChR partial agonists in alleviating CCI-induced cognitive deficits and 
improving cellular outcomes. 
 
• Hypothesis #1 – PK11195 binding to TSPO can be used to detect 
differences in the timing and magnitude of microglial activation and 
macrophage infiltration following brain injury 
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• Specific Aim 1: Conduct a detailed time-course of [3H]-PK11195 
autoradiography in a CCI model of TBI and make assessments of the 
changes in binding that occur in multiple brain regions 
• Specific Aim 2: Compare the timing and magnitude of changes in [3H]-
PK11195 binding to a marker of activated microglia/macrophages and to a 
marker of neuronal death 
 
• Hypothesis #2 – Administration of the α7 nAChR antagonist MLA after 
experimental brain injury will spare cortical tissue, reduce neuroinflammation, 
and improve cognitive outcomes 
• Specific Aim 1: Evaluate cognitive performance in rats administered 
either MLA or saline following CCI 
• Specific Aim 2: Assess the neuroprotective effects of MLA by conducting 
a cortical tissue sparing analysis 
• Specific Aim 3: Determine the effect of MLA on post-CCI α7 nAChR 
binding and measure the magnitude of post-CCI neuroinflammation using 
[3H]-PK11195 autoradiography 
• Hypothesis #3: - Administration of a α7 nAChR partial agonist following 
brain injury will improve spatial learning in the MWM, spare cortical tissue 
and attenuate neuroinflammation 
• Specific Aim 1: Compare the post-CCI cognitive performance of rats 
treated with either tropisetron or saline 
• Specific Aim 2: Determine whether post-CCI tropisetron is 
neuroprotective, and resolve regional differences in neuroinflammation 
• Specific Aim 3: Assess the effect of tropisetron on CCI-induced α7 
nAChR binding deficits 
• Specific Aim 4: Evaluate two other α7 nAChR partial agonists as 
potential treatments for post-CCI cognitive impairments 
Copyright  Thomas M Woodcock 2009  
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2. CHAPTER 2 
 [3H]-PK11195 Autoradiography as a Tool to Assess TBI-Induced Brain 
Inflammation 
2.1 Introduction 
Over one and a half million people sustain a TBI every year in the United 
States alone, and the majority of these people will be left with motor and/or 
neuropsychiatric impairments that significantly affect sufferers’ quality of live.  
The majority of TBI cases are the result of motor vehicle accidents, yet while 
great advances have been made in automobile safety and accident prevention 
there has been no significant improvement in the pharmacological interventions 
available clinically for those that suffer a TBI.  The lack of drugs specifically 
tailored to TBI reflects the complexity and heterogeneity of the condition, and 
comes despite intensive research in the area.  Several promising candidate 
pharmacological strategies and lead compounds have all failed in human clinical 
trials for neuroprotection and functional recovery following TBI (Bolland et al., 
1998; Harders et al., 1996; Marmarou et al., 1999; Marshall et al., 1998; Morris et 
al., 1999; Muizelaar, 1994; Muizelaar et al., 1993; Stewart et al., 1999; Ward, 
1950). 
A large proportion of the research conducted in TBI to date has focused 
on the idea of excitotoxicity.  The primary insult causes shearing and tearing of 
axons and cell bodies that releases non-physiological amounts of the excitatory 
neurotransmitter glutamate.  Glutamate binds to and activates NMDA receptors, 
which are highly permeable to calcium; therefore, over-stimulation of these 
receptors will lead to calcium overload, mitochondrial dysfunction, free radical 
formation, endonuclease, protease, and phospholipase activation, culminating in 
neuronal cell death via apoptotic or necrotic mechanisms.  Thus blockade or 
inhibition of NMDA receptors could protect cells that survive the primary insult 
from an excitotoxic fate.  Unfortunately NMDA antagonists have lacked efficacy 
in human trials despite promising results in animal studies.  The failure of these 
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trials has prompted much discussion and speculation as to the possible reason 
for discrepancy between animal and human data (Albensi et al., 2004; Muir, 
2006).  One issue is the lack of a well defined time-course of cellular and 
molecular events that occur after TBI in animals and humans.  New markers of 
tissue damage could provide a better understanding of the pathogenesis of TBI, 
and help to define windows for possible therapeutic intervention. 
In recent years the role played by reactive gliosis has garnered increasing 
attention as inflammation is now though to play a significant role in many 
neurodegenerative conditions.  For example, the activation of brain-resident 
microglia has been implicated in the pathogenesis of AD (Eikelenboom et al., 
1994; Moore and O'Banion, 2002; Rogers, 1995), Parkinson’s disease (Gao et 
al., 2002; McGeer and McGeer, 2004), stroke (Denes et al., 2007; Wiart et al., 
2007), amyotrophic lateral sclerosis (ALS) (Almer et al., 2001; Weydt et al., 2002) 
and TBI (Adelson et al., 1998; Morganti-Kossman et al., 1997).  Activation of glial 
cells occurs as a graded response to insult, and is typically related to the degree 
of injury (Raivich et al., 1999).  Therefore, a selective and sensitive marker to 
facilitate the characterization of neuroinflammation in models of 
neurodegeneration and brain injury may be very useful. 
One promising candidate for such a marker is the peripheral 
benzodiazepine receptor (PBR).  As its name suggests, the PBR was initially 
found to be expressed in the peripheral tissues of the heart, liver, adrenal gland, 
testis, lymphatic cells, and hemopoietic cells (reviewed in Woods and Williams, 
1996).  Subsequent studies however, demonstrated that the brain (primarily 
olfactory bulb) also expresses PBRs (Benavides et al., 1984; Marangos et al., 
1982; Schoemaker et al., 1983), eventually leading to a change of nomenclature 
to the translocator protein 18kDa (TSPO) (Papadopoulos et al., 2006a).  The 
potential for the TSPO as a marker of inflammation is demonstrated by marked 
increases in expression following CNS damage.  Increased TSPO expression 
has been reported following chemical-induced injury, such as trimethyltin 
(Guilarte et al., 1995; Kuhlmann and Guilarte, 2000), domoic acid (Kuhlmann and 
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Guilarte, 1997), and MPTP (Kuhlmann and Guilarte, 1999).  Increases are also 
seen in ischemic stroke models (Stephenson et al., 1995) and patients (Gerhard 
et al., 2000; Gerhard et al., 2005; Pappata et al., 2000).  Other studies have 
demonstrated increases in TSPO expression in neurodegenerative disease 
(Cagnin et al., 2001; Gerhard et al., 2003; Versijpt et al., 2003), and brain trauma 
(Miyazawa et al., 1995; Raghavendra Rao et al., 2000).  Changes in the levels of 
TSPO expression are therefore thought to reflect the progression of 
neuroinflammation. 
A growing body of evidence suggests that the TSPO is localized primarily 
on the outer mitochondrial membrane (Anholt et al., 1986; Antkiewicz-Michaluk et 
al., 1988; Bribes et al., 2004; Garnier et al., 1994).  However, early evidence of 
TSPO expression on erythrocytes (Olson et al., 1988), which lack mitochondria, 
and studies in other tissues (O'Beirne et al., 1990; Woods and Williams, 1996) 
suggest a possible plasma-membrane population of TSPO.  In addition, some 
evidence exists for nuclear localization of TSPOs in glial cells (Kuhlmann and 
Guilarte, 2000).  Several different functions have been attributed to the TSPO 
such as porphyrin transport (O'Hara et al., 2002; Taketani et al., 1994), 
explaining the mitochondrial localization (porphyrin is needed for hemoglobin 
synthesis in mitochondria).  Other functions suggested include cholesterol 
transport and regulation of steroid synthesis (Costa et al., 1994; Jamin et al., 
2005; Lacapere and Papadopoulos, 2003; Li et al., 2001; Papadopoulos et al., 
2006b), regulation of apoptosis (Maaser et al., 2001) or proliferation (Galiegue et 
al., 2004), and others (Faure et al., 2003; Gavish et al., 1999; Lacapere and 
Papadopoulos, 2003; Larcher et al., 1989; Ostuni et al., 2004; Torres et al., 2000; 
Veenman and Gavish, 2006). 
The most widely used radioligand for tissue localization  of the TSPO is 
the isoquinoline carboxamide PK11195, possibly because of its high affinity for 
the TSPO (Le Fur et al., 1983) in animals and humans (Casellas et al., 2002).  
PK11195 has already been used to image inflammation in a number of brain 
inflammatory disorders including ischemia (Dubois et al., 1988), encephalitis 
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(Vowinckel et al., 1997), thiamin deficiency (Leong et al., 1994), and closed head 
injury (Raghavendra Rao et al., 2000).  Using [3H]-PK11195 autoradiography it is 
possible to track the evolution of brain damage over time in multiple brain 
regions.  In injured animals significant increases in [3H]-PK11195 binding have 
been observed in the ipsilateral cortex, hippocampus and thalamus (Grossman et 
al., 2003; Raghavendra Rao et al., 2000).  These increases are thought to reflect 
the activation of brain-resident microglia or the presence of infiltrating peripheral 
macrophages.  Comparisons of PK11195 with markers of microglia and 
macrophages support this idea, but until now the time-course of changes in [3H]-
PK11195 binding have not been carefully evaluated in a well-controlled animal 
model of TBI.  Therefore, the purpose of the present study is to establish the time 
course of microglial infiltration into rat brain regions following a cortical contusion 
injury. 
2.2 Materials and methods 
2.2.1 Animals and surgery 
All experiments were conducted in accordance with the guidelines of the 
University of Kentucky Institutional Animal Care and Use Committee (IACUC) 
that follows the guidelines set forth by the National Institutes of Health guide for 
the care and use of laboratory animals.  Experiments were designed to minimize 
animal suffering and the number of animals required for the study.  For all 
experiments, male Sprague-Dawley rats weighing 275-300 g housed 3 per cage 
were obtained from Harlan Breeding Laboratories (Indianapolis, IN) and 
randomly assigned into treatment groups.  Surgical manipulations were carried 
out as previously described (Verbois et al., 2003a; Verbois et al., 2002, 2003b; 
Verbois et al., 2000).  Briefly, animals were anaesthetized with 3% isoflorane and 
immobilized in a stereotaxic frame.  A 6 mm craniotomy was performed using a 
Michele trephine just above the somatosensory cortex (Bregma –2.8, 2.5 mm 
lateral) and an electronically controlled piston (5 mm diameter) was used to 
administer a 1.5 mm cortical deformation at a velocity of 3.5 m/s.  Following the 
injury the skull disc was replaced and sealed with dental acrylic.  
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2.2.2 [3H]-PK11195 autoradiography 
Animals were euthanatized 30 minutes, 12 hours, 2, 4 or 6 days following 
trauma and the brains immediately removed and frozen in isopentane.  Brain 
sections (16 µm) were prepared using a Lecia CM1850 cryostat and were 
mounted onto Super-Frost Plus™ slides (Fisher Scientific, Pittsburgh, PA).  The 
slides were stored at -80°C until radioligand binding studies could be carried out.  
Neuroinflammation was assessed by [3H]-PK11195 autoradiography on a set of 
slides from each animal.  For [3H]-PK11195 autoradiography, slides were 
warmed to room temperature and pre-incubated in buffer for 15 minutes, then 
transferred to fresh buffer containing 1 nM [3H]-PK11195 for 2 hours, then 
washed in buffer, and dried overnight.  The slides were exposed to RayMax Beta 
High Performance Autoradiography Film (ICN Biomedicals Inc., Aurora, OH) to 
visualize the areas of ligand binding.  Radioactive rat brain tissue standards were 
included with each film X-ray cassette in order to determine the response of the 
film to different amounts of radioactivity.  A Northern Lights illuminator with a 
digital camera (a CFW-1310M, Scion Corp) was used to capture images that 
were analyzed with ImageJ (v1.39) on an iMac.  Molar quantities of bound ligand 
were determined by constructing a standard curve from radioactivity tissue 
standards fitted to an exponential curve.  To test the specificity of [3H]-PK11195 
binding a parallel binding assay was carried out in the presence of a saturating 
amount of unlabelled Ro5-4864, which also has high affinity for binding to the 
TSPO.  Inclusion of an excess amount of Ro5-4864 reduced [3H]-PK11195 
binding to control levels, indicating that these ligands are competing for the same 
binding sites (data not shown).  Changes in [3H]-PK11195 binding following CCI 
were quantified in several regions of the cortex, hippocampus and thalamus.  
Binding density was measured in both the ipsilateral and contralateral cortex to 
give an indication of the inflammatory response in tissue directly affected by the 
impact.  This was achieved by outlining the cortex from its dorsal side, ventral to 
the entorhinal rhinal fissure.  In the hippocampus [3H]-PK11195 was measured in 
the CA1 and CA2/3 fields, the hilus, the lateral blade of the dentate gyrus, and 
the ventral blade of the dentate gyrus.  In addition to the cortex and 
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hippocampus, thalamic nuclei have numerous projections into the cerebral cortex 
(Castro-Alamancos and Connors, 1997), which could be affected by CCI. 
Therefore, binding was assessed in the lateral dorsal (LD) thalamus, and the 
ventral posterolateral (VPL) thalamic areas. 
2.2.3 Cortical tissue sparing analysis 
Tissue sparing analysis was carried out in each of the animals to follow 
the progression of tissue encavitation at each time point and to facilitate 
comparisons with binding data.  Analysis of the amount of tissue lost following 
injury was carried out as previously described (Scheff and Sullivan, 1999).  To 
summarize, 8 Cresyl violet stained sections from each animal were included in 
the analysis, each evenly spaced throughout the lesion site.  For each section 
the area of the ipsilateral cortex and contralateral cortex was measured 
separately.  The average area of each side of the cortex was calculated and by 
dividing the ipsilateral area by the contralateral area, then multiplying by 100, a 
percentage of cortical tissue remaining is produced. 
2.2.4 Fluoro-Jade B staining 
Fluoro-Jade B (FJ-B) staining was used to assess neuronal degeneration 
following CCI.  Fluoro-Jade (A) is an anionic fluorochrome that was first 
described in 1997 as sensitive marker for neuronal degeneration (Schmued et 
al., 1997).  In this study we utilized FJ-B; a related compound with higher 
specificity (Schmued and Hopkins, 2000a).  Dying and dysfunctional cells were 
visualized by FJ-B staining as described previously (Anderson et al., 2005).  
Briefly, fresh-frozen sections mounted on Super-Frost Plus™ slides (Fisher 
Scientific, Pittsburgh, PA) were post-fixed in 4% paraformaldehyde for 10 
minutes and washed in water prior to immersing in a solution of 1% sodium 
hydroxide in 80% ethanol for 5 minutes.  Slides were then hydrated in a series of 
ethanol washes and placed in a solution of 0.06% potassium permanganate for 
10 minutes.  Next, slides were rinsed in distilled water for 2 minutes and 
incubated in a 0.0004% solution of FJ-B (Histo-Chem Inc., Jefferson, AR) for 20 
minutes.  Lastly, the sections were then rinsed in distilled water, air-dried and 
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cover slipped.  FJ-B-positive neurons were visualized using an Olympus BX-51 
microscope with a fluorescein isothiocyanate (FITC) filter cube.  Individual 
stained cells were manually counted throughout specific regions of interest in 6 
equally spaced sections.  Regions of interest were the cerebral cortex (Bregma -
2.5 mm to Bregma -4.5 mm), the dentate gyrus (dorsal and ventral blades 
individually), the CA1 and CA2/3 fields of the hippocampus, the hilus, and the LD 
thalamus (Bregma -3.0 mm to Bregma -3.8 mm). 
2.2.5 Immunohistochemistry 
Immunohistochemistry for activated microglia and macrophages was 
carried out with a monoclonal mouse anti-rat CD68 [ED-1] antibody (Abcam, 
Cambridge, MA).  CD68 is a transmembrane protein expressed on macrophages 
and activated microglia, which is thought to be involved in cellular phagocytosis 
(Holness and Simmons, 1993).  Fresh-frozen tissue sections mounted on slides 
were post-fixed by immersion in 4% paraformaldehyde for 10 minutes.  Sections 
were washed in phosphate-buffered saline (PBS) containing 0.1% Triton-X and 
blocked in the same solution containing 3% normal horse serum for 1 hour.  
Endogenous peroxidases were quenched by incubating sections is PBS 
containing 0.3% hydrogen peroxide.  Next, the ED-1 antibody was diluted 1:100 
in blocking solution, applied to sections in a humidified chamber and incubated 
overnight at 4˚C.  Sections were then washed in PBS and incubated with 
biotinylated horse anti-mouse IgG (Vector Labs, Burlingame, CA) for 60 minutes.  
Following further washing, the secondary antibodies were detected using a 
Vector Avidin: Biotinylated enzyme Complex (ABC) Elite kit (Vector Labs, CA), 
and visualized by the addition of Nickel and Cobalt enhanced 
3,3'-Diaminobenzidine (DAB).  Finally, the sections were dehydrated and 
coverslipped prior to analysis.  ED-1 stained cells were counted in the same 
regions as FJ-B positive cells so that direct comparisons could be made. 
2.2.6 Statistics 
[3H]-PK11195 binding was measured in 6 equally-spaced sections for 
each region of interest and an average value was calculated.  Data from each 
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animal was analyzed by a 2-way analysis of variance (ANOVA) in which time-
point and hemisphere were independent variables, and the [3H]-PK11195 binding 
density was the dependant variable.  Individual group comparisons were 
assessed by carrying out a Tukey’s honestly significant difference (HSD) post-
hoc test. 
Tissue sparing analysis was analyzed with a one-way ANOVA, with time-
point as the independent variable and tissue sparing as the dependant variable.  
Group comparisons were analyzed using the Tukey’s HSD post-hoc test. 
For FJ-B staining and CD68 immunohistochemistry cells were counted 
within a defined region of interest in 6 equally spaced sections.  The cell count 
was averaged for each animal and data were analyzed using a Kruskal-Wallis 
test with time-point as the independent variable and number of cell profiles as the 
dependent variable.  Dunn’s multiple comparisons were used as the post-hoc 
test to address individual group differences.  All statistical analyses were carried 
out using GraphPad Prism (GraphPad Software Inc, La Jolla, CA). 
2.3 Results 
2.3.1 [3H]-PK11195 binding is a sensitive marker of tissue damage 
In the cortex increases in [3H]-PK11195 binding were visible after 2 days 
but only became significant 4 days after injury (Figure 2-1).  Data were analyzed 
by 2-way ANOVA, which indicated a significant effect of day (F(5,32) = 4.83, p < 
0.005) and hemisphere (F(1,32) = 14.1, p < 0.001), with a significant interaction 
(F(5,32) = 3.83, p < 0.01).  Interestingly [3H]-PK11195 binding appears to be 
elevated throughout the entire dorsal-ventral span of the cerebral cortex (Figure 
2-3). 
In the hippocampus increased [3H]-PK11195 binding is initially limited to 
the ipsilateral dentate gyrus 12 hours after injury, and by 24 hours is increased in 
other regions of the hippocampus (Figure 2-2).  In the dentate gyrus, CA1, 
CA2/3, and hilus a 2-way ANOVA revealed a significant effect of time-point 
(F(5,32) = 33.3, p < 0.001; F(5,32) = 23.9, p < 0.001; F(5,32) = 36.5, p < 0.001; F(5, 32) = 
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Figure 2-1 - The time-course of [3H]-PK11195 binding in the rat cerebral 
cortex following a 1.5 mm CCI 
In the ipsilateral cerebral cortex, increases in TSPO expression following injury 
began 2 days after injury and reached significance by the fourth day.  Mean 
binding densities +/- standard deviation are plotted for ipsilateral and 
contralateral regions of the cortex (n = 4).  Asterisks denote significant 
differences from binding in the contralateral hemisphere as found by Tukey’s 
HSD (*p < 0.05, **p < 0.01). 
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Figure 2-2 - [3H]-PK11195 binding in regions of the rat hippocampus 
following a 1.5 mm CCI 
Changes in [3H]-PK11195 binding were seen starting at 12 hours in some 
hippocampal regions, but significant increases were not found until 2 days after 
injury in this study.  Binding densities were measured in each of the dentate 
gyrus, CA1 field, CA2/3 field, and in the hilus at selected time-points following 
CCI (n = 4).  Data presented are for ipsilateral and contralateral areas and are 
mean binding densities +/- standard deviation.  Asterisks denote significant 
differences from binding in the contralateral hemisphere (**p < 0.01). 
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26.5, p < 0.001 respectively), hemisphere (F(1,32) = 82.2, p < 0.001; F(1,32) = 47.4, 
p < 0.001; F(1,32) = 128, p < 0.001; F(1, 32) = 96.3, p < 0.001 respectively), and a 
significant interaction term (F(5,32) = 12.7, p < 0.001; F(5,32) = 13.3, p < 0.001; F(5,32) 
= 29.7, p < 0.001; F(5, 32) = 15.2, p < 0.001 respectively).  Tukey’s HSD test was 
used for individual group comparisons.  In the dentate gyrus, CA2/3 field and 
hilus binding was significantly elevated in the ipsilateral hemisphere on day 2, 4, 
and 6 (p < 0.01), and in the CA1 field significantly increased binding was 
revealed on days 4 and 6 (p < 0.01). 
Interestingly, data for the contralateral dentate gyrus seemed to show an 
increase in binding at later time points.  When the contralateral dentate gyrus 
data was analyzed by one-way ANOVA a significant effect of time post-CCI was 
found (F(5,16) = 3.91, p < 0.05).  A small increase can be seen after 4 days (Figure 
2-3), and Tukey’s HSD post-hoc revealed a significant elevation 6 days after 
injury when compared to levels measured immediately after injury (p < 0.05). 
In addition to the cortex and hippocampus, localized increases in binding 
density were observed in the thalamus (Figure 2-4).  The thalamus is 3.5 mm 
distal from the surface of the impacted cortex (Paxinos and Watson, 1998).  
Despite this, significant increases in binding were seen in the ipsilateral side 
versus contralateral following a 1.5 mm CCI in the LD thalamus (F(5,32) = 38.4, p < 
0.001), and in the VPL thalamus (F(5,32) = 43.5, p < 0.001).  
Tukey’s HSD multiple comparisons were performed to reveal significant 
increases in binding to ipsilateral regions of the thalamus versus contralateral 
beginning 2 days after injury.  At 4 and 6 day time-points [3H]-PK11195 binding 
continued to increase in both thalamic regions (Figure 2-4, 2-5). 
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Figure 2-3 - [3H]-PK11195 binding in the contralateral dentate gyrus 
In the contralateral dentate gyrus, increases in [3H]-PK11195 binding were 
found versus ipsilateral measurements that became significant 6 days after 
CCI (*p < 0.05).  This could represent a delayed damage to this region, 
possibly mediated by disruption of commissural fibers connecting the two 
hemispheres.  Data plotted are means +/- standard deviations (n = 4). 
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Figure 2-4 - [3H]-PK11195 binding in the lateral-dorsal and ventral-
posterolateral thalamus at selected time-points after CCI 
Increases in [3H]-PK11195 binding in the thalamus began at 2 days after injury 
and steadily increased at 4 and 6 days (n = 4).  These data for the LD and VPL 
thalamus were analyzed by two-way ANOVA, and individual comparisons were 
made using Tukey’s HSD.  Significant increases in binding were found between 
hemispheres in both regions at 2, 4, and 6 day time-points (**p < 0.01). 
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Figure 2-5 - Im
ages of coronal brain sections representative of [ 3H
]-PK
11195 binding at each tim
e-point post-C
C
I 
This figure show
s the tim
e-course of increases in binding follow
ing a 1.5 m
m
 C
C
I.  N
ote the early increases in the dentate 
gyrus at 12 hours, and the increases in the thalam
ic regions at 4 and 6 days post-injury. 
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2.3.2 Cortical tissue loss following CCI 
There was no apparent tissue loss on days 1 to 4 post-CCI, and an 83% 
tissue sparing observed 6 days after injury (Figure 2-6).  The data were analyzed 
by one-way ANOVA, which demonstrated an overall effect of time post-CCI on 
cortical tissue loss (F(17,5) = 7.15, p < 0.001).  Subsequent Tukey’s HSD post-hoc 
tests revealed a significant loss of tissue at day 6 post-CCI compared to other 
time-points (p < 0.05). 
2.3.3 Increases in FJ-B positive cells occur early after CCI 
Numerous FJ-B positive cells were observed throughout the ipsilateral 
cortex at 12 hours and 24 hours after injury.  The majority of these cells are 
clustered around the impact site (Figure 2-13).  By 2 days there were fewer dying 
cells, and FJ-B positive cells continued to decrease in number through day 6 
(Figure 2-7).  This is in direct contrast to [3H]-PK11195 binding density, which 
only begins to increase at 2 days and is significantly elevated versus control at 4 
and 6 days post-CCI. 
Cell count data were analyzed using a Kruskal-Wallis test, which reported 
a significant effect of time-point on the number of FJ-B-positive cells (H = 17.64, 
df = 5, p = 0.0034, N = 30).  Comparisons of each group to the 30 minute control 
group were made with a Dunn’s multiple comparisons test.  Significant increases 
in FJ-B positive cells were found in the 12 hour and 1 day time-point groups (p < 
0.01, p < 0.05 respectively). 
In the hippocampus FJ-B positive neurons were first observed at the 12 
hour time-point, and were also most numerous at this time-point (Figure 2-8).  In 
the dentate gyrus a Kruskal-Wallis test determined that the group means did not 
significantly differ.  However, a Dunn’s multiple comparison found significant 
increases in FJ-B-positive cells at 12 hours, 1 day and 2 days.  In the CA1, 
CA2/3 and hilus there was a significant effect of time-point on the number of FJ-B 
positive cells ([H = 11.77, df = 5, p = 0.0381, N = 30], [H = 14.75, df = 5, p = 
0.0115, N = 30], [H = 13.22, df = 5, p = 0.0214, N = 30] respectively).  For each 
region Dunn’s multiple comparisons were made between the 30 minute time-
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Figure 2-6 - Tissue sparing analysis performed at various time-points after 
a 1.5 mm CCI in the rat 
There was no apparent tissue loss at time-points up to 4 days post-CCI, but an 
83% tissue sparing was found on day 6 post-CCI.  Data were analyzed by one-
way ANOVA with Tukey’s HSD post-hoc (*p < 0.05).  Data plotted are means 
plus or minus standard deviation (n = 4). 
 44 
 
 
Figure 2-7 - The time-course of FJ-B positive cells in the cerebral cortex 
following CCI in the rat 
FJ-B cells were abundant in the cortex at 12 hours post-CCI, with fewer 
positively stained cells counted in the region at subsequent time points.  Data 
for the ipsilateral cortex were analyzed by Kruskal-Wallis test, and Dunn’s 
multiple comparison was used to determine significant differences from the 30 
minute post-CCI group (asterisks denote a significant difference versus 30 
minute time-point [*p < 0.05, **p < 0.01]).  Data are plotted as means plus or 
minus standard deviation (n = 4). 
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Figure 2-8 - Time-course of FJ-B staining in the hippocampus following 
CCI 
FJ-B positive cells were counted in the dentate gyrus, CA1 field, CA2/3 fields 
and the hilus following CCI.  Data are plotted as means plus or minus standard 
deviation (n = 4).  Asterisks denote a significant difference from the 30 minute 
group as determined with a Dunn’s multiple comparisons test (p < 0.05). 
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point and each of the other groups.  In the CA2/3 fields and in the hilus significant 
numbers of FJ-B positive cells were found up to 24 hours after injury (p < 0.05).  
Interestingly, in the medial portion of the CA1 field of the hippocampus at the 12 
hour time point a small but significant (p < 0.05) number of FJ-B cells were seen. 
In the LD thalamus a Kruskal-Wallis test found a significant effect of time 
on the numbers of FJ-B positive cell profiles (H = 18.81, df = 5, p = 0.0021, N = 
30).  Significant numbers of FJ-B positive cell profiles were not quantified until 4 
days after injury, and significant numbers remained at the 6 day time-point 
(Figure 2-9, and Figure 2-14). 
2.3.4 The time-course of changes in CD68 positive cells following trauma 
The spatial and temporal pattern of CD68 positive microglia and 
macrophages was used to make comparisons to [3H]-PK11195 autoradiographs 
from adjacent brain sections.  CD68 positive cells were found in all regions where 
[3H]-PK11195 binding was elevated.  In the ipsilateral cortex CD68 positive cell 
profiles were observed in small numbers in the areas surrounding the contusion 
starting at 12 hours, and were present in large numbers by 4 days post-injury 
(Figure 2-10, and Figure 2-13).  A Kruskal-Wallis test revealed significant group 
differences (H = 17.61, df = 5, p = 0.0035, N = 30), and a Dunn’s post-hoc test 
showed that the numbers of CD68 positive cell profiles per section were 
significantly more in the 4 and 6 day post-CCI groups versus the 30 minute post-
CCI group (p < 0.005, and p < 0.05 respectively). 
In the dentate gyrus, hilus, and CA2/3 fields of the hippocampus CD68 
stained cell profiles were seen beginning at 12 hours post-CCI and were 
widespread and numerous by 1 day after injury (Figure 2-11).  Large amounts of 
staining persisted in these areas at all subsequent time points.  A Kruskal-Wallis 
test carried out on these data did not find any significant differences ([H = 7.531, 
df = 5, p = 0.1840, N = 30], [H = 9.079, df = 5, p = 0.1060, N = 30], and H = 
8.754, df = 5, p = 0.1193, N = 30, respectively.  The CA1 was unique in that only 
a few CD68 positive cell profiles were found in the region beginning at 1, 2 and 4 
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Figure 2-9 – FJ-B positive cell profiles in the lateral dorsal thalamus 
following CCI 
Very few FJ-B positive cells were seen in the thalamus up to 2 days after injury, 
but statistically significant numbers were observed in the region at 4 and 6 day 
time-points (Dunn’s multiple comparisons, *p < 0.05, **p < 0.01).  Data are 
plotted as means plus or minus standard deviation (n = 4). 
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Figure 2-10 - CD68 immunohistochemistry for activated macrophages in 
the cortex following CCI 
Activated macrophages and microglia were stained using ED-1 antibodies 
against the marker CD68.  Positively stained cell profiles were counted in the 
ipsilateral cortex and data are presented as means for each time-point plus or 
minus standard deviation (n = 4).  A significant increase versus data from the 
30 minute post-CCI group is denoted by an asterisk (p < 0.01). 
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Figure 2-11 - The time-course of CD68 positive cells in hippocampal 
regions following CCI 
CD68 positive cells were not seen in any hippocampal region 30 minutes after 
injury.  In the CA1 field a small number of cells were found at 1, 2 and 4 days 
post injury, but there was no significant effect.  In other regions CD68 positive 
cells were present from 12 hours and up to the 6 day time-point.  Data are 
plotted as means plus or minus standard deviation (n = 4). 
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days post-injury, and at no point was there a significant effect of time-point (H = 
7.760, df = 5, p = 0.1700, N = 30). 
The LD thalamus contrasts the cortex and hippocampus in that changes in 
the numbers of CD68+ cell profiles do not seem to mirror changes in [3H]-
PK11195 binding density.  Analysis of [3H]-PK11195 autoradiographs showed 
significant increases in binding density beginning at 2 days (Figure 2-4).  In 
comparison, very few CD68+ cells were observed in the LD thalamus at any time 
point (Figures 2-12), and although there appears to be a trend to increased 
numbers between 2 and 6 days post-injury, these changes were small and not 
significant (H = 5.731, df = 5, p = 0.3332, N = 30). 
2.3.5 Numbers of CD68+ cell profiles correlate with [3H]-PK11195 binding 
The amount of [3H]-PK11195 binding, CD68 staining, and FJ-B staining 
vary widely with time in the cortex.  As the largest area, and as the area most 
affected by the contusion, data for this region were the most robust and therefore 
used for correlation analysis (Figures 2-1, 2-7, 2-10).  Therefore, all three of 
these assessments were carried out in the same area of the cortex in each 
animal and correlations of CD68 and FJ-B were made to [3H]-PK11195 binding 
density (Figure 2-15).  Analysis of the data using a Spearman’s test revealed a 
moderate positive correlation between [3H]-PK11195 binding density and CD68 
staining, (r = 0.687 (19), p(two-tailed) = 0.0012).  In contrast there was a negative 
correlation between [3H]-PK11195 binding and FJ-B staining, (r = -0.4357 (21), 
p(two-tailed) = 0.0483). 
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Figure 2-12 - CD68 positive cells in the thalamus at selected time-points 
after CCI 
Very few cells stained positive for CD68 in the thalamus at any time-point 
following CCI.  A Kruskal-Wallis test did not report a significant effect of time on 
CD68 cell count, and no significant differences were found between any time-
point.  Data are plotted as means plus or minus standard deviation (n = 4). 
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Figure 2-13 - R
epresentative im
ages of FJ-B
 and C
D
68 staining in cortex follow
ing C
C
I 
N
o FJ-B
 or C
D
68
+ cell profiles w
ere seen in any anim
als at the 30 m
inute tim
e-point.  By 12 hours FJ-B
 staining w
as 
w
idespread in the cortex, w
hile relatively few
 C
D
68 cell profiles w
ere counted.  Four days after the injury the num
ber of 
FJ-B
 cell profiles had reduced significantly from
 their peak at 12 hours, w
hile the num
ber of C
D
68 positive cell profiles 
had increased significantly. 
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Figure 2-14 – FJ-B
 and C
D
68 staining in the hippocam
pus and thalam
us follow
ing C
C
I 
In the hippocam
pus at 4 days FJ-B
 staining w
as prim
arily seen in the dentate gyrus and hilus, w
hich corresponded w
ith 
increased num
bers of C
D
68 positive cells found In that region at the sam
e tim
e-point.  In the thalam
us at 6 days, very 
significant num
bers of FJ- B
 positive cells w
ere found, but interestingly very few
 C
D
68 positive cells w
ere present 
dem
onstrating difference in the pattern of TSP
O
 expression and C
D
68 expression in this brain region. 
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Figure 2-15 - Correlation of FJ-B and CD68 positive cell counts to [3H]-
PK11195 binding data 
There is a moderate positive correlation of CD68 cell counts with PK11195 
binding data.  Data for FJ-B and CD68 staining were plotted against PK11195 
binding data and a Spearman’s correlation coefficient was calculated (r = 0.687). 
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2.4 Discussion 
A thorough evaluation of the time-course of molecular and cellular events 
following TBI is essential to support the ongoing efforts to develop efficacious 
treatments for this condition.  The vast differences between laboratory animal 
and human brains in terms of size, organization, and complexity require that 
detailed assessments be made in both animal and human brain injury.  PK11195 
is a molecule of particular interest for this task because it has been utilized 
successfully to make assessments of inflammation in human patients as well as 
in post-mortem studies in laboratory animals (Chen and Guilarte, 2008).  
PK11195 can be used as a sensitive marker to assess and track inflammation in 
neurodegenerative conditions including TBI.  Correlations to cell specific markers 
(Raghavendra Rao et al., 2000; Venneti et al., 2008a; Vowinckel et al., 1997), 
and co-localization studies (Myers et al., 1991a; Venneti et al., 2007a), support a 
binding site in activated microglia and/or macrophages.  Furthermore, 
radiolabelled PK11195 has been successfully used to visualize inflammation in 
positron emission tomography (PET) studies (Bartels and Leenders, 2007; 
Gerhard et al., 2006; Venneti et al., 2008a; Vowinckel et al., 1997).  In rodent 
brain injury models, sham-operated animals show the expected pattern of [3H]-
PK11195 binding, i.e. binding is largely restricted to the choroid plexus, 
ependymal cells lining the ventricles, and olfactory bulb (Raghavendra Rao et al., 
2000).  Previous studies that used PK11195 to visualize neuroinflammation 
following TBI found significant increases in PK11195 binding sites in the 
hippocampus and thalamus at 3 and 14 days post-injury (Raghavendra Rao et 
al., 2000), and a co-localization of PK11195 binding sites with CD68-positive 
cells (Venneti et al., 2007a).  Furthermore, previously published data from other 
groups have demonstrated that increases in [3H]-PK11195 binding following 
brain injury are not due to a change in receptor affinity (Pedersen et al., 2006; 
Raghavendra Rao et al., 2000).  At all time points assessed, TBI had no effect on 
Kd values in either the ipsilateral or contralateral brain regions.  This study builds 
on previous research from other laboratories by providing a detailed assessment 
of [3H]-PK11195 binding in multiple brain regions following CCI. 
 56 
 
There is a clear difference between individual brain regions with respect to 
the time-course of [3H]-PK11195 binding following injury.  As expected, in sham-
operated animals [3H]-PK11195 binding was very low with the expression only 
detected in the choroid plexus lining the ventricles.  In the cortex relatively 
modest increases were found at 4 and 6 days post-injury.  While it was not 
possible to quantify binding in discrete regions of the cortex due to the nature of 
the injury, visual assessment of the autoradiographs (Figure 2-5) reveals that the 
highest densities are found surrounding the lesion.  An additional observation 
was that at 2, 4, and 6 days post-injury [3H]-PK11195 binding was elevated 
throughout the ipsilateral cortex.  This could represent the disruption of neuronal 
networks associated with the lesioned portion of the cortex.   
The most obvious increase in [3H]-PK11195 binding density began in the 
dentate gyrus at just 12 hours after injury, and reached significance at 2 days.  
Binding increases in this region occurred before any significant increases were 
measured in other brain regions, including the contused cortex.  In a previous 
study in our laboratory we were able to detect a significant increase in [3H]-
PK11195 binding in the dentate gyrus just 6 hours after injury (Figure 2-16).  The 
sensitivity of the dentate gyrus to CCI is further highlighted by the detection of 
significant increases in [3H]-PK11195 binding in the contralateral dentate gyrus 6 
days after injury (Figure 2-3).  The sensitivity of cells in the region to injury has 
been reported previously (Baudry and Altar, 1991).  In that study, chemical 
lesioning of the entorhinal cortex resulted in a significant increase in [3H]-Ro5-
4864 (a TSPO ligand) binding to ipsilateral dentate gyrus homogenates (Deller et 
al., 1996).  One other interesting observation was a small but significant increase 
in binding to contralateral dentate gyrus homogenates 4 days after the lesion was 
induced.  The vulnerability of dentate gyrus cells could be due to excitotoxicity 
brought about by the release of glutamate as a result of injury to neurons in the 
entorhinal cortex that project into the hippocampus. 
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Figure 2-16 - [ 3H
]-PK
11195 binding follow
ing a 2 m
m
 C
C
I 
In the dentate gyrus of the hippocam
pus significant increases in [ 3H
]-P
K
11195 binding w
ere found just 6 hours after a 2.0 
m
m
 C
C
I.  M
axim
al [ 3H
]-P
K
11195 binding in all hippocam
pal regions occurred on day 7, and by day 21 w
as returning to 
sham
 levels.  S
ignificant differences from
 contralateral regions w
ere found by Tukey’s H
S
D
 (*p < 0.05, **p < 0.01, ***p < 
0.005).  D
ata plotted are m
eans +/- standard deviations (n = 8). 
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In the thalamus we found that binding of [3H]-PK11195 does not robustly 
increase until approximately 3 days after CCI, and increases through all 
subsequent time points examined.  Delayed microglial activation in the thalamus 
may represent retrograde cell death of thalamocortical neurons as a result of 
deafferentation in the projection region of the somatosensory cortex.  This finding 
fits well with previous studies from our laboratory that have shown a delayed loss 
of nicotinic receptor binding in the thalamus, starting at 21 days post injury 
(Verbois et al., 2002).  Further support for this mechanism as the basis of 
delayed microglial activation in the thalamus comes from studies in which lesions 
of the thalamus lead to a delayed loss of nicotinic binding in the cortex (Gioanni 
et al., 1999; Lavine et al., 1997).  In addition, we have collected data in a 
previous study which shows that 3 weeks after injury [3H]-PK11195 binding is 
returning to sham levels in all regions except for the thalamus (Figure 2-16, and 
2-17).  
The anionic fluorescein derivative FJ-B was utilized in brain sections 
adjacent to sections used for [3H]-PK11195 autoradiography to assess the 
numbers of degenerating neurons.  It has been shown that FJ-B staining 
correlates to a high degree with silver stains; a traditional marker of neuronal 
degeneration (Schmued and Hopkins, 2000a).  In this study the time-course of 
FJ-B staining in the post-CCI rat brain was found to be different to the time-
course of [3H]-PK11195 binding.  In the cortex a significant amount of FJ-B 
staining was seen at 12 hours after injury, but less at 24 hours and 2 days, and 
very little staining thereafter.  In contrast, [3H]-PK11195 binding begins increasing 
in the cortex at 2 days and peaks at 6 days. 
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Figure 2-17 - [ 3H
]-PK
11195 binding in the thalam
us follow
ing a 2 m
m
 C
C
I 
In the thalam
ic regions, C
C
I results in significant increases in [ 3H
]-P
K
11195 binding that persist for at least 21 days.  
U
nlike other regions m
easured, there w
as an increase in [ 3H
]-P
K
11195 binding betw
een 7 and 21 days post injury.  A
ll 
data are displayed as m
eans +/- standard deviation, w
ith significant differences from
 contralateral m
easurem
ents as 
found by Tukey.s H
S
D
 show
n by asterisks (*p < 0.05, **p < 0.01, ***p < 0.005).   
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In the hippocampus numerous FJ-B stained neurons were visible in the 
dentate gyrus, CA4 (hilus), and in the CA2/3 field at 12 hours after injury.  
Significant numbers of degenerating neurons persisted in the CA2/3 and CA4 
regions at the 1 day time-point and at later time points fewer were seen.  In 
comparison, a large number of FJ-B stained neurons remained visible in the 
dentate gyrus at 2, 4 and to a lesser extent 6 days after CCI.  A previous 
assessment of FJ-B staining in the hippocampus after CCI using stereological 
techniques made similar findings (Anderson et al., 2005).  In the dentate gyrus 
FJ-B staining was confined to the granule cell layer at all time-points.  The 
significant amount of neurons degenerating in this region for a prolonged length 
of time could significantly affect cognitive performance of these head injured 
animals.  In addition to the dentate gyrus, the CA1, CA2/3, and CA4 (hilus) fields 
of the hippocampus also contain areas of neuronal degeneration.  In the CA1 a 
small population of neurons in the medial portion of the field was stained at 12 
hours and to a lesser extent at later time points.  Then in the CA2/3 field of the 
hippocampus a large number of cells are stained starting just 12 hours with the 
highest numbers counted 24 hours after CCI.  It has been suggested that 
proportionately, the amount of dying neurons in this region of the hippocampus is 
greater than any other (Anderson et al., 2005). 
Finally, in the thalamus no significant numbers of FJ-B stained cells were 
seen until 4 and 6 days after CCI.  The presence of degenerating neurons in this 
region at these time points lends credence to the hypothesis that the increased 
[3H]-PK11195 binding is due to retrograde degeneration of thalamocortical 
projections.  More FJ-B cells were counted in the thalamus at 4 days than at 6 
days, although the difference was not significant.  In comparison, [3H]-PK11195 
binding increases begin on day 2 and increase at each subsequent time-point.  
There was a significant increase in [3H]-PK11195 binding between day 4 and 6 
when assessed by Tukey’s HSD (p < 0.01). 
In an effort to correlate CD68 staining with [3H]-PK11195 binding we 
quantified the numbers of CD68 positive cell profiles in different brain regions.  In 
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the cortex, as with [3H]-PK11195 binding data, significant increases in the 
numbers of CD68 positive cells were found at 4 and 6 days post injury.  
Interestingly, a larger number of CD68 positive cells were found on day 4 versus 
day 6 after CCI, this may represent a difference in the expression of each of 
these markers.  In the hippocampus the time points with the most CD68 staining 
appeared to be 1 and 2 days post injury.  However, staining persisted in all 
regions at 4 and 6 days, and overall there were no significant differences 
between time-points.  Interestingly the pattern of CD68 staining in the 
hippocampus seems to follow the pattern of FJ-B staining, in that an increase in 
FJ-B staining at one time-point is followed by an increase in CD68 staining at the 
subsequent time-point.  This observation was also made in the cortex, where 
large numbers of FJ-B staining at 12, 24 and 48 hours is followed by increased 
CD68 staining at 24 and 48 hours, and increasing till 4 days post-CCI.  Since the 
post-CCI cortex contained large numbers of CD68 positive cells and FJ-B 
positive neurons, [3H]-PK11195 binding was assessed in this area and correlated 
with these markers.  While there was no positive correlation of [3H]-PK11195 
binding with FJ-B staining, there was a moderate positive correlation with CD68 
staining (r = 0.69).  By squaring the r-value one can make a crude assessment of 
the amount of variation in [3H]-PK11195 binding that CD68 positive cells are 
responsible for, in this case ~48%.  It is likely that other changes in [3H]-PK11195 
binding can be explained by sub-phagocytic activation of microglia, as has 
already been suggested (Banati et al., 1997).  This fits with our assessment of 
CD68 staining in the thalamus, where very few CD68 positive cell profiles were 
counted despite the increases in [3H]-PK11195 binding in this region. 
Indeed, this previous assessment of [3H]-PK11195 determined that [3H]-
PK11195 binding was associated with an ‘activated’ microglial phonotype in 
addition to the ‘phagocytic’ phenotype without any difference in the binding 
density of [3H]-PK11195 (Banati et al., 1997).  One might hypothesize that the 
neurons in the thalamus are distressed/dysfunctional but not dying at the same 
rate as neurons in the cortex or hippocampus.  Therefore, microglia in the 
thalamus are becoming activated to provide support to these neurons thereby 
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expressing [3H]-PK11195 binding sites.  Since the CD68 antigen is a marker of 
phagocytic cells it may suggest that [3H]-PK11195 is binding to microglial cells 
that are activated, but have not made the transition to a phagocytic phenotype. 
A final consideration in these studies pertains to the possibility of 
increases in [3H]-PK11195 binding being related to the process of astrocytosis.  
Astrocytosis is defined as an activation and accumulation of astrocytes as a 
response to injury.  It is a key element of neuroinflammation and as such 
increased astrocyte activation and accumulation would be expected to occur at 
the same times as increases in microglial activation.  Indeed, one previous study 
has found a moderate positive correlation of [3H]-PK11195 binding with GFAP 
immunoreactivity following CNS injury (Raghavendra Rao et al., 2000).  It may 
therefore, have been beneficial to perform some co-labelling experiment to 
determine the contribution of astrocyte activation to increases in [3H]-PK11195 
binding in the CCI model. 
In conclusion, this study provides a detailed assessment of [3H]-PK11195 
binding following a mild/moderate CCI in rat brain.  The correlation of 
[3H]-PK11195 binding with ED-1 immunohistochemistry adds to a growing body 
of evidence that this ligand binds to activated microglia and macrophages (Banati 
et al., 1997; Myers et al., 1991b; Raghavendra Rao et al., 2000; Venneti et al., 
2007a; Venneti et al., 2008b; Vowinckel et al., 1997).  Microglia are the brains’ 
injury surveillance cells and are very sensitive to tissue damage.  When resting 
they are observed as having many long thin processes to ‘listen’ for signs of 
neuronal distress or death.  Upon activation the processes become thicker and 
often polarized towards the site of injury.  At this point they are believed to begin 
expressing the TSPO, most likely on the mitochondrial membrane.  Then, if they 
receive the appropriate signals they can take on a phagocytic role to clear 
cellular debris.  It is at this point that they start expressing the CD68 antigen, but 
no changes in the level of TSPO expression has been associated with this shift in 
phenotype.  Therefore, although PK11195 cannot discriminate between the 
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various activation stages of microglia, it can detect changes in microglial cells 
that conventional analysis by CD68 immunohistochemistry cannot. 
In addition, our study has highlighted the differences in the timing and 
magnitude of the microglial response, and indeed the pattern of neuronal 
degeneration following TBI.  This should be an important consideration for 
targeting of pharmacological therapies.  Moreover, PK11195 represents a useful 
marker for the assessment inflammation in animal models and human patients, 
and has significant potential for the evaluation of neuroprotective effects of 
pharmacological interventions. 
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3. CHAPTER 3 
Neuroprotective Actions of the Nicotinic Receptor Antagonist 
Methyllycaconitine Following Experimental Brain Injury 
3.1 Introduction 
It is estimated that over 1.4 million Americans experience a TBI every year 
(Sosin et al., 1996), however only a small fraction of these individuals sustain a 
injury that results in death or significant long term morbidity (Thurman et al., 
1999).  The remaining milder TBI patients also suffer from a wide variety of 
neuropsychological, behavioral and cognitive problems.  These deficits are 
frequently left untreated, can persist for years following TBI and significantly 
detract from the quality of daily life for those affected (Oddy et al., 1985; Rao and 
Lyketsos, 2002). 
It is well accepted that excessive synaptic levels of the excitatory amino 
acid glutamate can lead to a significant increase in neuronal dysfunction and cell 
death.  The neurotoxic properties of glutamate are thought to be mediated 
primarily through calcium permeable ionotrophic NMDA receptors that are widely 
expressed throughout the nervous system (Olney, 1969).  After traumatic injury 
sustained activation of NMDA receptors increases intra-neuronal calcium, 
leading directly or indirectly to mitochondrial impairment, an increase in ROS 
production, protein degradation, DNA damage, lipid peroxidation and ultimately 
neuronal death by necrosis and/or apoptosis.  Thus it is not surprising that NMDA 
receptor antagonists have drawn substantial attention as potential 
neuroprotective drugs that could be useful for the CNS disorders involving 
excitotoxicity including TBI, spinal cord injury and stroke.  However, human 
clinical trials of NMDA receptor antagonists for the acute and/or chronic 
treatment of these disorders have consistently ended in failure (Albers et al., 
1999; Bullock et al., 1999; Haley et al., 2005; Ikonomidou and Turski, 2002).  
One significant problem with the use of NMDA receptor antagonists for the 
treatment of neurotrauma may be an inadequate understanding of the 
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therapeutic window of opportunity for successful treatment.  While the acute 
actions of NMDA receptor antagonists might block some trauma-induced 
excitotoxicity, extended treatment might inhibit other critical functions of 
endogenous glutamate, including promotion of synaptic activity, neuronal survival 
and cognitive processing (Biegon et al., 2004).  One study found that 
administering NMDA itself to mice 24 or 48 hours after head injury improved 
cellular and functional outcomes (Biegon et al., 2004), challenging the dogma 
regarding NMDA blockers and neuroprotection.  Considering the short window of 
opportunity of NMDA receptor antagonist treatment and the importance of NMDA 
receptor stimulation in synaptic plasticity, an alternative approach to the acute 
treatment of TBI might be useful. 
Targeting the brain cholinergic system could be one such approach; 
persistent deficits in neuropsychological and cognitive function are common 
following mild or moderate head injury, and research has supported involvement 
of the brain cholinergic system (Dixon et al., 1994b; Dixon et al., 1999; Griffin et 
al., 2003; Pike and Hamm, 1997a, b; Pike et al., 1997).  Indeed, TBI has been 
shown to cause long-term changes in cholinergic function in the brains of both 
animals and humans (Dewar and Graham, 1996; Dixon et al., 1995b; Murdoch et 
al., 1998).  Previous studies from our laboratory have demonstrated a time-
dependant and consistent loss of α7 nAChR expression in rat cortical and 
hippocampal regions following experimental TBI (Verbois et al., 2003a; Verbois 
et al., 2002, 2003b; Verbois et al., 2000).  The mechanism underlying selective 
loss of α7 nAChR expression following CCI remains unknown, but we 
hypothesize an elevated level of cholinergic activity immediately following CCI 
may play a crucial role.  Similar to NMDA receptors, the α7 nAChR has high 
permeability to calcium ions (Zhao et al., 2003) and plays a role in hippocampal 
dependant cognitive processing.  Furthermore, studies support a predominant 
presynaptic localization of α7 nAChRs, where they regulate the release of other 
neurotransmitters including ACh and glutamate (Albuquerque et al., 1997; 
Lagostena et al., 2008; McGehee et al., 1995). 
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In the current study we evaluated the neuroprotective properties of the α7 
nAChR antagonist MLA.  MLA was originally isolated from the seeds of 
Delphinium brownii, and has been found to be a potent inhibitor of α-BTX binding 
to nAChRs (Macallan et al., 1988).  MLA is one of the most potent diterpenoid 
alkaloids found in Delphinium brownii, and is known to cause poisoning of 
livestock in the American Midwest due to its’ actions on the neuromuscular 
nAChR (Pfister et al., 1999).  As a potent and competitive antagonist of the CNS 
α7 nAChr, MLA has been found to be neuroprotective in models of β-amyloid and 
methamphetamine-induced toxicity (Escubedo et al., 2005; Martin et al., 2004b).  
The current study tested the hypothesis that antagonism of α7 nAChRs acutely 
following TBI will be associated with improved anatomical, histological and 
behavioral outcomes. 
3.2 Materials and methods 
3.2.1 Animals and surgery 
All experiments were conducted in accordance with the guidelines of the 
University of Kentucky Institutional Animal Care and Use Committee (IACUC) 
that follows the guidelines set forth by the National Institutes of Health guide for 
the care and use of laboratory animals.  All efforts were made to minimize the 
number of animals used in this study and to minimize animal suffering.  Male 
Sprague-Dawley rats weighing 275-300 g were obtained from Harlan Breeding 
Laboratories (Indianapolis, IN) housed 3 per cage and randomly assigned into 
five treatment groups (n = 8 per group).  Animals were anaesthetized with 3% 
isoflorane and immobilized in a stereotaxic frame.  A 6 mm craniotomy was 
performed using a Michele trephine just above the somatosensory cortex 
(Bregma –2.8, 2.5 mm lateral).  The stereotaxic frame was then positioned under 
a TBI 0310 impaction device (Precision Systems & Instrumentation, Fairfax 
Station, VA) that was used to administer a 1.5 mm cortical deformation at a 
velocity of 3.5 m/s (Baldwin et al., 1996; 5 mm impactor diameter).  Following the 
injury the skull disc was replaced and sealed with dental acrylic.  Sham animals 
underwent the same procedure with the exception of the administration of the 
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cortical contusion injury CCI.  Five minutes after surgery the animals were given 
an intraperitoneal injection of MLA (1, 5, or 10 mg/kg) or saline; animals received 
three additional injections of saline or MLA 8, 24 and 32 hours post-CCI. 
3.2.2 Behavioral testing 
Cognitive function was assessed on days 11-15 post-CCI, using a 
standard MWM procedure (Morris, 1984).  The behavioral testing room contained 
a circular 150 cm diameter pool with a 13.5 cm diameter submerged escape 
platform in the center of one quadrant.  Visual cues distributed throughout the 
room helped to aid spatial orientation.  All cognitive evaluations were videotaped 
and analyzed using Videomax software (Columbus Instruments, Columbus, OH).  
Quadrant entry was randomized for different starting positions, and animals were 
allowed to swim until they found the platform, up to a maximum of 60 seconds.  
Rats that were unable to locate the platform in 60 seconds were guided to and 
manually placed on the platform, and then allowed observe their position within 
the pool 15 seconds.  The acquisition phase of MWM testing consisted of four 
trials conducted each day for five consecutive days, with a 5 minute inter-trial 
interval.  Four hours following the last acquisition trial, the platform was removed 
and a 30 second memory retention trial was performed.  Videomax software was 
used to analyze several aspects of each animals search strategy on the retention 
trial.  MWM acquisition phase data were analyzed using the two-way repeated 
measure ANOVA (treatment × day), where the day of training was used as a 
repeated measure.  A Tukey’s HSD test was used to assess differences between 
the individual groups.  MWM retention data were analyzed by one-way ANOVA, 
and a Tukey’s HSD post-hoc test to determine individual group differences. 
3.2.3 Cortical tissue sparing analysis 
Following the completion of behavioral testing the animals were 
euthanatized and their brains were immediately removed and frozen in 
isopentane.  Brains sections (16 µm) were prepared using a Lecia CM1850 
cryostat and were mounted onto slides coated with gelatin, chromium potassium 
sulfate and poly-L-lysine to ensure tissue adhesion.  A cortical tissue sparing 
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analysis was performed to assess the potential neuroprotective actions of MLA 
administration.  Briefly, fourteen equally spaced cryostat sections through the 
damaged area were obtained from each animal and stained with cresyl violet.  
Images of each stained section were captured and digitized, then, using NIH 
image calibrated to measure area, the ipsilateral and contralateral cortices were 
outlined separately and measured.  The percentage of cortical tissue spared was 
calculated by dividing the mean cortical area for the ipsilateral cortex by the 
mean cortical area for the contralateral cortex (×100) (Scheff and Sullivan, 1999). 
3.2.4 Receptor autoradiography 
α7 nAChR density was measured using [125I]-α-BTX autoradiography, as 
previously described (Sparks and Pauly, 1999) using a ligand concentration of 
2.5 nmol [125I]-Tyr54-α-BTX (PerkinElmer Life Sciences, Inc., Boston, MA; specific 
activity = 102.9 Ci/mmol).  Sections adjacent to those used for [125I]-α-BTX 
binding were labeled with [3H]-PK11195 to identify the TPSO, formerly known as 
the PBR (Papadopoulos et al., 2006a).  This protein is thought to be primarily 
associated with mitochondrial cholesterol transport in activated microglia.  
Previous studies have used autoradiographic localization of [3H]-PK11195 
binding to detect the presence of activated microglia as a marker of 
neuroinflammation.  Briefly, slides were incubated in buffer containing 1 nM [3H]-
PK11195 for 2 hours, washed in buffer, and dried overnight.  RayMax Beta High 
Performance Autoradiography Film (ICN Biomedicals Inc., Aurora, Ohio) was 
used to visualize the areas of ligand binding.  Radioactive rat brain tissue 
standards were included with each film X-ray cassette in order to determine the 
response of the film to the increasing amounts of radioactivity.  Binding data were 
analyzed using NIH image v1.59 on a Power Macintosh connected to a Sony 
XC-77 CCD camera via a Scion LG-3 frame-grabber.  Molar quantities of bound 
ligand were determined by constructing a standard curve from radioactivity tissue 
standards fitted to a third degree polynomial curve.  Changes in [125I]-α-BTX 
binding following CCI and MLA treatment were quantified in several hippocampal 
sub-regions.  [125I]-α-BTX binding data were normalized relative to levels 
measured in sham animals since two separate binding experiments had to be 
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performed on these sections.  Based on the results from Chapter 2, [3H]-
PK11195 binding was measured in the cortex, the dentate gyrus, the hilus, the 
CA1 and CA2/3 fields, and in the lateral dorsal and ventral posterolateral 
thalamus.  Binding data were analyzed by a 2-way ANOVA where treatment and 
hemisphere were the independent variables and binding density the dependant 
variable.  Tukey’s HSD post-hoc tests were used when the ANOVA found a 
significant overall effect. 
3.3 Results 
3.3.1 Post-CCI MLA administration produces modest improvement in MWM 
performance 
Figure 3-1 depicts the acquisition of spatial learning in groups of animals 
tested in the MWM following CCI and MLA administration.  ANOVA results 
indicated a significant main effects of training day (F(4,112) = 19.65, p < 0.001) and 
treatment (F(4,112) = 20.99, p < 0.001), as well as a significant treatment X day 
interaction (F(16,112) = 1.76, p < 0.05).  Each dose of MLA administered resulted in 
a slight decrease in escape latency on each test day of acquisition testing.  
However, Tukey’s HSD post-hoc analysis revealed significant group differences 
on day 4 of testing only.  Compared to CCI animals treated with saline, treatment 
with 1 or 5 mg/kg MLA significantly decreased distance traveled to platform on 
day 4 of acquisition testing (p < 0.05).  However on day 5 of acquisition testing 
MLA-treated animals performed much more poorly than would be expected by 
the trajectory of learning observed on days 1 to 4.  This was unexpected, and the 
reasons for this apparent relapse of behavior on day 5 of testing are unclear. 
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Figure 3-1 - The effect of M
LA
 treatm
ent on M
W
M
 acquisition phase perform
ance 
M
LA
 treatm
ent partially attenuates cognitive deficits follow
ing C
C
I in the acquisition phase of M
orris w
ater m
aze 
testing.  D
ay 1 represents the day of the first trial and also the 11th day after injury.  The m
ean distance traveled by 
anim
als in each group w
as calculated and plotted against day of trial (m
ean ± S
D
).  A
nim
als treated w
ith 1 m
g/kg or 
5 m
g/kg M
LA
 perform
ed better than saline treated anim
als on day 4 of testing (*p<0.01). 
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Four hours following the completion of the acquisition phase of the MWM 
test, the platform was removed from the pool and animals swim strategy was 
assessed for 30 seconds (Figure 3-2).  One-way ANOVA found a significant 
effect of treatment on entries made into target quadrant (F(4,36) = 3.05, p < 0.05), 
time spent in the target quadrant (F(4,36) = 3.35, p < 0.05), and distance traveled 
in target quadrant (F(4,35) = 4.26, p < 0.01).  However post-hoc analysis showed 
that sham operated rats performed better than injured animals in each measure, 
and there were no improvements associated with MLA treatment.  The lack of 
clear cognitive enhancement in the retention phase of MWM testing was not 
surprising since the performance of these groups in acquisition trials on day 5 
was also unexpectedly poor. 
3.3.2 Post-CCI MLA administration results in dose-dependent cortical tissue 
sparing 
One-way ANOVA analysis of cortical tissue sparing data revealed a 
significant effect of treatment, F(4,32) = 5.44, p < 0.005; Figures 3-3, 3-4).  Fifteen 
days following CCI, saline treated animals had 76% of their cortical tissue spared 
ipsilateral to the site of impact.  In contrast, animals treated 4 times over 2 days 
with 1 mg/kg (85%) or 5 mg/kg (87%) MLA has significantly greater tissue 
sparing as compared to saline treated animals (p < 0.05).  In rats that treated 
with the highest dose of MLA, 93% of cortical tissue was spared, which was not 
significantly different from estimated cortical volume in sham-operated animals. 
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Figure 3-2 - The effect of MLA treatment on memory retention in the MWM 
High dose MLA generally impairs memory performance in a 30 second 
retention test, conducted one day following the completion of MWM acquisition 
training.  CCI animals treated with saline surprisingly had only deficits in 
distance traversed in the target quadrant (TQ) compared to sham operated 
controls (mean ± SD).  In contrast animals treated with 5 mg/kg and 10 mg/kg 
MLA were significantly impaired compared to sham operated animals in terms 
of entries into, time spent in, and distanced traveled in the target quadrant (*p 
< 0.05, **p < 0.01).  Animals treated with the lowest MLA dose (1 mg/kg) 
performed at the same level as sham-operated controls on each measure of 
memory retention, and there were no group differences in swim speed. 
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Figure 3-3 - Cortical tissue sparing in rats treated with MLA following CCI 
There is a dose-related cortical tissue sparing following post-CCI MLA 
administration.  Saline treated animals had 76% (mean ± SD) cortical tissue 
spared (**p < 0.005 versus sham operated animals) compared to 83% sparing 
in animals that received 1 mg/kg MLA (*p < 0.05 versus sham operated 
animals), 88% sparing after 5 mg/kg MLA (*p<0.05 versus sham operated 
animals) and 93% spared following 10 mg/kg (not significantly different from 
sham operated controls).  Furthermore, the animals treated with 10 mg/kg MLA 
had a significantly higher tissue sparing than saline treated animals following 
CCI (#p < 0.01). 
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Figure 3-4 - R
epresentative im
ages of cresyl violet-stained rat brain sections 
R
epresentative nissl-stained tissue sections illustrating dose-related cortical tissue sparing follow
ing post-C
C
I saline or 
M
LA
 
adm
inistration. 
A
ll 
im
ages 
w
ere 
obtained 
from
 
the 
epicenter 
of 
the 
cortical 
tissue 
loss 
in 
each 
group 
(approxim
ately B
regm
a -2.8 m
m
). 
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3.3.3 MLA administration exacerbates CCI-induced loss of hippocampal α7 
nAChR expression 
In saline injected animals, CCI was associated with a significant loss of α7 
nAChR expression in the ipsilateral stratum oriens and CA2/3 regions of the 
hippocampus (Table 3-1), consistent with previous studies from our lab.  
Surprisingly, all animals treated sub-acutely with MLA had significant reductions 
in hippocampal α7 nAChR binding.  In MLA treated rats, bilateral reductions in 
[125I]-α-BTX binding were seen throughout the hippocampus. 
3.3.4 Post-CCI administration of MLA reduces regional brain inflammation 
Previous studies have shown that CCI produces a widespread and 
significant increase in [3H]-PK11195 binding beginning within hours in areas 
proximal to the injury, and persisting for days to weeks in brain regions more 
distal to the site of injury (Banati et al., 1997; Miyazawa et al., 1995; 
Raghavendra Rao et al., 2000).  Our analyses focused on hippocampal, cortical 
and thalamic neuroinflammation.  The cortex adjacent to the impaction site and 
the hippocampus have early expression of inflammatory markers following TBI, 
and thalamic inflammation is more delayed and may occur only secondary to 
cortical tissue encavitation (Chapter 2).  Table 3-2 shows the effects of TBI and 
MLA administration on changes in the density of [3H]-PK11195 binding 
(Representative tissue sections are depicted in Figure 3-5).  In saline treated 
animals subjected to a 1.5 mm TBI, significant increases in [3H]-PK11195 were 
observed on the ipsilateral side of the brain, in each area evaluated (p < 0.001) 
consistent with previous studies.  Animals treated with the lowest dose of MLA 
had no significant changes in regional brain inflammation compared to saline 
treated TBI animals, except that a significant increase in [3H]-PK11195 binding 
was observed in the laterodorsal nucleus of the thalamus.  In comparison, 5 
mg/kg and 10 mg/kg MLA both caused a significant attenuation of 
neuroinflammation in the somatosensory cortex adjacent to the injury, and the 
CA1 and CA2/3 sub-regions of the hippocampus.  Post TBI administration of 
MLA did not affect [3H]-PK11195 binding in the dentate gyrus of the 
hippocampus or thalamus.  
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Sham
 
0 m
g/kg M
LA
 
1 m
g/kg M
LA
 
5 m
g/kg M
LA
 
10 m
g/kg M
LA
 
Ipsi 
C
ontra 
Ipsi 
C
ontra 
Ipsi 
C
ontra 
Ipsi 
C
ontra 
Ipsi 
Stratum
 oriens 
1.00±0.21 
1.02±0.09 
0.84±0.08**,† 
0.84±0.28** 
0.82±0.20** 
0.78±0.20** 
0.71±0.14** 
0.86±0.25** 
0.87±0.23** 
H
ippocam
pal C
A
1 
field 
0.99±0.15 
0.97±0.08 
0.98±0.06 
0.76±0.28** 
0.75±0.28** 
0.83±0.23** 
0.86±0.17** 
0.85±0.31** 
0.85±0.25** 
H
ippocam
pal 
C
A
2/3 field 
0.99±0.12 
0.97±0.11 
0.88±0.08**,† 
0.77±0.28** 
0.79±0.22** 
0.84±0.17** 
0.82±0.17** 
0.86±0.23** 
0.88±0.17** 
H
ippocam
pal C
A
4 
field (H
ilus) 
0.99±0.15 
0.94±0.14 
0.94±0.11 
0.90±0.22* 
0.98±0.22 
0.79±0.25** 
0.80±0.20** 
0.95±0.23 
0.98±0.20 
D
entate gyrus 
(dorsal blade) 
0.95±0.15 
0.88±0.11 
0.90±0.06* 
0.73±0.25** 
0.73±0.22** 
0.79±0.20** 
0.79±0.20** 
0.85±0.23** 
0.86±0.11** 
 Table 3-1 - The effect of post-C
C
I M
LA
 adm
inistration on binding density of [ 125I]-α-B
TX in selected brain regions 
[ 125I]-α-B
TX
 binding to α7 nA
C
hR
s follow
ing C
C
I and M
LA
 adm
inistration.  In sham
-operated anim
als there w
ere no 
hem
ispheric differences in the density of [ 125I]-α-B
TX
 binding, so regional data w
ere averaged (m
ean ± S
D
), and the 
rem
ainder of the data w
ere expressed as a percent of sham
-operated control values.  C
C
I follow
ed by saline 
adm
inistration resulted in a unilateral deficit in [ 125I]-α-B
TX
 binding in the stratum
 oriens, C
A
2/3 and dorsal blade of the 
dentate gyrus.  Surprisingly acute post-C
C
I adm
inistration of M
LA
 caused significant bilateral reductions in α7 nA
C
hR
 
expression in all areas m
easured, persisting for up to 15 days post-injury. 
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Sham
 
0 m
g/kg M
LA
 
1 m
g/kg M
LA
 
5 m
g/kg M
LA
 
10 m
g/kg M
LA
 
C
ontra 
Ipsi 
C
ontra 
Ipsi 
C
ontra 
Ipsi 
C
ontra 
Ipsi 
C
ontra 
Ipsi 
C
ortex 
0.78±0.10 
1.02±0.16 
0.78±0.12 
3.44±0.65* 
0.99±0.31 
3.37±0.69* 
1.00±0.23 
2.12±0.83*† 
0.91±0.16 
2.29±1.25*† 
H
ippocam
pal C
A
1 
field 
0.79±0.07 
0.82±0.08 
0.94±0.16 
4.19±1.14* 
0.90±0.16 
3.38±1.37* 
0.84±0.12 
2.72±1.12*† 
0.90±0.12 
3.10±1.28*† 
H
ippocam
pal 
C
A
2/3 field 
0.81±0.09 
0.84±0.08 
0.85±0.15 
4.85±1.52* 
0.86±0.17 
4.55±1.18* 
0.80±0.15 
3.27±0.61*† 
0.86±0.14 
3.69±1.03*† 
H
ippocam
pal C
A
4 
field (H
ilus) 
0.83±0.08 
0.85±0.08 
1.01±0.30 
5.21±1.55* 
1.05±0.26 
5.09±0.97* 
0.88±0.12 
4.64±0.69* 
1.03±0.26 
5.23±1.45* 
D
entate gyrus 
(dorsal blade) 
1.09±0.11 
1.11±0.11 
1.28±0.36 
4.02±0.99* 
1.45±0.35 
4.06±0.86* 
1.17±0.15 
3.34±0.99* 
1.38±0.30 
3.39±1.17* 
D
entate gyrus 
(ventral blade) 
1.11±0.10 
1.12±0.13 
1.46±0.36 
4.11±0.73* 
1.64±0.38 
3.72±1.21* 
1.30±0.17 
3.56±0.79* 
1.63±0.40 
4.31±1.00* 
Lateral dorsal 
thalam
us 
0.72±0.06 
0.73±0.06 
0.67±0.12 
2.75±0.63* 
0.78±0.14 
3.49±0.79*† 
0.73±0.15 
2.80±0.57* 
0.81±0.19 
3.14±0.42* 
Ventroposterolater
al thalam
us 
0.73±0.07 
0.74±0.07 
0.64±0.06 
2.60±0.52* 
0.67±0.12 
2.65±0.71* 
0.66±0.13 
2.42±0.51* 
0.79±0.15 
2.48±0.61* 
 Table 3-2 - The effect of post-C
C
I M
LA
 adm
inistration on binding density of [ 3H
]-PK
11195 in selected brain 
regions 
N
euroinflam
m
ation follow
ing C
C
I and M
LA adm
inistration as assessed by [ 3H
]-P
K
11195 autoradiography.  A
ll C
C
I 
anim
als had significant increases in [ 3H
]-P
K11195 binding com
pared to sham
-operated controls (*p < 0.01).  H
ow
ever, 
anim
als treated w
ith 5 or 10 m
g/kg M
LA
 had significantly less neuroinflam
m
ation in several regions evaluated (†p < 0.01 
com
pared to the ipsilateral side in saline-treated controls) 
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Figure 3-5 - Autoradiographs of rat brain sections bound w
ith [ 3H
]-PK
11195 
R
epresentative sections dem
onstrating [ 3H
]-P
K
11195 binding in anim
als treated w
ith saline or M
LA
 follow
ing C
C
I.  The 
sensitivity of [ 3H
]-PK
11195 binding as a m
arker of neuroinflam
m
ation follow
ing brain injury is illustrated by the increased 
binding seen ventral to the craniotom
y site in sham
-operated anim
als (arrow
).  In C
C
I-saline anim
als a highly significant 
increase in binding w
as pervasive in the cerebral cortex, hippocam
pus, and thalam
us.  The 5 m
g/kg and 10 m
g/kg doses 
of M
LA
 significantly attenuated TBI-induced increases in neuroinflam
m
ation in the cerebral cortex, and the C
A
 fields of 
the hippocam
pus. 
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3.4 Discussion 
Previous studies from our lab have postulated that α7 nAChR activation 
may contribute to calcium-mediated neurotoxicity following TBI.  The high 
calcium permeability of α7 nAChR (Gilbert et al., 2009) and their prominent 
location in brain regions affected indirectly and directly by TBI make these 
receptors plausible targets for neuroprotection.  Pharmacological antagonism of 
these receptors during the first 32 hours following injury produced some 
beneficial results, but other outcome measures were unaffected or exacerbated.  
The most consistent outcome measure in this study was cortical tissue sparing, 
where post-injury MLA administration was associated with dose dependant 
preservation of tissue.  In saline treated animals, a 1.5 mm CCI was associated 
with loss of 26% of ipsilateral cortical volume, 15 days following the initial 
surgery.  Loss of cortical mass was attenuated by post-surgery MLA 
administration, with the highest dose (10 mg/kg) producing a level of tissue 
sparing that was not significantly different from sham-operated animals.  
However neuroprotection evidenced by preservation of cortical mass was 
generally not correlated with improved outcomes in the hippocampal-dependant 
MWM spatial memory task.  In fact animals treated with 10 mg/kg MLA, had the 
greatest cortical tissue sparing, but no cognitive improvement compared to CCI 
animals treated with saline in the acquisition phase of testing.  Furthermore 
animals treated with the higher doses of MLA performed worse than saline 
treated CCI rats in the memory retention phase of cognitive testing.  The dose 
inversion of the MWM results suggests that higher doses of MLA may produce 
pharmacological actions that are inconsistent with improved functional outcomes, 
in spite of significant cortical tissue preservation. 
Studies from the Levin laboratory have conclusively shown that acute, 
intracerebral injection of nicotinic receptor antagonists impairs performance in 
cognitive tests including the radial arm maze.  When the α4β2 nAChR antagonist 
dihydro-β-erythroidine (DHβE) or MLA were injected into the basolateral 
amygdala or ventral hippocampus, cognitive deficits were observed (Addy et al., 
2003; Nott and Levin, 2006).  There were no additive effects of DHβE and MLA 
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when administered simultaneously, however DHβE co-administration prevented 
the amnestic actions of MLA delivered into the ventral hippocampus, suggesting 
a more complicated interaction between nicotinic receptor subtypes and 
regulation of cognitive function.  Also in the Levin studies, behavioral 
performance was assessed 10 minutes following injection of nAChR antagonists.  
In our experiment, rats received 4 injections of MLA in the first 32 hours following 
experimental injury, and no further drug treatments.  Behavioral testing ensued 9 
days later, and continued across days 11 to 15 post-injury.  Since the half-life of 
MLA is only approximately 20 minutes in rodents (Stegelmeier et al., 2003; Turek 
et al., 1995) it seems highly unlikely that residual MLA caused cognitive 
impairment by direct blockade of α7 nAChRs.  However long-term functional 
changes in nicotinic receptor sensitivity following acute administration of nAChR 
antagonists are not without precedence.  Several studies have previously shown 
that a single injection of the nicotinic receptor antagonist chlorisondamine blocks 
the actions of a nicotine challenge dose for up to 5 weeks, or more (Clarke, 1984; 
el-Bizri and Clarke, 1994).  Thus it is possible that the nAChR blocking actions of 
MLA greatly outlast receptor occupancy, and confounded the MWM results in our 
study, particularly at the higher doses that were employed.  Another surprising 
action of MLA that was observed in these studies was a persistent down 
regulation of hippocampal α7 nAChR expression.  In saline treated animals, 1.5 
mm CCI caused ipsilateral down-regulation of α7 nAChR expression in the 
stratum oriens, CA2/3 and the dentate gyrus, consistent with previous findings 
from our lab (Verbois et al., 2003a; Verbois et al., 2002, 2003b; Verbois et al., 
2000).  Each dose of MLA administered caused a bilateral decrease in 
hippocampal α7 nAChR expression that persisted for up to 13 days following the 
last MLA injection.  However [125I]-α-BTX deficits caused by MLA administration 
were generally not dose-dependent. 
Interestingly in spite of MLA-associated deficits in α7 nAChR expression, 
each dose of MLA administered to rats after trauma was associated with some 
degree of improvement in the acquisition phase of MWM testing.  This effect was 
most pronounced in rats given 1 mg/kg MLA on the fourth day of testing.  On the 
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same day rats administered 5 mg/kg MLA showed some improvement over 
saline animals, and the 10 mg/kg MLA group did not perform significantly better 
than saline-injected animals.  This inverse-dose response suggests that while 1 
mg/kg MLA is therapeutic, higher doses of MLA are detrimental to the function of 
neurons involved in acquisition of the MWM task.  It is possible that the higher 
doses of MLA impeded the recovery of neurons by inhibiting basal levels of 
signaling required for survival or for the induction of LTP.  On the fifth day of 
testing there were no significant differences in performance of MLA-treated 
animals versus saline-treated animals.  MLA treated animals took longer to find 
the platform [data not shown], and traveled further around the pool before finding 
the escape platform.  There is no obvious explanation for this sudden relapse in 
performance.  Coincidentally, the animals also performed poorly on the memory-
retention phase of the MWM that was carried out later on the same day.  In this 
phase of the MWM the search strategy of each animal was assessed without the 
submerged platform for 30 seconds.  The distance traveled in, entries into, and 
time spent in the quadrant of the pool that had contained the platform were 
measured.  Sham animals performed well by all measures, and saline treated 
CCI animals performed poorly as expected.  Unexpectedly, animals which had 
received MLA injections did not perform any better than saline-treated controls.  
The apparent lack of effect of MLA in this memory retention task could be linked 
to the poor performance of these animals on the fifth acquisition trial carried out 
on the same day. 
In contrast to the inverse-dose response found in the MWM, cortical tissue 
sparing analysis revealed a direct relationship between dose and tissue sparing.  
Indeed, the 10 mg/kg dose of MLA spared 93% of cortical tissue; a figure that 
was not significantly different from sham-operated animals.  A dose of 5 mg/kg 
spared 88% of cortical tissue, 1 mg/kg spared 84%, and saline spared 76%.  
Clearly MLA is sparing cortical neurons in a dose dependant manner.  We 
believe this effect is due to the inhibition of the α7 nAChRs by MLA, since the 
reduced calcium flow into cells expressing these receptors will attenuate the 
calcium load and protect them from cellular death. 
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The lack of concordance between the dose response curves for tissue 
sparing and cognitive recovery in the MWM was intriguing.  Animals given 1 or 5 
mg/kg of MLA performed better than animals that received a dose of 10 mg/kg, 
while the highest level of tissue sparing was achieved in animals that received 
the highest dose of MLA.  While the highest dose may protect neurons from 
excitotoxicity, it may also cause long-term changes in neuronal function that 
affect the learning and memory process.  Importantly, it should be noted that the 
MWM is a hippocampal dependant task (Liang et al., 1994) and that we only 
measured tissue loss in the cerebral cortex.  The use of a cortical-dependant test 
such as pre-pulse inhibition could have yielded a positive correlation between 
functional and tissue sparing results. 
Autoradiographic study of TSPO expression (a marker of inflammation 
and cellular damage) revealed a marked increase in [3H]-PK11195 binding in the 
ipsilateral cortex, hippocampus and thalamus of all injured animals.  However, 
treatment with 5 and 10 mg/kg MLA significantly reduced binding in the CA1, 
CA2/3 and cortex.  This reduction corresponds well with results from the tissue 
sparing analysis, supporting the notion that inhibition of the α7 nAChR by MLA is 
protecting cells from apoptosis and necrosis.  In contrast to the attenuation of 
[3H]-PK11195 binding in the cortex and hippocampus, no measurable effect of 
MLA was found in the thalamus.  This could merely be a timing issue, since 
increases in thalamic [3H]-PK11195 binding are delayed compared to those in 
the cortex and hippocampus (Chapter 2).  Elevated [3H]-PK11195 binding first 
appears in the thalamus about 3 days after injury and may still be increasing 2 
weeks after injury.  It is possible that any changes in thalamic binding of 
[3H]-PK11195 would not be seen until later time points. 
Our results show that MLA attenuates cognitive deficits following CCI, 
spares tissue, and reduces tissue damage as assessed by [3H]-PK11195 
binding.  While these actions are most likely to be mediated via the α7 nAChR, it 
should be noted that MLA has affinity for other nicotinic subunits including α3 and 
α6 (Anderson et al., 2008; Mogg et al., 2002).  Furthermore, MLA has a relatively 
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large molecule with an atomic mass of 683, so there are some questions about 
its ability to cross the BBB.  To date there has only been one detailed 
pharmacokinetic analysis of plasma and brain levels of MLA following 
intravenous or intraperitoneal administration (Turek et al., 1995).  In this study 
peak plasma levels of MLA were attained approximately 15 minutes following IP 
MLA administration, and brain levels peaked about 15 minutes later.  Brain levels 
of MLA were approximately 95% lower than that observed in plasma, indicating 
minimal BBB penetration.  However, we were undeterred by these results since 
CCI is known to cause transient and delayed opening of the BBB (Baldwin et al., 
1996).  The primary insult leads to a compromise of the BBB from the time of 
impact until about 3 hours post-injury.  The BBB then opens again between 12 
and 48 hours after injury, possibly caused by a secondary wave of brain damage 
(Baldwin et al., 1996). 
Another consideration in this study is the possibility of MLA acting 
indirectly via the cerebrovascular response to generate positive functional 
outcomes.  For example, stimulation of basal forebrain cholinbergic receptors 
can increase cerebral cortical blood flow (Linville et al., 1993).  In addition, there 
is some evidence to suggest that acetylcholine receptors located on the vessel 
walls could modulate vascular tone, though current data support a role for 
muscarinic receptors only (Elhusseiny and Hamel, 2000).  However, the 
expression of α7 nAChR on cortical vessel walls has been demonstrated (Clifford 
et al., 2008), so a role in regulation of cerebral blood flow cannot be ruled out.  
Control of cerebral blood flow via these mechanisms by a nicotinic antagonist 
and resultant changes in the supply of oxygenated blood could potentially effect 
outcome from CCI. 
An additional concern in the use of MLA is inhibition of a cholinergic anti-
inflammatory pathway (Wang et al., 2003).  Electrical stimulation of the vagus 
nerve has been shown to cause a significant decrease in tumor necrosis factor 
(TNF) release from macrophages, which express α7 nAChRs; the effects of 
vagal activation were blocked by administration of MLA and absent in α7 nAChR 
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knockout mice.  More recently it has been found that in the CNS microglia 
express α7 nAChRs and that exposure to ACh or nicotine reduces inflammatory 
markers following the administration of lipopolysaccharide (Shytle et al., 2004).  
α7 nAChR antagonists attenuated the effects of nicotine and ACh, directly 
implicating the α7 nAChR as a mediator of these responses.  Thus α7 nAChRs 
are key players in the cholinergically mediated anti-inflammatory pathway in the 
periphery and CNS, and MLA inhibition of this system might limit the usefulness 
of this compound, especially in long-term studies. 
Taken together, these results show that blockade of α7 nAChR stimulation 
immediately following CCI can be neuroprotective.  This is the first study aiming 
to assess the effects of MLA in an in vivo animal model of TBI; some important 
issues have been raised.  The validation of our hypothesis relies on MLA being 
administered early in the acute phase of injury in which cholinergic activity is 
elevated.  In rat brain the acute period of cholinergic excitotoxicity appears to be 
followed by a more chronic period of cholinergic hypofunction (DeAngelis et al., 
1994; Dixon et al., 1994a; Dixon et al., 1995a; Dixon et al., 1996; Dixon et al., 
1997; Saija et al., 1988).  The precise timing of the post CCI-changes in 
cholinergic activity have yet to be fully elucidated.  The first MLA injection was 
administered immediately following surgery, and then subsequent injections were 
administered at 8, 24 and 32 hours thereafter.  It is possible that the window of 
opportunity for efficacious MLA treatment is relatively short and that 
administering drug at later time-points is detrimental to neuronal survival.  An 
improved understanding of the time frame of cholinergic hyperactivity is required 
to guide future cholinergic treatment regimens. 
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4. CHAPTER 4 
Alpha-7 Nicotinic Acetylcholine Receptor Partial Agonists Improve 
Functional Outcome Following Controlled Cortical Impact in the Rat 
4.1 Introduction 
Increased public awareness of TBI has been brought about in recent 
years by the wars in Afghanistan and Iraq (Galarneau et al., 2008).  While reports 
are widespread on the effects of TBI on the many soldiers and civilians who are 
victims of improvied explosive devices (IEDs), many more people fall victim to 
TBIs each year in the USA as a result of motor vehicle accidents or falls 
(Langlois et al., 2006).  The vast majority of TBI sufferers recover from the 
physical effects of their injuries, but many are left with significant behavioral, 
emotional, and cognitive deficits that remain untreated (Corrigan et al., 2004; 
Resch et al., 2009).  These deficits often result in significant reductions in quality 
of life measures for patients, place a great burden on families and care-givers, 
and make the transition back into the workforce very difficult (Oddy et al., 1985; 
Rao and Lyketsos, 2002).  Despite an estimated 1.5 million people suffering a 
TBI in the USA alone each year (Sosin et al., 1996; Thurman et al., 1999), and 
the huge financial burden imposed by this condition, there is no pharmacological 
treatment for TBI.  There is a great need for new and novel approaches aimed at 
reducing secondary damage and improving functional and cognitive outcomes. 
While there has been widespread interest in researching the role of 
excitatory amino acids (EAAs) in brain injury, the roles played by nAChRs have 
been largely ignored until recently.  These receptors are known to be widely 
distributed and highly expressed in the brain (Sargent, 1993), and are intimately 
involved in cognition and other neurobiological processes (Kadir et al., 2006).  
Among nAChRs, the α7 nAChR is of particular interest due to its high levels of 
expression in the hippocampus; a region known to be vitally important for 
learning and memory, and also very sensitive to brain injury related pathology 
(Verbois et al., 2000).  Furthermore, the α7 nAChR possesses a uniquely high 
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permeability to calcium ions (Delbono et al., 1997), which play a significant role in 
the well characterized secondary injury cascades.  Studies into the expression of 
the α7 nAChR in AD and Parkinson’s disease have demonstrated a decreased 
α7 nAChR expression with increased severity of disease (Perry et al., 2000; 
Schmaljohann et al., 2004; Wevers et al., 1999). 
Our laboratory has been investigating the potential role played by the α7 
nAChR in brain injury induced post-traumatic cognitive impairment.  Initial studies 
found that the α7 nAChR is particularly sensitive to experimental brain injury and 
exhibits significant reductions in expression in several brain regions that can 
persist for weeks after injury (Verbois et al., 2002; Verbois et al., 2000).  These 
significant reductions in α7 nAChR expression were of particular interest because 
the α7 nAChR deficit was of greater magnitude than the NMDA receptor deficit 
after injury (Verbois et al., 2000).  Twice-daily nicotine administration following 
experimental brain injury attenuated some cognitive deficits in animals subjected 
to brain injury, but did not normalize deficits in α7 nAChR expression (Verbois et 
al., 2003a).  In a separate experiment chronic nicotine infusions were associated 
with an increase in post-surgical convulsions, and failed to spare cortical tissue 
(Verbois et al., 2003b). 
It is thought that immediately after a brain injury there is a period of 
increased extracellular ACh and excessive cholinergic receptor stimulation (Saija 
et al., 1988).  The excessive entry of cations into neurons overloads natural 
buffering systems and leads directly or indirectly to necrotic or apoptotic cell 
death.  We have shown that targeting the initial period of elevated cholinergic 
activity with an α7 nAChR antagonist results in significant tissue-sparing and a 
modest improvement in cognitive performance (Chapter 3).  At some-point after 
injury there is a transition to a more chronic hypocholinergic state (Arciniegas, 
2003).  Studies in our lab have shown that animals maintained on a diet 
containing choline, a selective α7 nAChR agonist, showed modest improvements 
in MWM performance, increased tissue-sparing, and reduced brain inflammation 
compared to rats on normal chow (Guseva et al., 2008). 
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The studies in Chapter 3 of this dissertation showed some beneficial 
effects of short-term treatment with nicotinic antagonists following CCI.  Other 
studies from our laboratory have shown that long-term dietary supplementation 
with the low affinity, but selective α7 nAChR full agonist choline, results in 
neuroprotection (Guseva et al., 2008).  However, the most efficacious time-points 
for administration of these compounds remains to be elucidated, and beyond the 
technical expertise of our research group.  While a detailed analysis of post-CCI 
cholinergic activity in rats could be useful for these rodent studies the time-
course may not accurately reflect the time-course in human head injury.  Indeed, 
the failures of several NMDA antagonists in clinical trials for TBI have been 
blamed in part on poorly predicted therapeutic windows in human versus rodent 
TBI (Albensi et al., 2004; Muir, 2006).  A potential solution to the animal versus 
human therapeutic “window of cholinergic hyper/hypofunction” conundrum may 
be to administer a partial agonist.  A partial agonist is simply an agonist that 
binds to a receptor but only has partial efficacy (compared to the full agonist of 
that receptor).  Theoretically, in the presence high concentrations of the 
endogenous full agonist ACh, a partial agonist would serve as a “functional” 
antagonist of α7 nAChR, possibly contributing to an attenuation of calcium 
mediated excitotoxicity.  Conversely, when endogenous levels of ACh are low, a 
partial agonist would provide some level of receptor agonism. 
The administration of a partial nAChR agonist during the initial period of 
hypercholinergic activity could be neuroprotective.  A high affinity partial agonist 
would compete with ACh for binding sites, but because it lacks full efficacy would 
lead to a relative reduction in the activation of receptors.  At later time-points 
when there is a deficit in cholinergic signaling, a partial agonist may help to 
maintain α7 nAChR cholinergic signaling.  Although a partial agonist may not be 
as effective as targeting a full antagonist to the period of hypercholinergic activity, 
and treating the deficit with a full agonist, it negates the need for these 
treatments to be carefully timed to avoid exacerbating the condition. 
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 In this study we assessed the neuroprotective and cognitive-enhancing 
potential of three α7 nAChR partial agonists tropisetron (Navoban®), 
ondansetron (Zofran®), and DMXB-A (also known as GTS-21) in TBI.  
Tropisetron is best known for its use as an anti-emetic following chemotherapy, 
and acts by antagonizing 5-HT3 receptors in the chemoreceptor trigger zone 
(CTZ).  In addition to its action on 5-HT3 receptors, tropisetron has been found to 
have a high affinity for α7 nAChRs at which it acts as a partial agonist (Macor et 
al., 2001).  Ondansetron is another 5-HT3 antagonist which acts as a partial 
agonist at α7 nAChRs, but with much lower affinity (Macor et al., 2001).  
Ondansetron is also used to reduce nausea and vomiting in chemotherapy 
patients (Framarino dei Malatesta et al., 1995).  A lot of interest currently 
surrounds the potential of DMXB-A to treat the symptoms of schizophrenia via its 
actions on the α7 nAChR (Freedman et al., 2008; Martin et al., 2004a; Olincy and 
Stevens, 2007).  It is also being investigated for treatment of AD (Kem, 2000; 
Wei et al., 2005). 
Given the beneficial effects of α7 nAChR agonists and antagonists in TBI 
we hypothesize that a partial agonist of the α7 nAChR will be neuroprotective 
and improve functional outcomes following brain injury.  The need for a well 
defined therapeutic window is negated by the partial agonist’s ability to reduce α7 
nAChR activation immediately after injury, while maintaining some cholinergic 
activity at later time points.  To test this hypothesis we began by assessing the 
effect of post-CCI tropisetron treatment on MWM performance, tissue sparing, 
and neuroinflammation.  We then tested two other α7 nAChR partial agonists in 
the same paradigm in order to demonstrate the therapeutic potential of α7 
nAChR partial agonists following brain injury. 
4.2 Materials and methods 
4.2.1 Animals and surgery 
All experiments were conducted in accordance with the guidelines of the 
University of Kentucky Institutional Animal Care and Use Committee (IACUC), 
which follow the guidelines set forth by the National Institutes of Health guide for 
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the care and use of laboratory animals.  All efforts were made to minimize the 
number of animals used in this study and to minimize animal suffering. 
4.2.1.1 Experiment 1 – Post-CCI tropisetron administration 
  A total of 35 male rats were obtained from Harlan Breeding Laboratories 
(Indianapolis IN) for the experiments.  Sprague-Dawley rats weighing 275-300 g 
were divided into 4 groups (8-10 animals per group).  All animals underwent 
surgery to administer a CCI of moderate severity as described previously 
(Verbois et al., 2000).  Briefly, animals were anesthetized in 5% isofluorane and 
placed in a Kropf stereotaxic frame (David Kopf Instruments, CA), then 
maintained at 2.5% isofluorane for the rest of the surgical procedures.  A 
longitudinal incision was made to expose the skull, and a 6 mm diameter 
craniotomy was made using a Michelle trephine laterally, midway between 
bregma and lambda.  The animal was then placed beneath the CCI device and 
oriented so that the impactor tip was aligned with the craniotomy.  A calibration 
was the performed to accurately set the position of the dural membrane and the 
device was programmed to perform a 1.5 mm deformation of the cortex at 3.5 
m/s with a dwell time of 400 ms.  Following impact, the animal was removed from 
the device and a piece of Surgiseal was placed on the wound.  The skull disk 
was then replaced and sealed with dental acrylic before stapling the wound 
closed.  Immediately after surgery the animals received 1, 2, or 5 mg/kg 
tropisetron (Sigma-Aldrich, MO), or saline via i.p. injections.  Animals received 
additional injections of tropisetron or saline 3, 24, 27, 48, 51, 72, and 75 hours 
later.  This dosing regimen was selected to target the initial period of cholinergic 
hyperactivity, and to coincide with the increases in microglial activation in all 
brain regions assessed in Chapter 2.  Behavioral testing began one day after the 
last injection had been administered.  The doses of tropisetron administered in 
this experiment were selected based on previously published data in rodents 
(Candelario-Jalil et al., 2008).  In this study sham-operated animals were not 
included in the interest of reducing animal usage and because our aim was to 
demonstrate an enhanced cellular and functional recovery versus saline-treated 
animals. 
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4.2.1.2 Experiment 2 – Post-CCI Ondansetron and DMXB-A treatment 
In addition to the groups described above, a further 14 male rats were 
obtained from Harlan Breeding Laboratories (Indianapolis IN) for this experiment.  
Rats weighing 275-300 g were divided into 2 groups (7 animals per group) and 
underwent surgery to administer a CCI of moderate severity as described above.  
Ondansetron (2 mg/kg) (Sigma-Aldrich, MO) or DMXB-A (10 mg/kg) (kindly 
provided by Dr. William Kem, University of Florida) was administered at 0, 3, 24, 
27, 48, 51, 72, and 75 hours after CCI.  Doses of these drugs were selected 
based on previous studies demonstrating beneficial effects in rodents (Fontana 
et al., 1995; Kem, 2000). 
4.2.2 Behavioral testing 
The MWM was used to assess cognitive performance in all animals 
following CCI (Brandeis et al., 1989; Vorhees and Williams, 2006).  Acquisition 
testing began in the MWM 4 days after surgeries and continued for a total of 4 
days, with a ‘retention’ test carried out on the fifth day.  The test room contained 
a 1.5 m diameter black plastic pool approximately 60 cm deep, filled with water to 
a depth of 30 cm.  The pool was arbitrarily divided into 4 quadrants by assigning 
the points N, E, S, and W at equidistant points around the circumference of the 
pool.  In the NE quadrant a 13.5 cm diameter platform was hidden by 
submerging it approximately 1 cm below the water’s surface.  The addition of 
black water-based powder paint to the water helped to conceal the platform from 
view and improved the contrast of the animal in the pool.  Visual cues were 
placed around the pool to enable the rats to orient themselves within the pool 
and facilitate spatial learning.  All tests were recorded on a digital camera placed 
above the pool and analyzed with Videomex software (Columbus Instruments, 
Columbus, OH). 
Each trial consisted of placing the animals one at a time in the pool at a 
randomly assigned point of the circumference (N, E, S, or W).  The animal was 
allowed to swim until it found and climbed onto the hidden platform, or until 60 
seconds had passed.  At this point any animal that had not found the platform 
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was placed onto the hidden platform and was allowed to remain on the platform 
for 15 seconds to gain awareness of the platform’s location.  The rat was then 
returned to its home cage for 5 minutes and then tested again.  A total of 4 such 
trials were carried out each day for 4 days to assess learning and memory.  
Although there was no significant difference in the swim speed of animals in each 
group the distance each animal traveled to the platform from the edge of the pool 
was used as a measure of performance to nullify possible intra-animal 
differences. 
On day 5 of cognitive testing the platform was removed from the pool and 
each animal was placed at the SW edge of the pool and allowed to swim for 60 
seconds.  This test is used to assess the animal’s search strategy and therefore 
memory retention.  Measures of performance in the retention test were ‘distance 
traveled in target quadrant’, ‘time spent in target quadrant’, and ‘entries made 
into target quadrant’. 
4.2.3 Cortical tissue sparing analysis 
Following completion of the MWM testing animals were euthanatized by 
rapid decapitation.  The brains were quickly removed, frozen in isopentane, and 
stored at -80˚C until further processing could be performed.  The brains were 
sliced on a Leica 1850 cryostat (Nussloch, Germany) at 16 μm thick and 
mounted on Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA).  Eight serial 
sets of sections were cut for each brain to enable comparisons to be made 
between subsequent autoradiographical and staining procedures.  For tissue 
sparing analysis a set of slides were stained with Cresyl Violet to visualize cell 
bodies and enable assessment of spared tissue (Scheff and Sullivan, 1999).  
Analysis was performed with ImageJ v1.34 (National Institutes of Health, MA) 
calibrated to measure area.  Twelve equally spaced sections throughout the 
lesion were chosen for analysis.  In each section the area of the ipsilateral and 
the contralateral cortex were measured separately and averaged over the 12 
sections.  To calculate tissue sparing, the area of the ipsilateral cortex remaining 
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was divided by the area of the contralateral cortex and multiplied by one 
hundred. 
4.2.4 Receptor autoradiography 
Autoradiography was used to assess nicotinic receptor expression and 
neuroinflammation/microglial activation following experimental brain injury and 
drug treatment.  Slides were removed from the freezer and thawed overnight in a 
desiccator at 4˚C.  For assessment of α7 nAChR expression [125I]-α-BTX binding 
was carried out as previously described (Sparks and Pauly, 1999) using 2.5 nM 
of [125I]-Tyr54-α-BTX (PerkinElmer Life Sciences Inc., Boston, MA).  A ligand of 
the TSPO, [3H]-PK11195 was used to assess neuroinflammation following injury.  
PK11195 binding has been shown to correlate well with the activation of 
microglia and macrophages (Stephenson et al., 1995; Vowinckel et al., 1997), 
which in turn are useful indicators of tissue damage and repair.  Briefly, slides 
were pre-incubated in 50 mM Tris-HCl buffer for 15 minutes at 4˚C, and then 
transferred to fresh buffer containing 2 nM [3H]-PK11195 (PerkinElmer Life 
Sciences Inc., Boston, MA) for 2 hours at 4˚C.  Slides were then washed, and 
dried overnight before being exposed to RayMax Beta High Performance 
Autoradiography Film (ICN Biomedicals Inc., Aurora, Ohio) for 8 weeks. 
4.2.5 Analysis of autoradiographs 
Films were imaged using a Northern Lights trans-illuminator with a 
monochrome digital camera (a CFW-1310M, Scion Corp) mounted directly 
above.  Settings on the lightbox and camera were adjusted to produce a high 
resolution image with the best possible contrast and then left unchanged during 
subsequent image captures.  Images were captured on an iMac G5 using 
Visi-capture software (Scion Corp.) and saved as lossless TIFF files.  Images 
from the same animal were combined into image ‘stacks’ without modification of 
individual images using ImageJ for ease of storage and analysis.  Image stacks 
were analyzed with ImageJ v1.34 with the ‘Measure Stack’ plug-in (OptiNav Inc., 
Bellevue, WA).  Briefly, the area of interest was outlined on each slice in the 
stack and then the mean pixel value was measured for each slice.  An average 
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pixel value for each region was then calculated for every animal in the study.  
Binding in each ipsilateral region was expressed as a percentage of the same 
region in the contralateral hemisphere.  Based on the results from Chapter 2, 
[3H]-PK11195 binding was measured in the cortex, the dentate gyrus, the hilus, 
the CA1 and CA2/3 fields, and in the lateral dorsal and ventral posterolateral 
thalamus. 
4.3 Results 
4.3.1 Tropisetron improves MWM performance 
Four days following CCI the rats began testing in the MWM to assess their 
spatial memory performance (Figure 4-1).  Two-way ANOVA analysis of the data 
revealed a significant effect of treatment (F[3,119] = 8.34, p < 0.001) and day (F[3, 
119] = 18.75, p < 0.001), but no significant interaction (F[9,119] = 1.00, p = 0.45).  
On average, saline-treated animals performed worse on all days, traveling further 
in the pool before reaching the platform than any other group.  All treated animals 
had shorter path-length traces for every day of the test, but only animals 
administered 2 mg/kg tropisetron performed significantly better than saline-
treated controls.    Post-hoc analysis using Tukey’s HSD test showed that on 
days 3 and 4 of testing, animals treated with 2 mg/kg tropisetron performed 
significantly better than saline controls (p < 0.01). 
Analysis of memory retention-test data did not reveal conclusive evidence 
of improved memory retention in any group (Figure 4-2).  Overall, one-way 
ANOVA found a significant difference between groups in terms of distance 
traveled in target quadrant (F[3,32] = 4.03, p = 0.016), entries made into the target 
quadrant (F[3,32] = 4.71, p = 0.008), and time spent in target quadrant (F[3,32] = 
1.62, p = 0.203).  Despite their performance in the acquisition phase of the test, 
animals treated with 2 mg/kg of tropisetron only performed marginally better than 
saline-treated animals in terms of distance traveled in the target quad, and the 
difference was non-significant. 
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Figure 4-1 - The effect of α7 nAChR partial agonist treatment on MWM 
acquisition performance 
Cognitive performance of each animal was assessed in the MWM beginning 4 
days after injury.  Partial agonist treatment reduced distance traveled to 
platform versus saline treatment on all days.  A significant effect of 2 mg/kg 
tropisetron treatment was observed on days 3 and 4.  Data have been plotted 
as means plus or minus standard deviations (n = 8).  Data-points have been 
slightly displaced for clarity and do not represent different testing times.  An 
asterisk represents a significant difference from saline-treated controls as 
determined by Tukey’s HSD (*p < 0.01). 
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Figure 4-2 - MWM retention task in brain injured animals treated with 
Tropisetron 
Spatial memory retention was assessed in injured animals by analyzing various 
parameters of their search strategy after the escape platform had been 
removed.  Mean values are plotted for each group with bars representing the 
standard deviation of the sample (n = 8).  Despite an overall effect of treatment 
found by one-way ANOVA, Tukey’s HSD tests did not reveal any differences 
between saline treated animals and tropisetron treated animals.  There was no 
significant difference in the swim speeds of animals between treatment groups. 
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4.3.2 There is no clear effect of tropisetron treatment on tissue sparing 
Following completion of behavioral testing the rats were euthanatized and 
their brains removed and processed for histological analysis (Figure 4-3).  Cresyl 
violet stained sections were used for assessment of cortical tissue sparing.  
There was a slight trend for animals treated with 2 mg/kg tropisetron to exhibit 
higher tissue sparing than saline-treated controls.  However, one-way ANOVA 
reported no significant difference between groups (F[3,36] = 2.32, p = 0.094). 
4.3.3  Post-CCI tropisetron does not have an effect on α7 nAChR expression 
For analysis of [125I]-α-BTX autoradiographs the binding density in the 
contralateral hemisphere was used as a baseline to which the effect of injury in 
the ipsilateral (injured) hemisphere was compared.  Binding in each brain region 
was therefore expressed as a proportion of the binding density in the 
contralateral hemisphere so that each brain acted as its own control (Table 4-1).  
One-way ANOVA did not report a significant effect of post-CCI tropisetron 
treatment on α7 nAChR expression in any of the regions analyzed.  Further 
analysis of the data using one-sample t-tests to determine differences between 
ipsilateral means and the theoretical contralateral mean binding density (100%) 
revealed significant reductions in the hilus and superior colliculus (p < 0.05) of 
saline treated animals. 
4.3.4 No effect of α7-nAChR partial agonist tropisetron on [3H]-PK11195 binding 
As with the [125I]-α-BTX binding data, [3H]-PK11195 binding was 
expressed as a proportion relative to the contralateral side of each brain (Table 
4-2).  Analysis of these data by one-way ANOVA failed to find a significant effect 
of tropisetron treatment on [3H]-PK11195 binding in any brain region.  However, 
as expected there were very significant increases in [3H]-PK11195 binding in all 
ipsilateral regions compared to contralateral (control) regions (assessed by t-test, 
p < 0.01 in every region). 
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Figure 4-3 - Cortical tissue sparing following CCI and tropisetron 
treatment 
There was no significant effect of treatment on cortical tissue sparing measured 
9 days after CCI.  Saline-treated controls had a 79% tissue sparing, and 
although 2 mg/kg tropisetron resulted in 88% tissue sparing, analysis of the data 
by one-way ANOVA reported no effect of treatment.  Data are plotted as mean ± 
standard deviation (n = 8). 
 
 
 
 
98 
 
Saline 
1 m
g/kg 
Tropisetron 
2 m
g/kg 
Tropisetron 
5 m
g/kg 
Tropisetron 
C
ortex layers 1-4 
0.97±0.08 
1.05±0.10 
0.97±0.07 
0.96±0.03* 
Stratum
 oriens 
0.98±0.07 
0.92±0.08* 
0.97±0.07 
0.97±0.09 
H
ippocam
pal field C
A
1 
0.97±0.07 
0.99±0.04 
0.98±0.07 
0.93±0.12 
H
ippocam
pal field C
A
2/3 
0.97±0.05 
0.95±0.07 
0.96±0.05* 
0.94±0.10 
H
ippocam
pal field C
A
4 (H
ilus) 
0.94±0.03* 
0.95±0.08 
0.95±0.07* 
0.91±0.05* 
D
entate gyrus (lateral blade) 
0.95±0.05 
0.99±0.04 
0.92±0.05* 
0.95±0.05* 
Superior colliculus 
0.97±0.02* 
0.96±0.04 
0.98±0.03* 
0.95±0.05 
 Table 4-1 - The effect of C
C
I and tropisetron treatm
ent on α7 nA
C
hR
 expression in the cortex and hippocam
pus 
[ 125I]-α-B
TX
 binding density w
as m
easured in both ipsilateral and contralateral regions of the cortex and hippocam
pus in 
order to assess post injury α7 nA
C
hR
 expression and any possible effects of tropisetron treatm
ent.  S
ince m
ore than one 
binding w
as perform
ed data for the ipsilateral (hit) side w
ere expressed as a proportion of the contralateral binding 
density.  In this w
ay each brain served as its ow
n control.  O
ne-w
ay A
N
O
V
A
 did not find any effect of treatm
ent on α7 
nA
C
hR
 expression.  S
ignificant reductions in α7 nA
C
hR
 expression in the ipsilateral hem
isphere versus a theoretical 
m
ean of 1 are signified w
ith an asterisk (*p < 0.05). 
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Saline 
1 m
g/kg 
Tropisetron 
2 m
g/kg 
Tropisetron 
5 m
g/kg 
Tropisetron 
C
ortex 
1.93±0.65 
2.21±0.31 
1.75±0.52 
2.03±0.58 
H
ippocam
pal field C
A
1 
2.34±0.82 
2.95±0.76 
2.18±0.95 
3.17±0.71 
H
ippocam
pal field C
A
2/3 
3.10±1.51 
3.99±0.93 
2.58±1.29 
3.80±0.68 
H
ippocam
pal field C
A
4 (H
ilus) 
3.42±0.80 
4.29±0.81 
3.40±1.29 
4.06±0.82 
D
entate gyrus (lateral blade) 
2.16±0.48 
2.72±0.34 
2.14±0.57 
2.58±0.43 
Thalam
us (Lateral dorsal) 
2.40±0.81 
2.84±0.44 
2.07±0.48 
2.76±0.62 
Thalam
us (Ventral posterolateral) 
2.38±0.74 
2.37±0.46 
1.89±0.38 
2.71±0.31 
 Table 4-2 - Effect of injury and post-C
C
I tropisetron treatm
ent on [ 3H
]-PK
11195 binding in the cortex, 
hippocam
pus and thalam
us 
D
ata are presented are binding in ipsilateral regions expressed as a proportion of the binding density in the corresponding 
contralateral region.  B
inding density in the ipsilateral hem
isphere w
as increased in all regions analyzed, how
ever, 
tropisetron treatm
ent did not have any significant effect on [ 3H
]-P
K11195 binding w
hen com
pared to saline. 
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4.3.5 Animals treated with other α7 nAChR partial agonists after CCI show 
modest improvement in the MWM 
Two other α7 nAChR partial agonists; DMXB-A and ondansetron were 
tested for efficacy in this model.  In the MWM acquisition phase animals treated 
with either partial agonist traveled a shorter distance to the platform on every day 
of the test (Figure 4-4).  Two-way ANOVA revealed a significant effect of 
treatment (F[2,78] = 6.28, p < 0.005) and test-day (F[3,78] = 13.45, p < 0.001) on the 
distance travelled, but no significant interaction term (F[6,78] = 0.47, p = 0.83).  
Post-hoc analysis by Tukey’s HSD revealed that on the fourth day of testing 
animals treated post-CCI with DMXB-A traveled a significantly shorter distance tp 
the platform than saline-treated animals (p < 0.05). 
In the memory retention test (Figure 4-5) one-way ANOVA returned a 
significant effect of treatment with regard to both distance traveled in the target 
quadrant (F[2,19] = 4.57, p < 0.05) and entries made into the target quadrant (F[2,19] 
= 9.19, p < 0.005).  Animals treated with DMXB-A traveled significantly further in 
the target quadrant than saline-treated animals (Tukey’s HSD, p < 0.05).  
However, when entries into the target quadrant and time spent in the target 
quadrant were analyzed DMXB-A treated animals did not perform significantly 
better than saline-treated controls.  Also of note is the fact that ondansetron-
treated animals performed significantly better than saline-treated animals with 
regard to the number of entries they made into the target quadrant during the 
memory retention trial (Tukey’s HSD, p < 0.05).  There were no significant 
differences in the mean swim speeds of animals in each treatment group (F[2,19] = 
1.23, p = 0.31). 
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Figure 4-4 - The effect of α7 nAChR partial agonist treatment on CCI-
induced cognitive deficits measured in the MWM acuisition phase 
Partial agonist treated animals exhibited shorter path lengths to the platform 
versus saline treated animals on all days of testing.  However, a significantly 
reduced distance traveled to platform was only found in DMXB-A treated 
animals on the fourth day of acquisition testing.  Data plotted are means plus or 
minus standard deviation (n = 8).  An asterisk denotes a significant difference 
from saline-treated animals (p < 0.05). 
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Figure 4-5 - Post-CCI differences in memory retention in animals treated 
with α7 nAChR partial agonists 
Post-CCI DMXB-A and ondansetron treatment resulted in a modest 
improvements in memory recall in some measures.  For example, animals 
treated with DMXB-A travelled significantly further than saline-treated animals 
in the target quadrant (which had contained the escape platform in preceding 
acquisition trials.  In addition, animals treated with ondansetron made 
significantly more entries into the target quadrant compared to saline-treated 
animals.  A significant difference from saline-treated controls is denoted with an 
asterisk (p < 0.05). 
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4.3.6 Neither DMXB-A nor ondansetron have any effect on cortical tissue 
sparing following CCI 
Cortical tissue sparing analysis did not reveal any significant effect of 
partial agonist treatment (Figure 4-6).  Saline animals has an 83% tissue sparing, 
and although DMXB-A treatment resulted in an 88% tissue sparing it was not 
statistically significant (p = 0.06).  Data were analysed by one-way ANOVA which 
reported no significant differences (F[2,19] = 1.85, p = 0.19). 
4.3.7 Ondansetron exacerbates post-CCI α7 nAChR deficits 
In saline treated animals there were significant reductions in α7 nAChR 
expression in the hilus and superior colliculus following injury (t-test versus 
theoretical mean of 1; p < 0.05).  Similar deficits were observed in animals 
treated with DMXB-A and ondansetron.  One-way ANOVA reported a significant 
effect of treatment in the CA2/3 field of the hippocampus (F[2,16] = 4.60, p < 0.05), 
and in the superior colliculus (F[2,16] = 6.90, p < 0.05).  Post-hoc analysis revealed 
significant differences between ondansetron and saline treated animals in the 
superior colliculus (p < 0.05), and between DMXB-A and ondansetron treated 
animals in the CA2/3 and superior colliculus (p < 0.05). 
4.3.8 Ondansetron treatment exacerbates neuroinflammation in the 
hippocampus following CCI 
As expected, [3H]-PK11195 binding was significantly increased following 
injury in all regions analyzed (Table 4-4).  Analysis of the data by one-way 
ANOVA revealed a significant effect of treatment in the hilus only (F[2,20] = 4.52, p 
< 0.05).  Further post-hoc analysis revealed a significantly higher binding density 
in ondansetron-treated animals versus saline treated animals (p < 0.05).  
Interestingly, [3H]-PK11195 binding was higher in ondansetron treated animals 
than in saline or DMXB-A treated animals all regions of the hippocampus.  An 
additional observation was the trend towards a reduction in PK11195 binding in 
DMXB-A treated animals versus saline treatment.  However, there was no 
significant difference in any of the regions assessed. 
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Figure 4-6 - Tissue sparing analysis in animals treated with DMXB-A or 
ondansetron 
Neither DMXB-A, nor ondansetron has any effect on cortical tissue sparing 
following experimental brain injury.  Saline treated animals had an 83% tissue 
sparing, while DMXB-A and ondansetron resulted in 88% and 82% sparing, 
respectively.  Data are presented as means plus or minus standard deviation (n 
= 6). 
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 Saline 10 mg/kg DMXB-A 
2 mg/kg 
Ondansetron 
Cortex layers 1-4 0.97±0.08 1.00±0.10 0.94±0.06 
Stratum oriens 0.98±0.07 1.00±0.03 0.99±0.05 
Hippocampal field CA1 0.97±0.07 0.97±0.05 0.92±0.09 
Hippocampal field CA2/3 0.97±0.05 0.99±0.02 0.92±0.04*# 
Hippocampal field CA4 (Hilus) 0.94±0.03* 0.93±0.04* 0.90±0.03* 
Dentate gyrus (lateral blade) 0.95±0.05 0.97±0.05 0.91±0.08 
Superior colliculus 0.97±0.02* 0.98±0.02* 0.93±0.03*# 
 
Table 4-3 - The effect of DMXB-A or ondansetron on α7 nAChR expression 
following CCI 
α7 nAChR expression was assessed by [125I]-α-BTX binding density and results 
are presented for the ipsilateral regions only expressed as a proportion of binding 
in the contralateral regions.  An asterisk indicates a significant difference from the 
theoretical mean of 1 as assessed using a t-test (p < 0.05), and the pound sign 
(#) denotes a significant difference from saline as found using Tukey’s HSD (*p < 
0.05). 
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 Saline 10 mg/kg DMXB-A 
2 mg/kg 
Ondansetron 
Cortex 1.93±0.65** 1.83±0.56* 1.53±0.44* 
Hippocampal field CA1 2.34±0.82*** 1.84±0.35** 2.97±1.14** 
Hippocampal field CA2/3 3.10±1.51*** 2.40±0.66** 3.57±0.99*** 
Hippocampal field CA4 (Hilus) 3.42±0.80*** 3.03±0.66** 4.49±1.09***# 
Dentate gyrus (lateral blade) 2.16±0.48*** 1.91±0.29*** 2.55±0.60*** 
Thalamus (Lateral dorsal) 2.40±0.81*** 2.05±0.44** 2.51±0.52*** 
Thalamus (Ventral posterolateral) 2.38±0.74*** 1.75±0.35** 2.43±0.46*** 
 
Table 4-4 - Post-CCI [3H]-PK11195 binding density in animals treated with 
DMXB-A or Ondansetron 
[3H]-PK11195 binding density in the ipsilateral hemisphere expressed as a 
proportion of the binding density in equivalent contralateral region.  Significant 
differences from the theoretical mean of 1 are shown with an asterisk (*p < 0.05, 
**p < 0.01, and ***p < 0.005).  A significant effect of treatment was found in the 
hilus only, and Tukey’s HSD found a significant difference between the saline 
and ondansetron groups (#p < 0.05). 
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4.4 Discussion 
In chapter 3 we demonstrated the therapeutic potential of the α7 nAChR 
antagonist MLA following experimental brain injury.  However, the highest dose 
of MLA was not the most efficacious for reducing cognitive deficits in the MWM 
despite sparing tissue and reducing neuroinflammation.  Bilateral reductions in 
α7 nAChR binding in all brain regions following MLA treatment could have 
effected MWM performance.  This result suggests the need for some α7 nAChR 
stimulation, and therefore the possible utility of a α7 nAChR partial agonist.  The 
use of partial agonists as therapeutic agents is well established; buprenorphine, 
for example, is a μ-opioid receptor partial agonist that has been used since the 
1980s as an analgesic, and more recently was approved for the treatment of 
opioid dependence (McClellan, 2002).  Other approved partial agonists include 
aripiprazole, a D2 partial agonist used to treat schizophrenia and bipolar disorder, 
and buspirone, a 5-HT1A partial agonist approved as an anxiolytic and 
antidepressant.  More recently the α4β2 partial agonist varenicline (Chantix) has 
been approved for smoking cessation treatment (Cahill et al., 2008; FDA, 2006). 
This study has demonstrated that partial agonists of the α7 nAChR have 
therapeutic potential in treating TBI.  Rats that were treated with tropisetron or 
DMXB-A performed significantly better in the MWM acquisition task than did 
animals given saline-only injections.  Attenuation in cognitive deficits resulting 
from CCI was most pronounced in animals treated with 2 mg/kg of tropisetron, 
while animals treated with DMXB-A preformed significantly better than saline-
treated controls on day 4 only.  It is however, interesting to note that the mean 
distance traveled to the escape platform by all treatment groups was lower than 
for saline-treated animals.  Despite this result in the acquisition phase of the 
MWM task there was no clear trend of improved performance in the retention test 
for any treatment group.  The finding that tropisetron attenuates cognitive deficits 
in a model of TBI adds to other findings in which tropisetron has reduced 
cognitive deficits in a mouse model of schizophrenia (Hashimoto et al., 2006; 
Pitsikas and Borsini, 1997).  In addition, the more modest effect of DMXB-A in 
attenuating cognitive deficits is in agreement with other studies that have 
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demonstrated DMXB-As cognitive enhancing effects (Arendash et al., 1995b; 
Nanri et al., 1998a).  The lack of any cognitive-enhancing effect for ondansetron 
is surprising, since several previous studies in rodents (Boast et al., 1999; Diez-
Ariza et al., 2003; Fontana et al., 1995; Harder and Kelly, 1997; Hodges et al., 
1996; Kumar and Kela, 2004; Reeta et al., 1999; Roychoudhury and Kulkarni, 
1997), and primates (Barnes et al., 1989; Barnes et al., 1990) have reported 
improvements in cognition.  While cognitive enhancement after insult has been 
reported for doses up to 10 mg/kg, one study assessing the effect of ondansetron 
in ameliorating cognitive deficits after atropine injection found a loss of efficacy at 
doses above 3 mg/kg (Fontana et al., 1995).  It is possible that had a lower dose 
of ondansetron been tested beneficial effects may have been found.  
Interestingly, ondansetron treatment exacerbated post-CCI α7 nAChR binding 
deficits, a finding which could help to explain the lack of a favorable functional 
outcome.  In chapter 3 of this dissertation a similar exacerbation of α7 nAChR 
binding deficits was found following α7 nAChR antagonist treatment in the same 
model.  A more thorough investigation of ondansetron in TBI will be required to 
assess its effects on α7 nAChR expression and cognition following injury. 
In this study there was no significant effect of any treatment or dose on 
tissue sparing.  In contrast, a recent study from our laboratory with an α7 nAChR 
full agonist (choline) produced a marked increase in tissue sparing following 
injury (Guseva et al., 2008).  Another study in which rats were treated with a full 
α7 nAChR antagonist immediately after CCI also showed significant increases in 
tissue sparing versus saline-treated animals (Woodcock et al., 2008).  The 
absence of an effect here could be due to these molecules lacking full efficacy at 
α7 nAChRs, or could be due to some other mechanism possibly involving their 
antagonism of 5-HT3 receptors.  It should also be noted here that a recent study 
found that tropisetron administered to rats prior to permanent middle cerebral 
artery occlusion (pMCAO) failed to reduce infarct size, and actually led to a 
higher mortality rate and exacerbated neurological deficits (Candelario-Jalil et al., 
2008).  However, this does not deter us from our results since the doses used in 
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that study were relatively high (5-10 mg/kg), and the mechanism of injury in 
pMCAO is very different to that in the CCI injury model we used. 
In this study [3H]-PK11195 autoradiography was utilized as a more 
sensitive marker of tissue damage.  PK11195 binds to the TSPO, which is 
thought to located on the outer mitochondrial membrane within activated 
microglia and macrophages.  We have previously shown that increases in 
[3H]-PK11195 binding can be detected just 6 hours after CCI in the hippocampus, 
while significant increases are not detected in the cortex until 12-24 hours after 
injury (refer to chapter 2).  Interestingly, there is a delayed increase in binding in 
the thalamus, possibly due to retrograde degeneration of axonal projections to 
the injured cortex.  The pattern of [3H]-PK11195 binding was in agreement with 
our previous studies using this tool.  In our past study we found that 
[3H]-PK11195 binding peaks in the cortex and hippocampus at 3-7 days, so the 8 
day time-point in this study comes just after the peak.  In this study there was no 
significant effect of treatment in the cortex, thalamus or any hippocampal region 
measured.  Furthermore, cortical tissue sparing was used to assess 
neuroprotective effects of α7 nAChR partial agonist treatment but failed to detect 
any significant effect of treatment.  There was a trend for animals treated with 2 
mg/kg tropisetron to have a greater tissue sparing, but this did not reach 
significance.  The lack of a neuroprotective effect for any of the partial agonists 
tested in this study was unexpected.  MLA treatment following CCI resulted in a 
significant neuroprotective effect and a modest improvement in functional 
outcomes.  It is possible that a full agonist is needed immediately following injury 
in order to facilitate neuroprotection.  The lack of efficacy of partial agonists in 
this model may dictate the need for combination therapies with which to treat 
TBI.  
As mentioned earlier, tropisetron and ondansetron are both approved for 
clinical use as antiemetics that function via their competitive antagonism of the 
5-HT3 receptor, but it is recognized that they also act on α7 nAChRs.  Both α7 
nAChRs and 5-HT3 receptors are members of the cys-loop ligand-gated ion 
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channel superfamily, which also includes other nAChRs, GABAA receptors and 
glycine receptors (Sine and Engel, 2006).  All receptors in the superfamily form 
pentameric ion channels and each subunit has a characteristic loop formed by a 
disulphide bond.  The receptors can be homomeric (made up of 5 identical 
subunits) like the α7 nAChR and 5-HT3A, or heteromeric as can be the case for 
some 5-HT3 receptors.  For example, the 5-HT3 subunit subtypes 5-HT3B, 5-HT3C, 
5-HT3D and 5-HT3E can form functional receptors in combination with the 5-HT3A 
subtype (Barnes et al., 2009).  While the 5-HT3 receptor does not bind ACh it 
does share more structural homology with nAChRs than it does to other 
serotonin receptors.  It is this homology that makes it unsurprising that some 
ligands with affinity for the 5-HT3 receptor also have affinity for the α7 nAChR 
and vice-versa.  Tropisetron and ondansetron are both competitive partial 
agonists of α7 nAChRs, although ondansetron seems to have a lower affinity for 
these receptors (Macor et al., 2001).  DMXB-A is slightly different, having been 
developed as a partial agonist of α7 nAChRs (Briggs et al., 1995; de Fiebre et al., 
1995), it is also a weak competitive antagonist of α4β2 nAChRs. In vivo 
experiments have since demonstrated that DMXB-A is also a weak antagonist of 
5-HT3 receptors (Machu et al., 2001), though possibly through a non-competitive 
mechanism (Gurley and Lanthorn, 1998; Kem, 2000).  Given our results it is 
possible that both antagonism of the 5-HT3 receptor and partial agonism of the 
α7 nAChR are beneficial in TBI. 
Interestingly, there is evidence that 5-HT3 antagonists might be able to 
increase cholinergic tone via an indirect mechanism.  It has been shown that 
5-HT3 receptors in the entorhinal cortex are located on GABAergic neurons, 
which inhibit cholinergic function (Barnes et al., 1989).  Therefore, antagonism of 
the 5-HT3 receptor could potentially improve cholinergic function independent of 
the α7 nAChR.  Equally, 5-HT3 antagonism immediately after injury could 
exacerbate excitotoxicity via this mechanism, and could explain the detrimental 
effects of pretreatment with tropisetron in pMCAO (Candelario-Jalil et al., 2008).  
This emerging evidence suggests that the 5-HT3 receptor itself could be a novel 
target for neuroprotective strategies.  Also worthy of further study is the 
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selectivity for each 5-HT3 antagonist for different isoforms of the receptor, and the 
roles that these different 5-HT3 receptors might play in the CNS.  Different 
affinities and efficacies of ondansetron and tropisetron for the various 5-HT3 
receptors may help to explain the different effects we observed in this study. 
An interesting aspect of this study was with regard to the results obtained 
for DMXB-A treatment following CCI.  DMXB-A has been shown to be 
neuroprotective in several studies and continues to be extensively evaluated, 
especially with regard to its potential therapeutic effects in AD (Kem, 2000; 
Meyer et al., 1998a; Nanri et al., 1998a; Nanri et al., 1998b; Ren et al., 2007).  In 
this study DMXB-A significantly improved MWM performance versus saline, and 
although not statistically significant it also resulted in a greater degree of tissue 
sparing and reduced [3H]-PK11195 binding in all regions assessed when 
compared to saline treatment.  Further assessment of this molecule in 
neurotrauma studies, including a refinement of the dosing and administration 
regimen might uncover neuroprotective effects for this drug following brain injury.  
In conclusion, our results have demonstrated that α7 nAChR partial 
agonist treatment following CCI can produce modest improvements in functional 
outcomes.  This study adds to previously reported findings that tropisetron can 
reverse cognitive deficits (Hashimoto et al., 2006; Koike et al., 2005; Pitsikas and 
Borsini, 1997).  The precise mechanism by which these drugs act to improve 
cognition remains to be determined.  The role of 5-HT3 receptors cannot be ruled 
out, and their involvement in excitotoxicity and neuroprotection will require further 
research. 
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5. CHAPTER 5 
Discussion and Conclusions 
5.1 Review 
The wars in Afghanistan and Iraq have brought traumatic brain injuries 
into the limelight.  Blast injuries from IEDs are increasingly common among 
combat soldiers (Galarneau et al., 2008), however, significant numbers of 
Americans also suffer TBIs, primarily as a result of motor vehicle accidents 
(Langlois et al., 2006).  In addition to the physical effects of trauma many TBI 
patients are left with behavioral and cognitive deficits that frequently go untreated 
(Corrigan et al., 2004; Resch et al., 2009).  As a result, many patients suffer 
significant quality of life reductions and make the transition back into society and 
the workforce difficult  (Rao and Lyketsos, 2002).  It is estimated that more than 
1.5 million people sustain a TBI every year in the USA, which creates an 
immense financial burden (Thurman et al., 1999).  Despite the scale of the 
problem there are no successful pharmacological treatments for TBI, and 
therefore there is a great need for new and novel treatment strategies aimed at 
improving outcomes. 
The present lack of efficacious treatments targeted at secondary injury 
mechanisms in TBI means that injury prevention is of utmost importance.  This 
can be achieved by raising awareness of the condition and encouraging people 
to take preventive or safety measures (such as wearing seatbelts and helmets).  
Raised awareness, improvements in automobile safety, and advances in other 
safety technologies must remain a focus if the impact of TBI on society and the 
emotional wellbeing of individuals is to be reduced (Kraus and Peek, 1995).  A 
future pharmacological intervention could potentially improve the lives of 
thousands of people by attenuating the behavioral and cognitive deficits brought 
about by TBI.  The studies outlined in this dissertation add to the current 
understanding of the time-course of secondary injury, and demonstrate the 
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potential therapeutic effects of targeting α7 nAChRs of the cholinergic system 
following a TBI. 
The experiments detailed within this dissertation have demonstrated that 
(1) [3H]-PK11195 is a sensitive and selective marker of microglial and 
macrophage activation within the injured brain, which can be used to track 
neuronal damage and potentially repair in many brain regions following injury 
(Chapter 2); (2) Short-term administration of an α7 nAChR antagonist after CCI is 
neuroprotective and leads to some improvement in cognitive performance 
(Chapter 3); and (3), partial agonists of the α7 nAChR can attenuate cognitive 
deficits associated with brain injury to a degree, but do not produce any 
measurable neuroprotective effect (Chapter 4). 
5.1.1 The time-course of damage and repair in TBI 
It is difficult to generalize the time-course of tissue, cellular and molecular 
changes that occur following a brain injury because of the heterogeneity of the 
condition (Saatman et al., 2008).  Affected brain regions can vary considerably 
by injury method, severity and location.  The injury paradigm we used in these 
studies models a focal closed-head injury (immediately following injury the skull 
cap is replaced and fixed in place with dental acrylic).  We have found that a 
small change in injury severity (1 mm cortical deformation versus 2 mm cortical 
deformation) produces a markedly different pattern and intensity of [3H]-PK11195 
binding throughout the brain (Figure 5-1).  However, in order to assess the 
efficacy of any treatment in TBI and models of TBI there need to be clear 
assessments made of the effect of injury on various measures of tissue and 
cellular damage as well as the functional and cognitive consequences of the 
injury.  These assessments need to be validated in human TBI so that 
meaningful evaluations of TBI treatments can be made in our various models. 
The easiest and most commonly employed methods for assessing injury 
severity and neuroprotective effects are lesion volume analysis and tissue 
sparing analysis, respectively.  While it is excellent as an initial validation of injury 
severity and uniformity and can be used to detect neuroprotective effects, its 
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Figure 5-1 - Comparison of [3H]-PK11195 binding in rat brain following 
different injury severities 
[3H]-PK11195 binding to the TSPO 14 days after CCI surgery shows great 
sensitivity to the degree of injury.  Following a 2 mm CCI increased [3H]-
PK11195 binding is found throughout the injured cortex, in the hippocampus, 
and in parts of the thalamus.  In contrast, a 1 mm CCI only leads to modest 
increases in binding to the ipsilateral cortex, small increases in the dentate 
gyrus and hilus of the hippocampus, and no significant increases in binding in 
the thalamus.  Furthermore, [3H]-PK11195 autoradiography can detect 
microglial activation in the cortex directly beneath the site of craniotomy 
following sham surgery (see arrowhead, ▼). 
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utility in relating to clinical results is very limited.  Barring the fact that nissl 
staining cannot be carried out on live patients, this is chiefly due to significant 
differences in size, shape, and structure of the human cortex compared to rat 
brain.  Furthermore, an analysis of this type would be restricted to assessment of 
injury in focal brain injured patients (possibly by computerized tomography [CT]), 
who represent a relatively small proportion of the total brain injuries (Langlois et 
al., 2006).  In addition, analysis of this type would not pick up smaller, but 
potentially more significant disruption of other brain regions. 
A more pertinent analysis of post-injury damage and possible 
neuroprotective effects is to assess neuronal dysfunction and death (e.g. FJ-B 
staining or de Olmos silver staining), or neuronal survival (e.g. NeuN 
immunohistochemistry).  Although more laborious than tissue sparing analysis, a 
thorough appraisal of neuronal survival following injury and experimental 
therapies can provide more detailed information on the brain areas affected and 
the relative severity of injury that together could help to explain physical and 
neurological alterations.  Again though, there is no way of accurately measuring 
neuronal death in live patients. 
Glial cells, which account for more than half of the cells in the primate 
brain (Azevedo et al., 2009) may be the key to relating injury in animals to human 
patients.  Microglia in particular have been attracting a lot of attention in recent 
years as the critical role played by inflammation in many neurodegenerative 
conditions becomes apparent.  Microglia are the brain’s resident immune cells, 
and play an important role in detecting damage to the brain parenchyma 
(Carbonell et al., 2005).  Following injury microglia quickly become activated, 
taking on a different morphology and expressing a range of neurotrophic, 
proinflammatory, and potentially neurotoxic factors (Ransohoff and Perry, 2009).  
Whether these activated cells are detrimental to neuronal survival or promote 
recovery from injury is still a topic of much contention, however, what is clear is 
that their presence corresponds well to areas of neuronal dysfunction and death.  
We therefore set about evaluating the potential of the microglial marker [3H]-
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PK11195 to image tissue damage and repair in a model of TBI (Chapter 2).  Our 
experiments have demonstrated the potential of [3H]-PK11195 as a marker of 
microglial and macrophage activation, which in turn are markers of tissue 
damage and neuronal dysfunction. 
[3H]-PK11195 is believed to bind to the TSPO within activated microglia 
and macrophages; a conclusion supported by the discovery of correlations 
between [3H]-PK11195 binding density and immunohistochemical detection of 
macrophages/microglia (Fujimura et al., 2008; Myers et al., 1991a; Venneti et al., 
2008a; Venneti et al., 2007a; Venneti et al., 2007b).  In our study we were able to 
confirm this correlation of [3H]-PK11195 binding to CD68, a marker of 
phagocytosis.  However, this correlation only held up in the injured cortex and not 
in the thalamus where increases in [3H]-PK11195 binding were not accompanied 
by any substantial increase in the numbers of CD68 positive cell profiles.  This 
finding could be due to the presence of activated, but not phagocytic, microglia.  
As mentioned earlier, CD68 is a marker of phagocytic cells, yet microglia are 
known to go through distinct ‘phases; of activation.  Our study therefore, has 
shown that the PK11195 binding site is expressed before significant numbers of 
phagocytic microglia can be detected.  Thus [3H]-PK11195 is a very sensitive 
marker of tissue damage because it increases in injured regions before neuronal 
death occurs. 
The potential for use of the TSPO as a marker of neuroinflammation is 
heightened by the development of PK11195 and other TSPO ligands for use in 
PET.  PET is a 3D imaging technique that uses a positron-emitting 
radionucleotide tracer introduced into the body of a patient or animal.  PET is 
often performed alongside a CT or MRI scan to give anatomical information in 
addition to the biochemical information afforded by PET imaging.  The use of 
[11C]-(R)-PK11195 in PET has been demonstrated in AD (Edison et al., 2008), 
Parkinson’s disease (Gerhard et al., 2006), Huntington’s disease (Pavese et al., 
2006; Tai et al., 2007a, b), schizophrenia (van Berckel et al., 2008), individuals 
with human immunodeficiency virus (Hammoud et al., 2005), multiple sclerosis 
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(Debruyne et al., 2003; Vas et al., 2008; Versijpt et al., 2005), ALS (Turner et al., 
2004a), stroke (Gerhard et al., 2000; Gerhard et al., 2005), and others (Banati et 
al., 1999; Leong and Butterworth, 1996; Leong et al., 1994; Leong et al., 1996).  
Most recently a study has found that PK11195 binding in AD brain correlates with 
mini mental state exam (MMSE) scores (while amyloid load did not) (Edison et 
al., 2008).  Other interesting findings have been a correlation with HD severity 
(Pavese et al., 2006), a correlation with brain atrophy in MS (Versijpt et al., 
2005), and a correlation with burden of upper motor neuron signs in ALS (Turner 
et al., 2004a).  Other studies have proposed that the utility of PK11195 in PET is 
not limited to the nervous system, but may also be a valuable tool to detect 
inflammation in atherosclerotic plaques (Fujimura et al., 2008), or in the lungs 
(Hardwick et al., 2005).  Despite the promising clinical results obtained using 
PK11195 in PET studies, the molecule does have some disadvantages which 
have prompted the development of new TSPO ligands.  These disadvantages 
include a relatively high level of non-specific binding in humans and primates 
(Petit-Taboue et al., 1991; Shah et al., 1994), poor signal to noise ratio, 
pharmacological effects independent of TSPO binding, and the necessity of 
labeling PK11195 with carbon-11 which has a very short half-life (~20 min) 
meaning that tracers must be synthesized very close to the point of use 
(Chauveau et al., 2008). 
PET is not limited to human patients.  Recent advances in technology 
have made PET with PK11195 possible in animal models, and a mini-PET device 
is now available that can be attached to a rat’s head for ‘live’ measurements 
(RatCAP, Brookhaven National Laboratory, NY).  PK11195 binding, detected by 
PET has been studied in rat transient focal ischemia (Rojas et al., 2007), a rat 
model of ethanol injury (Toyama et al., 2008), a transgenic mouse model of AD 
(Venneti et al., 2008a), and a macaque model of HIV encephalitis (Venneti et al., 
2007b). 
While this technique promises great things for the future of animal studies, 
technology is still expensive and out of reach for most labs.  In the meantime 
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[3H]-PK11195 autoradiography allows us to make detailed assessments of 
microglial activation in post-mortem human and animal brain.  Our studies have 
revealed widespread increases in [3H]-PK11195 binding in the rat brain during 
the days following CCI.  Furthermore, we reported that these increases vary 
significantly in timing and magnitude between distinct brain regions.  Increased 
binding became apparent in the dentate gyrus of the hippocampus just 6 hours 
after injury.  This observation highlights two important aspects of this technique; 
firstly, it demonstrates the sensitivity of [3H]-PK11195 autoradiography in 
detecting cellular disruption at a time when no significant changes were found in 
the impacted cortex.  Secondly, it demonstrates how PK11195 binding can be 
used to detect small and discrete areas of cellular damage and dysfunction distal 
from the injury.  The latter inference is further supported by our other finding that 
[3H]-PK11195 binding sites are expressed in distinct thalamic nuclei after injury, 
but increases are not observed until later time points and a peak is not reached 
until after at least 6 days.  We have hypothesized that this is due to lesioning of 
the cortex as a result of the injury, and subsequent retrograde degeneration of 
thalamocortical afferents culminating in neuronal death in the thalamus.  Support 
for this hypothesis comes from studies involving lesioning of the thalamus, in 
which a delayed loss of nicotinic binding was observed in the cortex (Gioanni et 
al., 1999; Lavine et al., 1997).  In addition, more recent studies have 
demonstrated secondary thalamic damage following cortical injuries (Langen et 
al., 2007), and delayed increases in thalamic PK11195 binding in stroke patients 
in a PET study (Pappata et al., 2000).  One similar study concluded that PET 
with PK11195 would be a useful way in which to investigate remote changes in 
neuroinflammation (i.e. via retrograde or anterograde degeneration) following 
ischemic stroke (Gerhard et al., 2005).  The most recent, and most compelling 
evidence in support of this hypothesis found that the thalamic nuclei that 
exhibited the greatest increases in inflammation varied depending on the area of 
the cortex that was lesioned (Langen et al., 2007). 
A further interesting observation in the thalamus from our study was the 
presence of significant increases in PK11195 binding without any significant 
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increase in CD68 staining in that region at the same time-point.  This was 
surprising but not without possible explanations.  First and foremost CD68 is an 
antigen found on activated microglia and peripheral macrophages, while 
PK11195 binds to a completely different site on these cells not necessarily 
related to CD68.  Secondly, PK11195 binding is not limited to microglia and 
macrophages.  For example, in brain displaying a normal pathology PK11195 
binding can still be observed in the choroid plexus and endothelium.  It is also 
expressed to some extent on erythrocytes.  However, the most likely candidates 
for TSPO expression in the brain besides microglia and macrophages are 
astrocytes.  It is now established that astrocytes express TSPO (Butterworth, 
1990; Cosenza-Nashat et al., 2009; Panickar et al., 2007; Veiga et al., 2007; 
Vlodavsky and Soustiel, 2007), and since they also lack CD68 this implicates 
them in PK11195 binding increases seen in the thalamus.  Evidence to support 
this hypothesis comes from a recent study of a novel TSPO ligand (DPA-714)  in 
a rat model of focal cerebral ischemia (Martin et al., 2009).  In this study 
immunohistochemistry was used to stain microglia (OX-42/CD11b), astrocytes 
(GFAP), and the TSPO (NP155).  Following the ischemic insult DPA-714 binding 
increased, peaked at 11 days, and then decreased but not to control levels by 30 
days.  This pattern matched well the temporal changes in TSPO-positive 
microglia.  Furthermore, numbers of TSPO-positive astrocytes increased at each 
consecutive time-point to 30 days, but there was no resultant increase in DPA-
714 binding.  The lack of concordance between DPA-714 and TSPO/GFAP 
staining in this study could be due to a lower level of TSPO expression by 
astrocytes or possibly the presence of another subtype of TSPO with differing 
affinity for the ligand.  Regardless, astrocytic expression of TSPO following brain 
injury, especially at later time-points may help to explain the increased PK11195 
binding seen in the thalamus.  In order to delineate the cellular expression profile 
of TSPO in brain injury it might be interesting to double-stain brain sections with 
GFAP and TSPO antibodies and look for double labeled cells within the 
thalamus. 
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Having assessed PK11195 binding in untreated rats after subjecting them 
to a CCI we applied this technique to our pharmacological studies.  In the first 
study, 5 or 10 mg/kg MLA was found to significantly reduce [3H]-PK11195 
binding versus saline-treated controls (Table 3-2).  These differences were found 
in the cortex and hippocampus, suggesting that either MLA is having a direct 
effect on neuroinflammation, or that these changes in [3H]-PK11195 binding are 
secondary to the neuroprotective effect of MLA that we observed.  The first 
scenario seems unlikely, because current evidence suggests an inhibitory role for 
nicotinic agonists on inflammation (Gallowitsch-Puerta and Tracey, 2005),  in 
fact, the anti-inflammatory effects of nicotine in the brain are thought to be 
mediated by the α7 nAChR receptor (Nizri et al., 2009; Shytle et al., 2004).  
Therefore, we would certainly not expect an α7 nAChR antagonist to reduce 
inflammation, but rather exacerbate microglial activation.  Further evidence 
suggesting the reductions in [3H]-PK11195 binding we observed are not due to a 
direct effect of MLA comes from a recent in vivo study in which rats were injected 
Intracerebroventricularly with LPS to induce an inflammatory response and 
cytokine expression was measured following drug treatment (Tyagi et al., 2009).  
Nicotine treatment reduced cytokine expression, and pretreatment with MLA 
antagonized nicotine’s effect, while DHβE (an α4β2 antagonist) had no effect. 
In chapter 4 of this dissertation we tested partial agonists of the α7 nAChR 
for neuroprotective effects and for their ability to improve functional outcomes.  
We also measured neuroinflammation in these animals using [3H]-PK11195 
autoradiography.  In this study none of the partial agonists reduced [3H]-PK11195 
binding, but ondansetron treatment did significantly increase [3H]-PK11195 
binding in the hilus.  This increase could be due to ondansetron’s agonistic effect, 
since MLA reduced inflammation.  A second important observation from this 
study was the lack of any tissue sparing with partial agonist treatment.  This 
could be the reason why there was no effect on neuroinflammation, suggesting 
that the reduction in [3H]-PK11195 we observed in Chapter 3 with MLA treatment 
was secondary to the tissue sparing effect. 
  
121 
 
We conclude that [3H]-PK11195 autoradiography is an excellent tool with 
which to assess the time-course of tissue disruption, which combines low cost 
with sensitivity and resolution.  It has already been utilized in an array of animals 
models (Giannaccini et al., 2000; Katchanov et al., 2003; Mankowski et al., 2003; 
Sitte et al., 2001), including brain injury (Grossman et al., 2003; Raghavendra 
Rao et al., 2000), although our study was the first to fully characterize it in a CCI 
model.  In addition, we have demonstrated in each of our studies that 
autoradiography with this ligand is a very sensitive technique for detecting injury 
and neuroprotective effects (Chapter 2, Chapter 3.3.4, and Chapter 4.3.4).  We 
demonstrated large and robust increases in [3H]-PK11195 binding in several 
brain regions that were very consistent between animals (Chapter 2).  
Furthermore, significant reductions in [3H]-PK11195 binding were detected in 
some brain regions following CCI and MLA treatment (Chapter 3.3.4), 
demonstrating its potential in detecting the effects of drug treatment.  
Additionally, it has not escaped our attention that while PET studies with 
PK11195 are becoming more common, an assessment of PK11195 binding sites 
in human brain injury patients has yet to be conducted.  Such a study would help 
to completely validate the technique as a method to assess the effectiveness of 
experimental therapies.  Coupled with CT scanning, it could also be a valuable 
method for the determination of injury type and severity in a clinical setting to 
help direct treatments and therapies to individual TBI victims.  Indeed, a recent 
workshop was convened with the purpose of recommending ways in which to 
develop a classification system for TBI that could be used to better target 
therapies (Saatman et al., 2008). 
In summary, imaging of the TSPO has great potential in providing a 
detailed and quantitative assessment of neuroinflammation both in the laboratory 
and in the clinic.  TSPO binding could be a valuable biomarker for use in 
determination of inflammation in drug development and early clinical trials. 
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5.1.2 Excitotoxicity mediated by the α7 nAChR 
Studies of excitotoxicity are generally focused on the NMDA receptor 
because of its high degree of calcium permeability.  However, despite promising 
drug candidates all clinical trials to date have failed (Albers et al., 1999; Bullock 
et al., 1999; Haley et al., 2005; Ikonomidou and Turski, 2002).  While the 
difficulties in translating doses and therapeutic windows from well controlled 
rodent models to the heterologous human condition could be partly to blame, it 
would be worthwhile to investigate alternative strategies to the treatment of 
excitotoxicity in TBI. 
We chose to investigate the effects of α7 nAChR blockade on CCI induced 
neuropathologies and functional recovery due to its interesting parallels with the 
NMDA receptor.  Firstly, the α7 nAChR is selectively and highly permeable to 
calcium like the NMDA receptor.  Studies in Xenopus oocytes have shown that 
α7 subunits form functional homopentamers, and that stimulation of the receptors 
causes a rapid influx of calcium (Hovda et al., 1995; Wolf et al., 2001; Young, 
1992).  Calcium flux through the α7 nAChR could lead directly to excitotoxicity 
and may also lead to an increased probability of glutamate release from pre-
synaptic terminals (Dickinson et al., 2008; Jiang and Role, 2008; Marchi et al., 
2002).  Secondly, the α7 nAChR is widely expressed in the brain, and is thought 
to be involved in cognitive processes.  α7 knockout mice have been produced 
(Orr-Urtreger et al., 1997), and although they do not display cognitive deficits, 
antisense knockdown of the α7 gene in rats does result in loss of α7 nAChR 
expression and cognitive deficits as measured in the MWM (Curzon et al., 2006).  
In our laboratory we tested the hypothesis that these α7 nAChR knockout mice 
would be less sensitive to post-CCI tissue loss and neuroinflammation (Kelso et 
al., 2006).  However, there were no differences in tissue sparing or 
neuroinflammation between wildtype, heterozygous, and knockout mice.  This 
result was surprising since we believe the α7 nAChR is involved in calcium-
mediated excitotoxicity following brain injury.  However, when interpreting results 
from genetic knockout animals care must be taken since compensatory 
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mechanisms may confound the results.  All together, these results suggest that 
α7 knockout mice may exhibit some compensatory developmental features. 
Since we believe that the α7 nAChR is integral to induction of 
excitotoxicity following a brain injury, modulation of this receptor might be 
therapeutic.  Fortunately, the well recognized therapeutic potential of nAChRs as 
targets for treating neurodegenerative conditions has led to a number of 
companies that are developing selective nicotinic agonists, antagonists and 
PAMs (positive allosteric modulators, which increase receptor activity indirectly 
via an allosteric site) for the α7 nAChR (Cincotta et al., 2008; Faghih et al., 
2007).  Some recent compounds of interest are A-867744, an α7 nAChR PAM 
which has been shown to potentiate ACh-evoked currents in recombinant α7 
nAChR expressed in oocytes (Malysz et al., 2009), and SEN12333, another α7 
nAChR PAM with demonstrated procognitive and neuroprotective properties 
(Roncarati et al., 2009).  Continued progress in the area promises to provide 
researchers with a multitude of novel pharmacologically active compounds with 
which to target nAChRs. 
In chapters 3 and 4 of this dissertation we tested the neuroprotective 
potential of an α7 nAChR antagonist and three different α7 nAChR partial 
agonists for neuroprotective potential when administered after CCI.  We 
hypothesized that the increased cholinergic activity in the brain after an injury 
could be damaging by adding to calcium-mediated excitotoxicity via α7 nAChRs.  
A full antagonist would be expected to block α7 nAChR activation, while a partial 
agonist would behave as an antagonist in the presence of high levels of 
endogenous agonist.  We found that MLA treatment had a significant effect on 
tissue sparing, an effect that was dose dependent and clearly demonstrated a 
neuroprotective effect.  In contrast, the α7 nAChR partial agonists tropisetron, 
ondansetron and DMXB-A all failed to produce any tissue sparing effect.  This 
was unexpected, but it is possible that in order to produce neuroprotection a full 
antagonist is required. 
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 We chose MLA as a full antagonist for investigation in these studies 
because it is readily available and represents a potent and selective antagonist of 
α7 nAChRs (Alkondon et al., 1992; Davies et al., 1999; Ward et al., 1990).  MLA 
is a plant alkaloid found in the larkspur, and its actions on the NMJ acetylcholine 
receptor implicate it in animal poisonings (Pfister et al., 1999).  In these 
experiments MLA was administered at 1, 5 or 10 mg/kg beginning immediately 
after CCI surgery, again 8 hours later and then again at 24 and 32 hours 
following CCI.  The doses were selected based on previous studies in which MLA 
was administered to rats in which no adverse effects were observed (Grottick 
and Higgins, 2000).  Since we were targeting excitotoxicity with this treatment we 
began the regimen as soon as the rat’s wound had been stapled closed.  
Because we were administering MLA via an intraperitoneal injection it is 
important to know that it is able to penetrate the BBB.  Based on previously 
published pharmacokinetic studies in rodents, MLA exhibits relatively poor brain 
penetration (approximately 5% of an IP dose) after peripheral injection (Turek et 
al., 1995).  However, since we are testing this molecule as a treatment for TBI its 
access to the brain will be improved by a disruption of the BBB.  Studies in the 
CCI model of TBI have shown significant BBB disruption following injury (Baldwin 
et al., 1996), which should allow or drug to reach its target receptors.  This 
disruption appears to be biphasic, with maximal breach occurring in the minutes 
immediately following injury.  The BBB appears to recover by 3 hours, but 
increased disruption was observed between 1 and 2 days.  Based on these 
findings only the injection of MLA administered 8 hours after injury would have 
been impeded by the BBB.  Even so, the amount of MLA that is able to cross the 
BBB may still be therapeutic.  Despite these considerations, the ability of MLA to 
access the brain is supported by the detection of significant central effects in our 
study.  There was a clear and obvious dose-dependent effect of MLA treatment 
on cortical tissue sparing, such that animals receiving the highest dose of MLA 
(10 mg/kg) did not differ significantly from sham operated controls (Chapter 
3.3.2).  This neuroprotective effect is what would be expected of a treatment that 
attenuates excitotoxicity after injury.  In addition to this neuroprotection there was 
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some attenuation of cognitive deficits as measured in the MWM swim test.  The 
results of this test were mixed; all animals treated with MLA performed 
consistently better than untreated animals during the acquisition phase of the 
test.  However, significant differences were only found on day 4 (of 5) and 
occurred in animals treated with 5 or 1 mg/kg MLA (Chapter 3.3.1).  This finding 
was interesting in the regard that 10 mg/kg of MLA had yielded the greatest 
tissue sparing, but had failed to produce a significant attenuation of cognitive 
deficits.  There are several possible explanations for this finding; firstly, the MWM 
is a hippocampal dependant task, whereas our tissue sparing analysis 
exclusively measures changes in cortical tissue volume.  Secondly, it is 
conceivable that while α7 nAChR blockade is beneficial in the cortex it is 
detrimental to neuronal survival at higher doses in the hippocampus.  Indeed, 
when we extended MLA treatment to 4 days there was no significant 
improvement in MWM performance [unpublished data].  Thirdly, it is possible that 
while MLA was able to save cells from an excitotoxic fate it was not able to 
prevent the depression of cholinergic function that occurs in TBI.  Indeed, our 
assessment of α7 nAChR expression by [125I]-α-BTX binding actually revealed a 
reduction in binding in MLA treated animals.  This was unexpected, but could 
help to explain the lack of well defined cognitive improvements in these animals.  
Of course, there are other explanations for the apparent deficit in [125I]-α-BTX 
binding in these animals, including a change in affinity of the α7 nAChRs for 
[125I]-α-BTX.  However, we consider this scenario unlikely for two reasons, (1) the 
animals were euthanatized 15 days after injury, 13 days after the last MLA 
injection had been administered.  It is improbable that MLA-induced changes in 
affinity of the α7 nAChR would persist this long after cessation of treatment.  (2) 
We have previously carried out a saturation analysis of [125I]-α-BTX binding to rat 
brain tissue from animals euthanatized 2 days after CCI.  The analyses 
confirmed that changes in binding were due to changes in the number of binding 
sites (Bmax) rather than affinity (KD) of [125I]-α-BTX for the receptor (Verbois et al., 
2002).  A separate scenario could be the accumulation of a pharmacologically 
active MLA metabolite in the brain, which is unlikely but previously published 
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work has demonstrated such a scenario with nicotine (Ghosheh et al., 2001).  It 
would have been useful to include a sham-operated group treated with MLA, but 
this effect was not anticipated.  An appropriate control group would have helped 
us to explain the reduction in [125I]-α-BTX binding that we observed.  A final 
consideration is with regard to the selectivity of MLA for the α7 nAChR, since 
recent studies have determined that at certain concentrations it can interact with 
α4β2 and α6β2 nAChRs (Mogg et al., 2002).  With this in mind, the involvement 
of other nAChRs in the effects we observed cannot be ruled out.  Finally, the 
peripheral effects of MLA on the NMJ would be a concern for its administration 
clinically.  This work could be expanded upon by testing more selective α7 
antagonists as they become available, preferably with more favorable 
pharmacokinetic profiles. 
From these experiments we surmise that the α7 nAChR plays a significant 
role in post-traumatic cell death and possibly cognitive deficits.  Antagonism of 
the α7 nAChR at early time points after injury promotes cell survival in the cortex, 
and leads to small improvements in the MWM versus saline treatment.  We 
believe this effect is mediated by the blockade of α7 nAChRs immediately 
following injury when high levels of ACh are present.  This α7 nAChR blockade 
will directly reduce calcium-mediated excitotoxicity, and may also indirectly 
attenuate excitotoxicity by reducing α7 nAChR-mediated glutamate release 
(Jiang and Role, 2008; Konradsson-Geuken et al., 2009).  In any case, treatment 
strategies utilizing α7 nAChR antagonists would be better directed by a well 
defined time-course of cholinergic function after injury.  Furthermore, antagonists 
with better BBB permeability, pharmacokinetic profile, and selectivity for the α7 
nAChR would greatly benefit these studies. 
5.1.3 Cholinergic deficits following TBI 
Studies in our laboratory have consistently reported a reduced expression 
of α7 nAChRs following experimental brain injury in rodents (Guseva et al., 2008; 
Kelso et al., 2006; Verbois et al., 2003a; Verbois et al., 2002, 2003b; Verbois et 
al., 2000, Chapter 3.3.3, Chapter 4.3.3).  This deficit is most prominent 24 hours 
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after injury, and persists in many brain regions until at least 3 weeks after injury.  
Because there is a certain level of recovery from this deficit at later time points it 
is unlikely that the deficit is a result of cell death in those regions.  Furthermore, 
these deficits can be reversed by administration of nicotine via osmotic mini-
pumps (Verbois et al., 2003b), making cell loss an unlikely cause of reduced α7 
nAChR binding.  In addition, the involvement of the cholinergic system in 
cognition implicates the reduced expression of these receptors in the cognitive 
deficits observed after TBI.  As mentioned above, antisense knockdown of the α7 
nAChR in rat produces impairments in MWM acquisition and retention tests 
(Curzon et al., 2006).  Examination of cholinergic tone following brain injury has 
determined that there is an initial period of hyperactivity following brain injury 
(Saija et al., 1988), similar to the hyperactivity observed in the glutaminergic 
system that is responsible for excitotoxic injury.  We therefore hypothesized that 
an overactivation of the calcium-permeable α7 nAChR could lead to excitotoxicity 
and neuronal dysfunction.  Our hypothesis is supported by the finding that 
blockade of the α7 nAChR following CCI increases tissue sparing and reduces 
[3H]-PK11195 binding in some brain regions (Chapter 3).  Then, at some time 
point the excess cholinergic activity becomes a deficit that could affect cognitive 
function (Arciniegas, 2003; Murdoch et al., 1998).  This finding is validated by 
animal models in which significant reductions in ChAT (Leonard et al., 1994), 
reduced basal and evoked ACh release (Dixon et al., 1996), and reduced choline 
uptake (Dixon et al., 1994a) have been reported.  Past studies in our laboratory 
have shown that treatment with a non-specific nAChR agonist, nicotine, can 
restore α7 nAChR binding following injury (Verbois et al., 2003b) and when 
administered as a series of chronic intermittent injection can attenuate cognitive 
deficits (Verbois et al., 2003a).  Interestingly, chronic intermittent nicotine 
treatment did not restore α7 binding, suggesting that stimulation of the remaining 
receptors could be sufficient to improve cognitive function.  However, despite the 
benefits of nicotine there are some limitations to these studies.  Firstly, nicotine is 
not a selective agonist and therefore has numerous effects.  By binding to 
receptors in the adrenal medulla it can stimulate the release of epinephrine and 
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norepinephrine, which among other effects increase heart rate and blood 
pressure.  It can also promote the release of the neurotransmitter norepinephrine 
via its action on nAChRs in the hippocampus and amygdala (Fu et al., 1998).  
Furthermore, nicotine is a psychoactive drug and is well known to lead to 
dependence; unwanted qualities in a therapeutic compound.  In addition to the 
problems with the drug, there is an issue of when is the best time to administer 
the drug.  In the previous two studies conducted in our laboratory nicotine was 
administered beginning immediately after injury.  However, heightened levels of 
cholinergic activity occurring at this time combined with the nicotine being 
administered could have exacerbated excitotoxicity.  For these reasons we chose 
to explore the use of selective nAChR agonists and antagonists in TBI.  Having 
demonstrated the neuroprotective capability of an α7 antagonist, we explored the 
possibility of improving functional recovery using a selective α7 agonist. 
We have previously shown that α7 nAChR agonist choline, when 
administered in chow to male rats does not result in any significant phenotypic 
differences in terms of MWM performance but does significantly increase [125I]-α-
BTX binding in the hippocampus and cortex (Guseva et al., 2006).  We therefore 
hypothesized that dietary choline supplementation would improve functional 
outcomes by improving cholinergic tone following a TBI.  Choline 
supplementation in rats subjected to a CCI resulted in significant cortical tissue 
sparing, reduced neuroinflammation, and attenuated some TBI-induced deficits 
in nAChR expression (Guseva et al., 2008).  The results from these experiments, 
combined with the positive results garnered from the MLA study prompted us to 
test the therapeutic potential of α7 nAChR partial agonists. 
5.1.4 Partial agonists of the α7 nAChR 
In recent years a number of relatively selective α7 nAChR ligands have 
been discovered and developed.  While the emphasis on developing these 
ligands is driven by their therapeutic roles in AD and schizophrenia, parallels 
between these conditions and TBI led us to test these novel ligands in a CCI 
model of TBI.  Among these new ligands is DMXB-A, otherwise known as GTS-
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21, which along with its active metabolite 4-OH-GTS-21 have been found to be a 
selective partial agonists of the α7 nAChR (Meyer et al., 1998b).    DMXB-A has 
been found to enhance cognition (nootrophic effect) in healthy male volunteers 
(Kitagawa et al., 2003).  In laboratory studies DMXB-A has demonstrated 
neuroprotective effects in a rat model of neocortical atrophy (Meyer et al., 
1998a), ischemia (Shimohama et al., 1998), and ethanol-induced neurotoxicity 
(de Fiebre and de Fiebre, 2003; Li et al., 2002).  Most importantly, DMXB-A has 
shown great potential for the treatment of symptoms of schizophrenia (Freedman 
et al., 2008; Martin et al., 2004a; Olincy and Stevens, 2007; Simosky et al., 
2002).  In addition, there is evidence to suggest that DMXB-A may also be useful 
in treating AD (Kem, 2000) and nicotine dependence (Foulds et al., 2004).  We 
also tested two other α7 nAChR partial agonists, tropisetron and ondansetron, 
which unlike DMXB-A are high affinity antagonists of the 5-HT3 receptor.  Both 
are approved for clinical use, primarily used to treat chemotherapy induced 
vomiting, although they may also be administered to TBI patients as part of their 
treatment or following surgery.  The established safety of these drugs combined 
with their selective partial agonism at α7 nAChRs made them exciting molecules 
for investigation in a model of TBI.  Furthermore, as partial agonists they have 
the potential to be therapeutic regardless of the level of cholinergic activity when 
administered.  For instance, a full antagonist might be more efficacious in 
attenuating nAChR-mediated excitotoxicity, but could worsen cognitive deficits if 
administered outside its therapeutic window.  Alternatively, a full agonist could 
exacerbate excitotoxicity if administered before, or immediately after injury.  A 
partial agonist therefore would eliminate the need to carefully time treatment with 
a full agonist or antagonist.  In our study we administered partial agonists for 4 
days following injury and began cognitive testing the day after the last injection.  
Tissue sparing results did not demonstrate a significant neuroprotective effect of 
any partial agonist, and there was no reduction in neuroinflammation, this is 
possibly due to the agonist activity of the drugs.  It is also possible we could have 
produced a neuroprotective effect had we continued administering the drugs for a 
longer time-period after trauma.  However, we did find that some of our partial 
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agonist treatments attenuated cognitive deficits in the MWM (Chapter 4.3.1).  
This finding was most pronounced in animals that received 2 mg/kg of tropisetron 
or 10 mg/kg of DMXB-A.  Furthermore, these improvements were observed 
subsequent to the cessation of treatment, suggesting they result from 
neuroprotective effects of treatment rather than a direct enhancement of 
cognition.  It would be interesting to test whether accentuated effects can be 
achieved with extended treatment with these partial agonists. 
As in the antagonist study, it was discovered that the most efficacious 
dose of tropisetron was not the highest dose.  Neither 1 mg/kg, nor 5 mg/kg of 
tropisetron significantly improved MWM performance, or reduced [3H]-PK11195 
binding.  In addition, there was discrepancy between the effects of the different 
drugs.  It is possible that the doses we chose in the study are not optimal, and 
that a more thorough assessment of their use in TBI could achieve therapeutic 
effects.  It is also possible that the differences are due to differences in their 
pharmacological profiles.  For instance, potent antagonism of 5-HT3 receptors is 
well documented for ondansetron and tropisetron, while DMXB-A may be less 
potent at these sites (Gurley and Lanthorn, 1998).  In addition, their affinities for 
the α7 nAChR vary significantly, with DMXB-A and tropisetron displaying high 
affinity for the α7 nAChR, and ondansetron having much lower affinity.  Clearly 
there is a lot of difficulty in finding a molecule with good selectivity for the α7 
nAChR.  The action of 5-HT3 ligands at α7 nAChRs should be expected since 
they share a great deal of structural homology (Karlin and Akabas, 1995).  There 
is still hope for selective ligands though, since the potent α7 agonist α-anatoxin, 
the α7 antagonist MLA, and [125I]-α-BTX have been shown to be ineffective at 5-
HT3 receptors (Gurley and Lanthorn, 1998; Yang et al., 1992). 
5.1.5 The role of the 5-HT3 receptor 
An important consideration in our third study is the possible role that 
antagonism of the 5-HT3 receptor plays in neuroprotection and the recovery of 
function that we observed.  All three of the compounds tested in this study are 
known to be antagonists of the 5-HT3 receptor, and two were specifically 
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developed to target these receptors in the CTZ of the brainstem.  5-HT3 receptors 
are also found in the amygdala, hippocampus, and entorhinal cortex (Fletcher 
and Barnes, 1999; Miquel et al., 2002).  They are known to be located 
predominantly presynaptically (similar to α7 nAChRs), where they can regulate 
the release of neurotransmitters (Doucet et al., 2000; Turner et al., 2004b).  
Indeed, 5-HT3 receptors have been shown to regulate GABA release, which in 
turn inhibits ACh release (Bolanos et al., 2002; Ramirez et al., 1996).  This 
observation has been used as a rationale for treating AD with 5-HT3 antagonists 
to improve cholinergic activity (Gil-Bea et al., 2004).  Based on these findings it is 
conceivable that α7 nAChR partial agonists with 5-HT3 antagonist activity could 
be of higher value than more selective α7 nAChR partial agonists. 
5.2 Concluding Remarks 
The pharmacological studies described within this dissertation, combined 
with other pharmacological studies from our laboratory described in Chapter 1 
are summarized in Table 5-1.  Initial studies from our laboratory focused on the 
administration of the agonist nicotine, with the goal of reversing [125I]-α-BTX 
binding deficits and thereby facilitating improved MWM performance.  Chronic 
nicotine infusions succeeded in reversing [125I]-α-BTX binding deficits, but 
resulted in increased post-CCI seizures and did not spare cortical tissue.  When 
MWM performance was assessed in animals administered a series of chronic 
intermittent nicotine injections there was a clear improvement in MWM 
performance.  However, no reversal of [125I]-α-BTX binding deficits was detected.  
A more selective α7 nAChR agonist was next administered in the chow of rats 
that underwent CCI.  Choline administration improved cognitive function, spared 
tissue, and reduced inflammation, but did not reverse [125I]-α-BTX deficits.  
Questions remain as to the window of therapeutic opportunity for choline in order 
to achieve these results.  As described in detail in this dissertation, MLA 
produced significant improvements in MWM performance, spared cortical tissue, 
and reduced inflammation, but exacerbated [125I]-α-BTX binding deficits.  Partial 
agonists of the α7 nAChR improved cognitive function, but failed to significantly 
spare tissue, reduce neuroinflammation, or reverse [125I]-α-BTX binding deficits. 
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Despite a lack of knowledge concerning the precise time-course of 
cholinergic changes, and pharmacokinetics/pharmakodynamics of the 
pharmacological agents chosen for these studies, our results are nevertheless 
encouraging and merit further investigation.  While a lot of work remains to be 
done to characterize TBI related changes following injury, our results have 
helped to describe the binding profile of a promising marker of 
neuroinflammation, PK11195.  We have used this tool to assess 
neuroinflammation in two pharmacological studies that aimed to demonstrate that 
α7 nAChR modulation improves functional and cellular outcomes from.  Overall, 
the studies outlined herein have demonstrated that (1) the TSPO ligand PK11195 
can measure differences in the timing and magnitude of microglial activation 
following injury, making it an excellent translational instrument; (2) antagonism of 
the α7 nAChR after TBI is neuroprotective and moderately improves functional 
outcomes; (3) partial agonists of the α7 nAChR administered after an 
experimental brain injury only marginally improve spatial memory and do not 
significantly spare cortical tissue. 
Based on our findings, the most promising route for future research in this 
area is likely to be in the development of α7 nAChR antagonists with more 
favorable pharmacological characteristics.  The potential of potent and selective 
nicotinic agonists and antagonists is well recognized, and therefore drug 
discovery research in the field is progressing quickly (Haydar et al., 2009; Lopez-
Hernandez et al., 2009; Smith et al., 2009; Tasso et al., 2009).  Further studies 
with MLA or a novel α7 nAChR antagonist should firstly seek to dissect the α7 
nAChR binding reductions we found by including an appropriate sham + 
antagonist control group.  Studies could aim to refine the therapeutic window for 
α7 nAChR antagonist treatment and further elucidate treatment effects on other 
measures of cellular damage such as FJ-B or silver staining (Hall et al., 2008).  
Furthermore, an effect of these treatments of neurogenesis cannot be ruled out 
since has been shown to occur following CNS injury such as ischemia (Jin et al., 
2006; Jung et al., 2009), alcohol withdrawal (Nixon and Crews, 2004; Nixon et 
al., 2008), and TBI (Gao et al., 2009; Lu et al., 2005).  It would be very interesting 
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to determine whether neurogenesis is affected by our pharmacological 
interventions.  Finally, the disappointing results of our partial agonist study 
suggest that there may not be a single ‘silver bullet’ pharmacological agent with 
which to treat TBI.  The studies outlined in this dissertation, and the results of 
other studies from our lab suggest that a combination of α7 nAChR antagonists 
and agonists administered at the right times might provide most benefit. 
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APPENDICES 
APPENDIX I: list of acronyms and abbreviations 
5-HT  - 5-hydroxytryptamine 
ABC  - Avidin: Biotinylated enzyme complex 
ACh  - Acetylcholine 
AChE  - Acetylcholinesterase 
AD  - Alzheimer’s disease 
ALS  - Amyotrophic lateral sclerosis 
AMPA  - α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA - Analysis of variance 
AP5  - (2R)-amino-5-phosphonovaleric acid 
ATP  - Adenosine-5'-triphosphate 
BBB  - Blood-brain barrier 
BTX  - Bungarotoxin 
Ca2+  - Calcium (ion) 
CCI  - Controlled cortical injury 
ChAT  - Choline acetyltransferase 
CNS  - Central nervous system 
CPP  - Cerebral perfusion pressure 
CT  - Computerized tomography 
CTZ  - Chemoreceptor trigger zone 
DAB  - 3,3' Diaminobenzidine 
DAI  - Diffuse axonal injury 
DHβE  - Dihydro-β-erythroidine 
DMXB-A - 3-2,4 dimethoxybenzylidene anabaseine (a.k.a. GTS-21) 
DNA  - Deoxyribonucleic acid 
EAA  - Excitatory amino acid 
FITC  - Fluorescein isothiocyanate 
FJ-B  - Fluoro-Jade B 
FPI  - Fluid percussion injury 
GCS  - Glasgow coma score 
GFAP  - Glial fibrillary acidic protein 
HSD  - Honestly significant difference 
IACUC - Institutional Animal Care and Use Committee 
ICP  - Intracranial pressure 
IED  - Improvised explosive device 
LD  - Lateral dorsal 
LTP  - Long-term potentiation 
mAChR - Muscarinic acetylcholine receptor 
MLA  - Methyllycaconitine 
MMSE - Mini mental state exam 
MWM  - Morris water maze 
Na+  - Sodium (ion) 
nAChR - Nicotinic acetylcholine receptor 
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NeuN  - Neuronal nuclei 
NMDA - N-methyl-D-aspartic acid 
NMJ  - Neuromuscular junction 
PAM  - Positive allosteric modulator 
PBR  - Peripheral benzodiazepine receptor 
PBS  - Phosphate-buffered saline 
PET  - Positron emission tomography 
pMCAO - Permanent middle cerebral artery occlusion 
PNS  - Peripheral nervous system 
ROS  - Reactive oxygen species 
TBI  - Traumatic brain injury 
TUNEL - Terminal deoxynucleotidyl transferase mediated dUTP nick 
end labeling 
VPL  - Ventral posterolateral 
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APPENDIX II: supplemental figures 
 
 
 
 
  
 
Figure A1 - Molecular structure of six ligands that bind the α7 nAChR 
Skeletal diagrams showing the molecular structures of α7 nAChR ligands 
Methyllycaconitine (MLA), Nicotine, Acetylcholine (ACh), 3-(2,4-
dimethoxybenzylidene)anabaseine (DMXB-A), ondansetron, and tropisetron. 
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